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ABSTRACT
Toxicity associated with bioactive natural products is considered a major obstacle in the
process of drug discovery. Manzamine A (MA) is one such candidate that requires optimization
to overcome the toxicity problem. The manzamine alkaloids represent a unique class of natural
products that have shown a diverse range of bioactivities including antimicrobial, antiparasitic,
cytotoxicity, anti-inflammatory, pesticidial and was shown to possess activity against HIV-1 and
AIDS opportunistic infections.1 The greatest potential for the manzamine alkaloids appears to be
against malaria and neuroinflammation.1,14,45 Experimental and modeling studies suggested that
the planer β-carboline moiety can act as DNA intercalator and hence induce toxicity.14 Thus
either modification or the replacement of the β-carboline moiety with other heterocycles could
eliminate DNA intercalation and will be a straightforward step toward generating manzaminelike analogs with similar or better biological activities and reduced toxicity.
An optimized purification approach, that utilized an acid-base treatment of the acetone
extract of the Indonesian sponge Acanthostrongylophora sp., have been used to obtain a 100 g
scale of pure manzamine A and 8-hydroxymanzamine A. Further purification of the more polar
fractions led to the isolation of the known manzamines: manzamine F, 12,34-oxamanzamine E,
31-keto-12,34-oxa-32,33-dihydroircinal A, along with two new manzamine-related analogs,
acantholactone with unprecedented δ-lactone and 2,21,28-trioxomanzamine J.
Twenty manzamine A amides were synthesized through the nitration, reduction and
acylation of C-6 and C-8 of the β-carboline moiety. These analogs were evaluated for in vitro
ii

antimalarial and antimicrobial activities. The amides of MA showed significantly reduced
cytotoxicity against Vero cells, although were less active than MA. Two amides 6cyclohexyamidomanzamine A and 8-n-hexamidomanzamine A showed potent antimalarial
activity in vitro against Plasmodium falciparum and were further evaluated in vivo in
Plasmodium berghei infected mice. Oral administration of these analogs at the dose of 30 mg/kg
(once daily for three days) caused parasitemia suppression of 24% and 62%, respectively, with
no apparent toxicity.
Aminomanzmaines were observed to be unstable in solution and this instability affected
the yield of the amides. This instability inspired the development of a simple and practical
approach for the one-pot conversion of nitroarenes into amide derivatives. HOAc/Zn were
utilized as a reducing agent and acyl chloride/Et3N were used as the acylating agent in DMF with
good yield (~60%) of the amide. This method was applicable to 6-nitromanzamine A, where the
yield of 6-cyclohexamidemanzamine A was significantly improved (56%) by this approach
relative to starting with 6-aminomanzamine A (17%). N-Alkylation of the aminomanzamines
was also problematic because of the instability issue. Utilizing the same reducing system
(HOAc/Zn), a simple, mild, cost effective, and green approach for the reductive mono Nalkylation of nitroarenes was developed. Carbonyl compounds were utilized as the alkyl source
in methanol. Excellent yields were obtained with stoichiometric control of mono over dialkylated
products. In order to show the general applicability of our optimized conditions, five natural
products: harmane, estradiol, quinine, manzamine F and curcudiol were nitrated and modified
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using our green N-alkylation strategy. Our new reductive alkylation conditions were well
tolerated by the nitrated natural products and afforded moderate to excellent yields.
The straightforward oxidation of ircinal A to ircinoic acid inspired utilizing the
decarboxylative cross coupling (DCCC) approach for the replacement of the β-carboline moiety
with other heterocycles. Optimization of the DCCC reaction was completed using (S)-perillic
acid as a model compound; however, failed with ircinoic acid. We then switched to the ircinal
derived triflate and Suzuki coupling approach. Our proposed scheme was based on Birch
reduction of ircinal A followed by an oxidative deformylation that should generate the
corresponding oxo derivative that could be converted to the derived triflate. New and unexpected
sequences of reactions were observed in the Birch reduction of ircinal A under atmospheric air.
A sequential Birch reduction-elimination-oxidative deformylation occurred and yielded the
unexpected ircinal-derived enone. Further optimizations are needed to convert the new enone to
the corresponding triflate.
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CHAPTER I
NEW ONE-POT METHODOLOGIES FOR THE MODIFICATION OR SYNTHESIS OF
ALKALOIDS SCAFFOLDS

Published in Marine Drugs, 2010, 8, 2395-2416.
Authors: Amir E. Wahba and Mark T. Hamann
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Abstract: There are several avenues by which promising bioactive natural products can be
produced in sufficient quantities to enable lead optimization and medicinal chemistry
studies. Total synthesis of natural products is an important, but sometimes difficult,
approach and requires the development of innovative synthetic methodologies to simplify
the synthesis of complex molecules. Various classes of natural product alkaloids are both
common and widely distributed in plants, bacteria, fungi, insects and marine organisms.
This mini-review will discuss the scope, mechanistic insights and enantioselectivity aspects
of selected examples of recently developed one-pot methods that have been published in
2009 for the synthesis of substituted piperidines, quinolizidines, pyrrolidines,
hexahydropyrrolizines, octahydroindolizines, and γ-lactams. In addition, progress on the
synthesis of β-carboline (manzamine) alkaloids will also be discussed.
Keywords: one-pot synthesis; cascade reactions; marine alkaloids; total synthesis;
semisynthesis; organocatalysis
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I.1. Introduction
The challenging task of developing a drug candidate from a natural source to clinical usage
has many obstacles. Toxicity, development of resistance associated with the drug candidate, and
providing a sufficient amount of material needed for preclinical and clinical studies, all represent
major challenges. Although nature has been generous in providing structurally diverse molecules
with varying biological activities, it is not always possible to obtain the required quantities of the
target drug candidate. This lack of material has inspired innovative chemistry that develops new
methodologies, catalysts, and inventive synthetic routes for the synthesis and modification of
natural products.
Our research program has been involved in isolation and optimization process of a number of
marine alkaloids and peptides. Among the most intriguing is manzamine A (1) with impressive
antimalarial activity. A number of chemical stability challenges associated with its chemical
modification require significant attention due to the complexity of the structure. This compound
can be readily isolated from a marine sponge in good yields.1 This inspired the development of
new one-pot synthetic methodologies and conditions which are applicable to 1 and to other
bioactive natural products.
During lead optimization of the manzamine alkaloids, the importance of one-pot methods for
scaling certain drug leads became apparent. One-pot reactions are reactions in which two or
more bond-forming transformations take place under the same reaction conditions without
adding additional reagents or catalysts.2 These reactions have numerous applications in the field
of total synthesis of natural products, particularly in avoiding the costly protection/deprotection
processes and purification of intermediates.2–6 The importance of these reactions to the organic
synthesis community is illustrated by the numerous reviews that have discussed different aspects
3

of these reactions.2-11 Most of these reviews discuss one-pot reactions that were developed during
the total synthesis of selected examples of natural products (either as designed or serendipitous
developments) such as Nicolaou’s4-6 and Tietze’s2,3 reviews. Although outstanding one-pot
transformations designed for total synthesis of natural products were highlighted in these
reviews, other one-pot transformations designed for other purposes were omitted. Synthesis of
heterocycles by one-pot methodologies were discussed in detail in Padwa’s reviews.9,10 Specific
reviews on the construction of alkaloids are not found with the exception of Kobayashi’s review
that discussed new methodologies developed for the total synthesis of some select examples of
alkaloids.11
Owing to the growing interest in marine alkaloids, a detailed discussion of select, newly
developed one-pot methodologies that have been utilized for modification of marine alkaloids or
the synthesis of common alkaloid moieties emphasizing asymmetric synthesis, are presented
here. This mini-review discusses applications, mechanistic insights and enantioselectivity of
recently developed one-pot methods that have been published during 2009. Those reports that
could be applied in the synthesis of marine alkaloid scaffolds (i.e., alkaloid moieties found in
marine alkaloids) are emphasized. This mini-review will also cover our results for manzamine
alkaloids, as well as detailed asymmetric one-pot methods for the synthesis of substituted
piperidines, quinolizidines, pyrrolidines, hexahydropyrrolizines, octahydroindolizines and γlactams.

I.2. New One-Pot Methods Used in the Modification of Marine Alkaloids
One-pot reductive amidation of nitroarenes

4

Manzamine alkaloids are a unique class of compounds that contain a complicated ring system
coupled with a β-carboline moiety (Figure I.1). The first representative of this family is
manzamine A (1), which was first isolated by Higa and co-workers in 1986.11 This class of
alkaloids has shown a wide range of biological activities (antimicrobial, antiparasitic,
cytotoxicity, anti-inflammatory and pesticidal) and has also shown activity against HIV-1 and
AIDS opportunistic infections.12 The most potent activity for the manzamine alkaloids appears to
be against malaria. Manzamine A (1) and its natural analog 8-hydroxymanzamine A (2)
exhibited improved potency against malarial parasites both in vitro and in vivo relative to
chloroquine and artemisinin.13 However, toxicity associated with high dose schedules limited the
development of this class of compounds as new antimalarial drugs.

Figure I.1. Manzamine alkaloids.
Since the mechanism of action of manzamine alkaloids as antimalarial agents is not clear;
several structure activity relationship (SAR) and optimization studies using 1, 2 or 3 as starting
materials have been completed.14-18 Nitration of 1 yielded 6- and 8- nitromanzamines and after
reduction afforded the corresponding aminomanzamines (Scheme I.1). Aminomanzamines are
not stable, making them unsuitable for further amidation and N-alkylation reactions. However,
20 amide analogs were successfully synthesized in low yield.15
5

Scheme I.1. Nitration of manzamine A.
Inspired by the instability of aminomanzamines (7 and 8) and by the low yields of
amidomanzamine derivatives, a one-pot reductive amidation method was developed for the
conversion of nitroarenes to the corresponding amides.19 Reduction of the nitro group generally
requires a protic solvent as a carrier of the hydrogen generated in situ. However, amidation
reactions using acyl chloride require aprotic solvents as well as dry conditions to prevent side
reactions with the solvent. In addition, an amidation reaction using acyl chlorides requires basic
conditions in which the base will neutralize the hydrochloric acid liberated from the reaction as a
by-product. Because of this, a 3o amine base (triethylamine, Et3N) was added in the reduction
step where equimolecular amounts of acetic acid and zinc are used in addition to the acyl
chloride. Once the amine is formed in situ, it immediately reacted with the acyl chloride
facilitated by the tertiary amine. Dimethylformamide (DMF) was shown to be the best choice of
solvent for this reaction (Scheme I.2). Using the optimized conditions, several nitroarenes were
screened for one-pot conversion to amides. All reagents were added at once and complete
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conversion of the starting materials to the corresponding amines and amides was observed with
~60% yield of the amides.

Scheme I.2. Optimized one-pot conditions for the reductive amidation of nitroarenes.
As a validation of this method, a one-pot approach was used for the synthesis of
6-cyclohexamidomanzamine A (9). This amide showed potent antimalarial activity in vitro with
an IC50 of 0.032 µM against the D6 clone of Plasmodium falciparum, and was synthesized from
6-aminomanzamine A (7) through the normal amidation pathway with low yield (17%).15
Starting with 6-nitromanzamine A (5), and using the optimized one-pot reductive amidation
method, the yield of amide 9 was increased to 56% (Scheme I.3). It was surprising that the
reductive amidation of 5 proceeded without the addition of a 3o amine. A reasonable explanation
for this observation is that 5 has two internal 3o amino functionalities which could possibly
facilitate the reductive amidation reaction. To validate this, harmane was nitrated to produce the
closely related model compounds, 6- and 8- nitroharmanes. When optimized one-pot reductive
amidation conditions were applied to nitroharmanes without the addition of Et3N, no amides
were obtained, only aminoharmanes (Scheme I.4, Equation 1); however, by adding Et3N the
amide derivatives of harmane were isolated in good yield (60%) (Scheme I.4, Equation 2). These
experimental results validated the hypothesis regarding the 3o amino capacity of manzamine
alkaloids.
7

Although this method was developed particularly for the modification of manzamine
alkaloids, it has clear utility in the synthesis of other alkaloids. The nitration of several
biologically active natural products, as well as currently utilized drugs to generate the starting
nitro materials for this one-pot reductive amidation method is ongoing. The goal is to show the
general and practical applications for this method, as well as generating a library of compounds
for further optimization and biological evaluation.

Scheme I.3. Synthesis of 6-cyclohexamidomanzamine A (9) by direct and reductive
amidation approaches. Method A: 1.2 equiv. cyclohexylcarbonyl chloride, 1.1 equiv.
Et3N, cat. DMAP, THF, rt, 1 h; Method B: 2 equiv. Zn/4 equiv. HOAc, 2 equiv.
Et3N, 1.2 equiv. cyclohexylcarbonyl chloride, DMF, 40 °C, one-pot.
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Scheme I.4. Validation of the internal 3o amino functionalities in manzamine A
using nitroharmane as a model compounds.
I.3. New One-Pot Reactions Used in the Asymmetric Construction of Some Important
Alkaloid Moieties
I.3.1. One-pot asymmetric synthesis of substituted piperidines
Piperidine containing alkaloids are common in marine environments.20-22 Although there have
been several synthetic methods23-25 reported for construction of this moiety, stereoselectivity
remains a challenging task especially when three or more stereogenic centers or quaternary
substituted carbons are present. The Shi group developed a novel cascade approach for the
stereoselective synthesis of the piperidine moiety, based on their development of an
intermolecular cross-double-Michael addition between α,β-unsaturated carbonyl compounds and
nitroalkenes, facilitated by amines as Lewis bases (LB).26 Allylic nitro products are generated in
the process via β-elimination of LB (Figure I.2). The new cascade reaction encouraged Shi’s
group to extend the cascade by involving an activated electrophilic intermediate for the
construction of nitrogen containing heterocycles with two or more stereogenic centers.
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Figure I.2. Intermolecular cross-double-Michael addition facilitated by amines via β
elimination.
Based on their previous results, which showed that addition of the amine to nitroalkene is fast,
they proposed a one-pot cascade approach for the asymmetric synthesis of the piperidine
moiety.27 They postulated that adduct A (Figure I.3), the addition product of the amine with
nitroalkene, was suitable for Michael addition type reaction with an activated carbonyl to
generate adduct B. Ring closure then provides the substituted piperidine motif in a one-pot
approach with the generation of two stereogenic centers. To validate this proposed one-pot
cascade sequence, nitrostyrene was allowed to react with methyl vinyl ketone (MVK) in the
presence of a primary amine (Scheme I.5). Being a complex mixture with many possible side
reactions (i.e., Baylis-Hillman reaction), it was surprising that substituted piperidines, 13a and
13b, were obtained in excellent yields and good diastereoselectivities with no side products.
Solvent optimization of these one-pot conditions showed that THF gave the best yields with
good diastereoselectivities (97%, dr = 7:1 for 13a; 85%, dr = 15:1 for 13b). Formation of 13
confirmed the formation of adduct B (Figure I.3), which was trapped by a sequential Henry-aldol
cyclization. Although three stereogenic centers were generated in piperidine 13 only two C-4
diastereoisomers were obtained, of which the cis isomer of C-3 nitro and C-4 hydroxy groups
was the major product.
NO2
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R 1 -NH2
f ast equlibrium

R2

O

R 1HN

O

R1

adduct A

N

R2
NO2

adduct B

cyclization O 2N

R 2 OH

N
R1
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Figure I.3. Proposed one-pot cascade piperidine synthesis.

Scheme I.5. Optimized one-pot condensation for the asymmetric synthesis of piperidine moiety.
This one-pot reaction was compatible with a variety of nitroalkenes, amines and activated
carbonyls. Different aryl and alkyl substituted nitroalkenes generated variation at C-2. Moreover,
both alkyl and aryl ketones were suitable for this cascade one-pot process giving different
choices of substituents at C-4. Substituents at C-5 were possible through α-substituted enones,
while β-substituted enones delivered variation at C-6 only when ammonia was used. It is
interesting that only C-4 isomers were obtained in all cases.
The aza-Michael adduct B (Figure I.3) was not observed in their mechanistic studies (using
1

H-NMR); moreover, the piperidine products were stable under strong basic conditions. These

results strongly suggested that the irreversible Henry-aldol cyclization was the rate determining
step, which accounts for the piperidine diastereoselectivity through the chair-like transition state.
With the formation of the C-2 stereogenic center during the amine conjugate addition, it is
possible that the stereochemistry of the final piperidine product could be selectively induced by
chiral amines through its involvement in spatial arrangement of chair-like transition states. In this
case, a new stereogenic center at the exocyclic C-7 will be introduced in the piperidine product,
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which may result in the formation of four diastereoisomers. To investigate this proposed chirality
induction, arylethanamines 14a–c were applied in the one-pot piperidine synthesis and as
expected, piperidines 15a–c were obtained in good yields (Scheme I.6). The results showed
excellent diastereoselectivity at C-4 in 15a and 15b with dr > 10:1. In addition, modest chirality
induction by the C-7 center was observed with dr = 4:1.

Scheme I.6. Chirality induction by chiral amines.
X-ray analysis of the piperidine crystals revealed that exocyclic C-7 adopted a staggered
conformation with respect to the ring. Moreover, the chemical shifts of C-8 and C-9 were
significantly shifted upfield in an anti-parallel position relative to the nitrogen lone pair
electrons. This data suggest that N1-C7 σ-bond rotation was restricted. Based on these results, a
Henry-aldol cyclization chair transition state was proposed in Figure I.4. The N-1 nitrogen lone
pair electrons were placed in the axial position and the preferred staggered N1-C7 conformation
could be achieved when the small group at C-7 was placed anti (axial orientation) to N-1
nitrogen lone pair. Three syn-pentane interactions were expected in this staggered conformation
(as shown in Figure I.4); however, placement of the small group on C-7 anti to the lone pair will
12

minimize these interactions. This proposed transition state was consistent with experimental
observations. Also, stability of this transition state could be influenced by the n-σ* electronic
interaction between the nitrogen lone pair and the exocyclic axial small group.
upfield NMR shift, shielded by N
lone pair

staggered conformation of
N1-C7 bond observed in X-ray

preferred conformation to avoid
the syn-pentane repulsion

Figure I.4. Proposed chair transition state and the exocyclic chirality induction.

To validate the importance of this n-σ* electronic interaction in chirality enhancement,
methyl group in the chiral amine was replaced with a carboxylate group which is less bulky and
would produce a stronger n-σ* interaction. As expected, the reaction of the amino esters 16a, b
with enone 12a and nitroarene 10a yielded the corresponding piperidine products in moderate
yields (Scheme I.7). Interestingly, piperidines 17a, b were obtained in diastereomerically pure
form. Complete chirality induction was achieved through control via exocyclic asymmetry. This
new one-pot method opens the door for the asymmetric synthesis of several natural products that
contain a piperidine moiety.
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Scheme I.7. Enhanced exocyclic stereochemistry control by amino esters.
I.3.2. One-pot organo-catalytic synthesis of quinolizidine derivatives
An elegant one-pot method was recently developed by Franzen and Fisher28 for the
asymmetric synthesis of substituted quinolizidines. This moiety is widely represented in several
alkaloids isolated from plants, ants and marine organisms. Their retrosynthetic analysis for the
indolo[2,3-a]quinolizidine skeleton is shown in Figure I.5. They postulated that the stereogenic
center 12b could be generated through the asymmetric acyliminium ion cyclization of the imine
(19). This imine could be obtained from the aldehyde precursor 20, in which the aldehyde is
apparently the adduct of an enantioselective Michael addition.

14

Figure I.5. Retrosynthetic analysis of the indolo[2,3-a]quinolizidine skeleton.

This retro-analysis required the addition of an activated amide 22 to the unsaturated aldehyde
21, which has not yet been reported. To accomplish their synthetic plan, they optimized the
enantioselective Michael addition of cinnamic aldehyde 23 and an activated indol substituted
amide 22, using different proline derivatives as organocatalysts (Figure I.6), exploring different
solvents, temperatures, as well as various acids needed for the cyclization step of the acyliminium
ion (Scheme I.7). Dichloromethane (DCM) was the solvent of choice and yielded compounds
24a and 24b with full conversion at room temperature, but with low enantioselectivity (88% ee).
Enantioselectivity was increased to 94% by lowering the temperature to 3 °C, while further
cooling (−20 °C) resulted in only 5% conversion. The proline derivative (S)-A showed the best
selectivity, B was less selective and less active, while C and D were inactive for this reaction.
When trifluoroacetic acid (TFA) was used in the acid-catalyzed cyclization of the acyliminium
ion, indoloquinolidine products were obtained nonselectively as a 1:1 mixture. However, some
15

selectivity of 24a over 24b was observed when HCl was used. It was also noted that cooling
down the reaction mixture prior to the addition of HCl increased the selectivity up to 85:15. The
optimized conditions are highlighted in Scheme I.7.

Scheme I.7. Optimized one-pot, two step conditions for the synthesis of indoloquinolizidine
derivatives.

Figure I.6. Organocatalysts used for the optimization of the one-pot conditions.

This one-pot, two step method was applied to several aromatic α,β-unsaturated aldehydes
with good to excellent enantioselectivity. The indolyl moiety of 22 was replaced with an
electron-rich phenyl group, which should give direct access to the benzo[a]quinolizidine
16

skeleton. Reaction between 23 and the activated amide 25, in the presence of the organocatalyst
A, and subsequent addition of HCl, afforded the benzo[a]quinolizidines 26a and 26b with good
to high enantioselectivity (Scheme I.8).

It

was noted that the formation of the

benzo[a]quinolizidine moiety required stronger acidic conditions (40 mol%) relative to the
indolo[2,3-a]quinolizidine (20 mol%). This is explained by the poorer nucleophilicity of the
phenyl ring compared to the 3-indolyl moiety.

Scheme I.8. Optimized one-pot, two step synthesis of benzo[a]quinolizidine.

The absolute configuration of one of the benzo[a]quinolizidine derivatives was established by
X-ray analysis as 2R,3S,11bS, which provided important mechanistic insight (Scheme I.9). The
aryl groups in the catalyst will shield the Re face of the iminium intermediate 27, which will help
to establish S configuration on C-2 through the unshielded Si face. Intramolecular imine formation
with epimerization of the stereochemically labile C-3 stereogenic center will establish the
thermodynamically more stable 2R,3S-trans configuration of the intermediate imine 28. This
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acyliminium ion undergoes an electrophilic aromatic substitution with the aromatic moiety to
give quinolizidine products.

Scheme I.9. Proposed mechanism for the one-pot formation of quinolizidine moiety.

The excellent diastereoselectivity observed in the acid catalyzed cyclization could be
explained based on the reaction conditions. Considering the synthesis of indoloquinolizidines
24a and 24b (Scheme I.7), the major isomer was 24a with the indolyl moiety in an axial
orientation. Although the formation of 24a resembles a higher energy product, reaction via the
transition state I (Scheme I.10) is under kinetic control (−78 °C), owing to less steric hindrance
from the equatorial α−protons relative to the theromodynamic equatorial product.
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Scheme I.10. Kinetic versus thermodynamic product formation in the cyclization of the
acyliminium ion.

As a possible application of this one-pot method in the total synthesis of biologically active
marine alkaloids, the tricyclic core of schulzenine alkaloids could be readily constructed using
Franzen and Fisher’s method (Figure I.8). Schulzenine alkaloids were recently isolated from the
marine sponge Penares schulzei.29 Schulzenines A-C inhibit α-glucosidase with IC50 values of 48–
170 nM. Figure I.9 represents the proposed one-pot reaction that could be used for the synthesis
of the tricyclic core of schulzenine alkaloids.
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Schulzenine A: H-11b is α; R1 = H; R2 = CH3.
Schulzenine B: H-11b is β; R1 = R2 = H.
Schulzenine C: H-11b is α; R1 = R2 = H.

Figure I.8. Schulzenine alkaloids.

Figure I.9. Proposed one-pot synthesis of the tricyclic core of schulzenine alkaloids.
I.3.3. One-pot enantioselective synthesis of pyrrolidine, hexahydropyrrolizine and related
moieties
Recently, organocatalysis has been widely used in asymmetric synthesis due to its operational
simplicity, low toxicity, and ready availability compared to metal catalyzed reactions.30 Maruoka
and coworkers used an organocatalyst of type (S)-34 for one-pot construction of pyrrolidine,
hexahydropyrrolizines,

and

octahydroindolizine

moieties

with

a

high

degree

of

stereoselectivity.31 These core structures are commonly found in plant and marine alkaloids
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(Figure I.10).32,33 Their organocatalytic based retro-synthetic analysis is presented in Scheme
I.11.
.
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C 6H 13

O

Bistellettazole A

Lepadiformine

Figure I.10. Marine alkaloids that possess hexahydropyrrolizine and octahydroindolizine
moieties.
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Scheme I.11. Organocatalytic retro-synthetic approach for the alkaloid core.

The key strategy is based on the asymmetric conjugate addition of the Schiff base of glycine
ester 32 to α,β-unsaturated carbonyl compound 33 catalyzed by chiral phase transfer
organocatalysts (S)-34a–c. Organocatalytic Michael addition of 32 to 33 should give adduct 31
in enantiomerically pure form. This adduct can then undergo intramolecular reductive amination
facilitated by the Hantzsch ester to yield pyrrolidine derivative 30 as an intermediate. Acetal
hydrolysis followed by another intramolecular reductive amination of intermediate 30 will
furnish a bicyclic hexahydropyrrolizine skeleton.
First, asymmetric addition of the glycine derivative 32 to methyl vinyl ketone (MVK), under
the influence of an organocatalyst of type 34 (Scheme I.12), was examined. Optimization of the
reaction between 32 and MVK with K2CO3 and 10 mol% of CsCl at 0 °C gave the conjugate
adduct 35. This revealed that Et2O and the organocatalyst (S)-34b gave the best yield (85%), as
well as the best diastereoselectivity (94% ee). Subsequently, optimization of the intramolecular
reductive amination of 35 with the Hantzsch ester for the synthesis of the substituted pyrrolidine
36 was studied. Optimization of the reaction conditions revealed that the Hantzsch ester (2
22

equiv.) and TFA (1 equiv.) in aqueous EtOH at 60 °C were the best conditions to build up the
2,5-disubstituted cis-pyrrolidine 36 stereospecifically in 84% yield.

Scheme I.12. Optimized conditions for the conjugate addition and intramolecular
amination steps in the synthesis of 2,5-disubstituted cis-pyrrolidine 36.

Next, synthesis of the octahydroindolizine skeleton 39 using their optimized conditions
(Scheme I.13) was performed. Asymmetric conjugate addition of the glycine ester 32 to the
enone 37 (2 equiv.) and K2CO3 (5 equiv.) under the influence of the chiral phase transfer catalyst
(S)-34b and CsCl in Et2O at 0 °C for 15 h gave the conjugate adduct 38 in 88% yield with 94%
ee. Hantzsch ester mediated intramolecular reductive amination with subsequent acetal
hydrolysis, followed by reductive amination, was effective to give the octahydroindolizine core
39 in 70% yield. The reaction sequence was done in a one-pot approach and performed without
any difficulty by sequential addition of the reagents to afford 39 in 48% overall yield.
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Scheme I.13. Synthesis of octahydroindolizine 39.

Hexahydropyrrolizine 42 was also obtained under the same optimized conditions (Scheme
I.14). Asymmetric conjugate addition of 32 to enone 40 yielded adduct 41 in 85% yield with
90% ee. It was noted that enantioselectivity was slightly decreased by switching the cyclic acetal
moiety of 38 to a 1,3-dioxolane (78% yield, 86% ee). The hexahydropyrrolizine skeleton 42 was
then formed in 55% yield by the action of Hantzsch ester mediated intramolecular reductive
amination. A one-pot reaction was also possible with an overall yield of 31%.
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Scheme I.14. Synthesis of hexahydropyrrolizine 42.

I.3.4. One-pot diastereoselective synthesis of γ-lactams

Cycloaddition of imines with succinic anhydride in a one-pot approach to construct the γlactam moiety in high yield was first reported three decades ago by Castagnoli et al.34 (Scheme
I.15, Equation 1). A mechanistic study was not published until 1983 when Cushman studied
electronic and steric effects on the stereochemical outcome.35 A low yield was obtained when
phenyl substituted succinic anhydride was used instead of succinic anhydride (Scheme I.15,
Equation 2). Also, variations in the structure of succinic anhydride were not explored in detail in
this methodology. Owing to the wide abundance of the γ-lactam moiety in natural products and
potential drug leads, the Shaw group has extensively studied the effect of substituents on the
iminolysis of succinic anhydride derivatives. In their first report, Shaw and coworkers
demonstrated the importance of electronic factors on the reactivity of phenylsuccinic anhydride
when reacted with the imines derived from benzaldehyde and o-bromobenzaldehyde,36
demonstrating that electron withdrawing groups in the phenyl ring led to excellent yields (>90%)
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(Scheme I.15, Equation 3). Following this yield improvement, Shaw and coworkers reported that
sulfur-substituted succinic anhydrides also gave excellent yields (90%) and showed the highest
diastereoselectivity (anti diastereoisomer) when reacted with different imines37 (Scheme I.15,
Equation 4).
In the case of the iminolysis of maleic anhydride, a possible zwitterionic enolate intermediate
could be generated through a prototropic shift which provides allylic stabilization. To validate
this, Shaw and coworkers studied the cyclization of several polycyclic imines with maleic
anhydride derivatives (Figure I.11) as a new one-pot synthesis of complex nitrogen
heterocycles.38 Thus, reaction of the imine 45 with maleic anhydride derivative 46 formed
intermediate 47, which could isomerize to 48. Attack at the α- or γ- positions of the dienolate
would lead to products 49a or 49b (Scheme I.16).

Equation 1

Castagnoli et al., 196934

Equation 2

Cushman et al., 198335
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Equation 3

Shaw et al., 200636

Equation 4

Shaw et al., 200737

Scheme I.15. Milestones of the one-pot synthesis of the γ-lactam moiety.

Figure I.11. Imines and substituted maleic anhydrides used by Shaw et al.38
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from α-attack

from γ-attack

Scheme I.16. Possible cycloaddition pathways of imines with maleic anhydrides.

Tetrahydrophthalic anhydride 44b reacted with several imines through path A to give the
formal cycloaddition products with high diastereoselectivity (anti configuration) and acceptable
yields (Scheme I.17, Equation 1 and 2). It was interesting that diastereoselectivity of the reaction
of 44b with 43b was reversed when triethylamine and triethylammonium hydrochloride were
present in the reaction mixture. Methyl and dimethyl-substituted anhydrides did not react with
several imines; however, an exomethylene-substituted lactam was obtained in good yield (59%)
with excellent diastereoselectivity (>95:5 anti:syn) when imine 43b was used (Scheme I.17,
Equation 3). Acyclic imines derived from aromatic aldehydes were less reactive relative to cyclic
imines.
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Equation 1

Equation 2

Equation 3

Scheme I.17. Polycyclic products from the reactions of anhydrides 44b and 44c with different
imines.

Although the 1H-NMR spectrum of the products obtained from reaction of cyclopentane-fused
maleic anhydride 44a with several imines initially appeared to be consistent with the anticipated
adduct, X-ray crystallographic analysis revealed the products to be N,O-acetals (Scheme I.18).
Mixing anhydride 44a with imines 43a and 43b at room temperature yielded an immediate
precipitate of N,O-acetals 53 and 54 in 78% and 71% yields, respectively. No γ-lactams were
produced upon further heating.
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Scheme I.18. Reaction of anhydride 44a with several imines to yield N,O-acetal products.

A completely different reaction manifold was observed in the reaction of ketimine 43c with
the maleic anhydride derivative 44c (Scheme I.19). A new γ-lactam was obtained. The
mechanism of formation of this new product is outlined in Scheme I.19. A prototropic shift of
acylated imine 55 will yield the enamide carboxylic acid 56, which is set up for an
intramolecular Michael-type addition of the enamide to the unsaturated acid to afford a new
lactam 58 through enamide 57.
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Scheme I.19. Mechanism of the formation of γ-lactam 58 obtained from the reaction of ketimine
43c with anhydride 44c.

Anhydrides 44d and 44b reacted similarly with ketimine 43c to produce the new γ-lactams 59
and 60, in yields of 74% and 59%, respectively (Scheme I.20). In case of the spiro γ-lactam 60, a
50:50 mixture of diastereoisomers was obtained after 15 min of reaction time. Continued heating
of 60 under reaction conditions shifted diastereoselectivity to a 70:30 mixture, favoring the anti
isomer. Product 61 was obtained in 72% yield when anhydride 44a was reacted with ketimine
43c. No stereoselectivity was observed in this case.
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Scheme I.20. New γ-lactams obtained from the reaction of ketimine 43c with several
anhydrides.

4. Conclusion
In this mini-review, we have highlighted a number of one-pot asymmetric methodologies
developed for the synthesis of important alkaloid moieties. One-pot reactions are highly practical
and ideal for scaling drug leads to gram scale and greater. Manzamine alkaloids are still inspiring
new chemistry in which one-pot methodologies are being developed and will be discussed in
separate reports. We anticipate a greater application of these methods and similar methodologies
in the field of total synthesis of marine alkaloids and have highlighted a possible route to
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schulzenine alkaloids. Two or more methodologies could be combined to design a complete
synthesis of a particular target. Alkaloid moieties highlighted in this mini-review (i.e., substituted
piperidines, quinolizidines, pyrrolidines, hexahydropyrrolizines, octahydroindolizines and γlactams) are common within the alkaloid family. Although there are many methods for the
synthesis of these moieties, development of one-pot methodologies to obtain high yields with a
high degree of enantioselectivity will provide numerous opportunities for the synthetic
community.
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CHAPTER II.

THE MANZAMINE ALKALOIDS

SECTION A
A SCALABLE PURIFICATION OF MANZAMINE A AND 8-HYDROXYMANZAMINE A
FROM THE INDONESIAN ACANTHOSTRONGLYPHORA SP. SPONGE
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Introduction:
The manzamines are an intriguing group of alkaloids of marine origin (Figure II.1). Their
structures are characterized by a penta- or tetracyclic nitrogen-containing ring system bound to a
β-carboline moiety. Some 80 related compounds have been described from more than a dozen
species of sponges since the first isolation of manzamine A (1) from an Okinawan genus
Haliclona in 1986.12 Manzamines exhibited diverse bioactivities including cytotoxicity,12
fungicidal,1 insecticidal39 and antibacterial40 and were shown to possess activity against HIV-1
and AIDS opportunistic infections.1 Several manzamines were reported to modulate the
generation of peroxide anion (O2-) and TXB2 generated by activated rat neonatal microglia.39,40
Manzamine A (1) was the most potent inhibitor and did not show in vitro toxicity to microglia.

Figure II.1. Manzamine alkaloids

Manzamine A (MA) and some of its analogs were identified as a new class of glycogen
synthase kinase-3 beta (GSK-3β) and cyclin-dependent kinase (CDK-5) inhibitors.41 These two
kinases belong to the cyclic-dependent, mitogen-activated, glycogen synthase and CDK-like
kinases group (CMGC), which is the largest group of kinases in the Plasmodium kinome.42
These two kinases are involved in tau pathological hyperphosphorylation.43 MA was shown to be
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effective in decreasing tau hyper-phosphorylation in human neuroblastoma cell lines, a
demonstration of its ability to enter cells and to interfere with tau pathology.14 Further, MA
shows an interesting and selective binding for human GSK-3β (Figure II.2). All these data
suggest that MA and its analogs could be used as potential therapeutic agents for Alzheimer’s
disease.
Recent studies indicated that the manzamines are extraordinarily active against the malaria
parasite, among which MA is the most potent and shows improved activity over artemisinin and
chloroquine both in vitro and in vivo.44,45 This activity is confirmed by repeated biological
evaluation in our lab and in laboratories in New Zealand, Japan, Australia, and Switzerland by
corporation through a WHO program. Oral treatment with 1 (2x100 µmol/kg) and 2 (2x100
µmol/kg) showed 90% reduction in parasitemia. Mice treated with a single dose (50 or 100
µmol/kg) of 1 or 2 also showed significant improvements in survival times over mice treated
with chloroquine or artemisinin.
Owing to all these promising biological activities, large amounts of MA were required for
further preclinical evaluation, which include efficacy in different animal models, toxicology,
pharmacokinetics, etc. On the other hand, large amounts of MA and its analogs such as 8hydroxymanzamine A (2) , manzamine F (3), and iricinal A (4) are required for the structure
activity relationship study and lead optimization.
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Figure II.2. (Left) Binding mode of MA and selected analogs shown in the activation loop (in
the vicinity surrounded by Arg96, Arg180 and Lys205) of human GSK-3β. Also, the ATP
binding region (pocket on right side of the enzyme) is shown with the key amino acids that make
hinge interactions with ATP-competitive inhibitors, Asp133, Val135 and Arg141. Protein
Connolly surface is shown. (Middle) Close-up view of part of GSK-3β showing MA docked into
the non-ATP-noncompetitive binding site of GSK-3β enzyme (X-ray: 1I09). The red regions on
the protein surface indicate hydrogen bond donors and blue regions indicate hydrogen bond
acceptors. (Right) Polar interactions in a docked conformation of MA in the ATPnoncompetitive binding pocket of GSK-3β (X-ray: 1GNG).
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Figure II.3. Photograph of the Indonesian sponge Acanthostrongylophora sp.
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Results and Discussion:
Large scale preparation of natural products needs additional consideration regarding
efficiency of the extraction method, solvent toxicity, and the economical factor. Although all
organic solvents such as methanol, ethanol, acetone, chloroform or methylene chloride (DCM)
and ethyl acetate could be used in the extraction step, miscible solvents with water are preferred
to avoid extra drying of the sponge material. However, methanol and ethanol extracts usually
have more impurities and are hazardous. Thus, acetone was selected as a suitable solvent for
extraction of manzamine alkaloids from the sponge.
Our collaborators in Gadjah Mada University (GMU) in Indonesia have contributed a great
deal to this project by providing crude extractions containing manzamine alkaloids from the
marine sponge, Acanthostrongylophora sp. (Figure II.3), collected primarily from the Northern
Sulawesi at Manado Bay (Bunaken) in Indonesia. Large quantities of the sponge were collected,
using SCUBA, frozen immediately, extracted with chloroform then acetone and shipped to our
lab to perform the purification.
The crude extract was first subjected to an acid-base process to remove non-alkaloidal
components from alkaloids (Figure II.4). The total alkaloid obtained by this treatment is much
cleaner than the crude extract, which significantly simplified the purification of pure alkaloids.
The total alkaloid content is about 30% (w/w) of the crude extract.
Aluminium oxide is suitable sorbent to separate manzamine alkaloids, particularly for the
separation of MA and 8-hydroxymanzamine A. However, aluminium oxide is more expensive
than silica gel and is denser which means more aluminium oxide will be used. Therefore, silica
gel is more favorable from the economical point of view. TLC eluent optimization revealed that
n-hexane:acetone:Et3N is a good solvent system to separate manzamine analogs on silica gel. To
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verify this method, a batch of 200 grams of total alkaloids were loaded to a 1.5 kg silica gel VLC
column and eluted with the above solvent system. Fractions were monitored by TLC. Promising
separation was achieved and the majority of MA, 8-hydroxymanzamine A, and manzamine F
were collected in >90% purity. A total of 24.4 grams of manzamine A (12%), 19.8 grams of 8hydroxymanzamine A and 17.7 grams of manzamine F were obtained. No pure ircinal A was
obtained under these conditions.
The fractions of MA were purified by crystallization in absolute ethanol which yielded
highly pure MA as a free base which contains one molecule of ethanol in the crystal. MA free
base was transferred to MA hydrochloric salt readily by adding one equivalent of 0.3% HCl in
methanol and then recrystallized from DCM and methanol. Based on our experience, MA HCl
salt is more stable and has higher solubility in water. The additional advantage for making the
salt is that it is much easier to crystallize relative to the free base.
Experimental:
Preparation of the total alkaloids: The crude extract is dissolved in DCM, mixed with
Celite 545 (Fisher Scientific) and allowed to dry under a hood. The dried mixture is packed into
a 5L Buchner funnel and eluted under vacua using 0.2N HCl aqueous solution. The elution is
monitored for precipitate formation by adding a 5% NaHCO3 aqueous solution. Elution is
stopped when precipitation is no longer observed. The eluent is pooled and adjusted to a pH of
8.0 using 5% NaHCO3 solution. The mixture is kept cool until all the precipitate is deposited.
The collected precipitate is filtered and dried affording the total alkaloids as an earthy-like
powder.
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Purification of manzamines: 200 grams of total alkaloids were dissolved in DCM and mixed
with 100 g silica gel and was allowed to complete dryness at room temperature. The resulting
mixture was loaded on a 1.5 kg silica gel VLC. Elution under vacuum starts with nhexane:acetone 90:10 solvent system with 100 mL fractions until MA was visualized by TLC.
Then Et3N was added as well as increasing the polarity of the solvent system as follow: nhexane:acetone:triethylamine 85:15:1, 75:25:1, 60:40,1 then 100% of acetone. Fractions that
contain MA were combined and evaporated under vacuum. The same was done for 2 and 3.
Crystalization of manzamine A: 27 g of MA free base were dissolved in DCM (20 mL) to
which 0.3N HCl (5 mL) in methanol was added slowly. The solution was mixed thoroughly and
was kept at room temperature for 1 h. The solution was then kept overnight in the refrigerator
and the formed crystals were collected by filtration.
1
(+)-Manzamine A (1): [α ]25
D + 102.0 (c 1.09, CHCl3); H- and

13

C-NMR spectra are shown in

Figure III.14. HRESIMS m/z 549.3589 (M+H)+ (calcd for C36H45N4O, 549.3515, ∆ +0.007
mmu). The 1H- and 13C-NMR chemical shifts were within ±1 ppm of the reported values. X-ray
crystal structure is shown in Figure II.5. The diffraction data are illustrated in Table II.1. 1H- and
13

C-NMR spectra are shown in Figure II.6.

(+)-8-Hydroxymanzamine A (24): (24 g); pale yellow crystals obtained from methanol; [α ]25
D +
118.0 (c 1.94, CHCl3); HRESIMS m/z 565.3539 (M + H)+ (calcd for C36H45N4O2 , 565.3464, ∆
+0.007 mmu). The 1H- and 13C-NMR chemical shifts were within ±1 ppm of the reported values.
1
(+)-Manzamine F (2): white crystals obtained from methanol; [α ]25
D + 47.7 (c 0.67,CHCl3); H-

and 13C-NMR spectra are shown in Figures III.16-17. HRESIMS m/z 581.3484 (M + H)+ (calcd
for C36H45N4O3, 581.3413, ∆ + 0.007 mmu). The 1H and 13C chemical shifts were within ±1 ppm
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of the reported values. X-ray crystal structure is shown in Figure II.7. The diffraction data are
illustrated in Table II.3.
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Crude acetone extract
Acid-base

Total alkaloids (30%)
Silica gel VLC (1:10)

I
Ircinal &
Manzamine A

II
Manzamine A

III
8-OH-MA
1 equiv.
HCl in MeOH

1 equiv.
HCl in MeOH
Manzamine A
hydrochloride

IV
Manzamine F

8-OH-Manzamine A
hydrochloride

Recry.

Recry.

High pure
Manzamine A
hydrochloride

High pure
8-OH-MA
hydrochloride

Figure II.4. Large scale purification scheme of manzamine alkaloids from the Indonesian
sponge Acanthostrongylophora sp.
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Figure II.5. ORTEP drawing of manzamine A HCl (1)
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Table II.1. X-ray diffraction data of manzamine A HCl (1)
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N

N
H
OH

H
N
H

N

Figure II.6. 1H- and 13C-NMR spectra of manzamine A (1) in CDCl3 at 400 and 100 MHz,
respectively
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Figure II.7. ORTEP drawing of 8-hydroxymanzamine A HCl (2)
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Table II.2. X-ray diffraction data of 8-hydroxymanzamine A HCl (2)
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Figuer.II.8. ORTEP drawing of manzamine F (3)
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Table II.3. X-ray diffraction data of manzamine F (3)
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CHAPTER II.

THE MANZAMINE ALKALOIDS

SECTION B
TWO NEW MANZAMINE ALKALOIDS FROM THE INDONESIAN
ACANTHOSTRONGLYPHORA SP. SPONGE
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Introduction:
As we discussed in section A of this chapter, we developed an efficient approach for the
production of MA and other manzamine alkaloids that enable kilo gram scale purification. This
approach was based on the acid-base treatment of the acetone extract of the Indonesian sponge
Acanthostrongylophora sp., which precipitated the alkaloids.11 Using this approach and
following the isolation scheme (Scheme II.4, page 42), we purified 100 g of MA. We envisioned
the presence of some minor manzamine-related alkaloids from the fractions that eluted after 8hydroxymanzamine A (using LCMS analysis). Although our major interest was to obtain enough
MA for SAR studies, we felt that purifying the minor metabolites and elucidating their structures
could add value to SAR. Herein, we describe the purification and structure elucidation of two
minor new manzamine-related alkaloids 2 and 3.
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Results and discussion:
The sponge, Acanthostrongylophora sp., was collected from Indonesia and successively
extracted with acetone. The crude acetone extract was subjected first to an acid-base process to
obtain the total alkaloid content. Using the general isolation scheme (Scheme II.4, page 42) and
further purification of the more polar fractions led to the isolation of the known manzamines:
manzamine A (1),12 8-hydroxymanzamine A (4),13 manzamine F,13 12,34-oxamanzamine E (6),45
31-keto-12,34-oxa-32,33-dihydroircinal A (7),58 along with two new manzamine-related analogs,
acantholactone (2) and 2,21,28-trioxomanzamine J (3).
Compound 2 was obtained as a pale yellow powder from DCM, and it was revealed to have a
molecular formula of C36H43N4O4 by HRESIMS (m/z 595.3416 (M+H)+) combined with 1H- and
13

C-NMR data (Table II.4). The 1H-NMR resonances at δ 8.28 (1H, d, J=5.2), 8.04 (1H, d, J=5.2

Hz), 7.73 (1H, d, J=7.5 Hz), 7.17 (1H, t, J=8.0 Hz), and 7.09 (1H, d, J=7.2 Hz) combined with
13

C-NMR resonances at 136.91, 121.70, 116.46, 113.66, and 113.43 confirmed the presence of

an 1,8-disubstituted β-carboline moiety with a hydroxy group at C-8 (144.42). HMBC
correlations of H-11 (δH 6.09, δC 121.44) to C-12 (83.62), C-26 (70.88), C-10 (140.21), and C-24
(43.99) confirmed that the β-carboline moiety is coupled with the typical cyclohexene ring found
in many manzamine alkaloids. The presence of the piperidine ring was confirmed by the HMBC
correlations of H-26 (δH 3.86, δC 70.88) to C-36 (70.75), C-25 (46.76), and C-24 (43.99). The
13

C-NMR resonance at 56.61 (δH 4.69, 3.97) was assigned to C-20 which showed an HMBC

correlations with the other two α-carbons of N-21 (C-22, 60.99; C-36, 70.75) in the piperidine
ring. The presence of the 13-membered ring in the molecule was confirmed by the 1H-1H-COSY
and HMBC correlations of the two olefinic 1H-NMR resonances, H-15 (δH 5.47, δC 131.40) and
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H-16 (δH 5.50, δC 131.80). The unprecedented δ-lactone ring was established based on the
HMBC correlations of H-34 (δC 36.42) methylene resonances at δ 3.04 and 2.90 to C-24 (δH
4.07, 43.99), C-25 (46.76), and C-35 (ester carbonyl) (173.87). The downfield chemical shifts of
C-12 (83.62), C-25 (46.76), C-36 (70.75), and C-26 (70.88) with the HMBC correlations
confirmed the δ-lactone ring to be connected between C-12 and C-26. The

13

C-NMR spectra

showed an additional carbonyl group which was shown to be the amidic carbonyl at C-28 based
on the HMBC correlations of H-26 (δH 3.86, δC 70.88), H-33 (δH 3.80, 3.58; δC 55.78), and H-29
(δH 1.92, 1.67; δC 29.27) to the C-28 carbonyl (179.60). The relative configuration of
acantholactone 2 was deduced from the detailed analysis of the NOESY spectrum. The chairboat conformation of the piperidine and the cyclohexene rings were assigned based on the
NOESY correlations of H-24, H-26 and H22. The new lactone ring was assigned as αorientation relative to the cyclohexene ring based on the NOESY correlations of H-24/H-36. The
clear NOESY corelation between H-20 and H-33 suggested the α-conformation of the lactam
ring.
The absolute configuration of acantholactone (2) was established by comparing the computed
electronic circular dichroism (ECD) spectra with experiment (Figure II.10). As a result of
conformational analysis, six low-energy conformations were generated using the Merck
Molecular Force Field (MMFF) calculations followed by the PM6 semi-empirical optimizations.
The optimized structures were then used for the hybrid density-functional theory (DFT)
calculation at the B3LYP/6-31G(d,p) level for the gas phase and for acetonitrile (using the
Polarizable Continuum Model (PCM)).46 The DFT optimized structures were subsequently used
for the TDDFT excited-state calculations at the BHANDHLYP/TZVP level for the gas phase and
for acetonitrile (PCM). The obtained rotational strengths were Boltzmann averaged and fitted to
54

Gaussian functions with the calculated excitation energies to simulate ECD curves of 2 which
were then overlaid with the experimental ECD spectrum for comparison. Based on the relative
configuration elucidated by the NMR experiments, the absolute configuration of acantholactone
(2) was thus assigned as 12S, 24R, 25R, 26R.

Figure II.9. Computed ECD curve (in acetonitrile) overlaid with the experimental ECD
spectrum of 2.

55

The molecular formula of compound 3 was determined as C36H45N4O4 from HRESIMS (m/z
597.4256 (M+H)+) and NMR analysis. The 1H- &

13

C-NMR spectra of 3 revealed a classical

manzamine skeleton with a substituted β-carboline moiety at C-1 (1H-NMR: 8.18, 1H, d, J=5.4;
7.95, 1H, d, J=8.1; 7.64, 1H, d, J=5.4; 7.40,1H, t, J=8.0; 7.13,1H, t, J=7.9; 7.13, 1H, d, J=8.0.
13

C-NMR: 140.80, 139.39, 139.13, 137.03, 133.53, 129.43, 127.36, 120.76, 118.54, 112.47,

110.41) and a 3o hydroxy group at C-12 (72.99) and was similar to those of N-oxide manzamine
J. The absence of the C-28 methylene resonance in the 13C-NMR and the HMBC correlation of
H-26 (δC 65.66, δH 4.42) to the carbonyl resonance at 174.97 suggested that C-28 was oxidized
to form the amide functionality. 1H-1H COSY and HMBC correlations of the olefinic resonances,
(δΗ 6.33, δC 148.97 ) and (δH 5.85, δC 120.11), as well as the absence of the C-34 methine
resonance in the

13

C-NMR supported the opening of the eight-membered ring. The

13

C-NMR

spectra of compound 3 showed only one oxygenated carbon resonance at 72.99 that was
attributed for C-12 (bearing the 3o hydroxy group) and a carbonyl carbon (C-28, 174.97). Based
on that, the remaining two oxygen atoms (from molecular formula) should be attached to
nitrogen atoms. One oxygen is attached to N-2 of the β-carboline moiety (NMR matches with Noxide manzamine J) and the other oxygen should be attached to N-21. The chemical shifts of C20 (52.27) and C-22 (48.42) are similar to those published for 2,21-dioxomanzamine A.14
Compound 3 was purified from the polar fractions of the total alkaloids extract and was found to
lack the typical fluorescence on Si 60 TLC (365 nm).
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Table II.4. 1H, 13C NMR and 2D data of compound 2 and 3 (δ in ppm, J in Hz)a
Acantholactone (2)b
Position

13

C-NMR

1

2,21,28-trioxomanzamine J (3)c

H-NMR

HMBC

COSY

NOESY

13

C-NMR

1

H-NMR

COSY

140.80 s

-

-

137.03 d

8.18 d, 5.4

4

112.47 d

7.64 d, 5.4

3

1

147.52 s

-

-

-

3

136.91 d

8.28 d, 5.2

3, 4a, 10

4

4

116.46 d

8.04 d, 5.2

3, 4a

3

4a

131.21 s

-

-

-

129.43 s

-

-

4b

130.96 s

-

-

-

133.53 s

-

-

5

113.43 d

7.73 d, 7.5

4b, 6, 7

6

6, 7, 11

120.76 d

7.95 d, 8.1

6

6

121.70 d

7.17 t, 8.0

8a, 8b

5

5, 11, 15, 16

118.54 d

7.13 t, 8

5, 7

7

113.66 d

7.07 d, 7.2

5, 8, 9

6

5, 11, 15, 16

127.36 d

7.40 t, 8

6, 8

8

144.42 s

-

-

-

110.41 d

7.13 d, 7.9

7

8a

121.92 s

-

-

-

139.39 s

-

-

9b

132.23 s

-

-

-

139.13 s

-

-

10

140.21s

-

-

-

144.34 s

-

-

11

121.44 d

6.09, s

-

138.05 d

6.55 s,

-

12

83.62 s

-

10, 12, 24,
26
-

72.99 s

-

-

13

39.15 t

2.94 m, 2.57
m

26

14

42.36 t

3.87 m, 3.51 d,
7.7

13, 14

14

28.70 t

1.91 m, 1.81
m

13, 15

25.01 t

1.73 m, 1.89 m

13, 14,
15

15

131.40 d

5.47, dd, 9.5.
4.8

14, 16

26, 24, 17,
16

131.06 d

5.47 dd, 10.1,
5.1

13, 16

16

131.80 d

5.50 m

15, 17

127.00 d

5.57 m

15, 17

17

25.52 t

16

20.62 t

2.38 m, 2.17 m

16, 18

18

27.46 t

26.85 t

1.49 m, 1.32 m

17, 19

19

23.01 t

23.39 t

1.75 m, 1.43 m

20

56.61 t

1.77 m, 1.65
m
2.47 m, 2.26
m
1.91 m, 174
m
4.69 d, 14,
3.97 m

26, 24, 17,
15
16, 15

52.27 t

2.62 m, 2.52 d,

19, 18

4, 6, 7, 11,
15, 16
3, 6, 7, 11

3, 4, 5, 6, 7,
24, 26

14, 16

16, 17a

20a, 19
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19, 20

9.7, 2

a

21

-

-

-

-

-

-

-

22

60.99 t

36, 23, 20

23

48.42 t

2.78 m, 1.97 m

22, 23

23

30.54 t

4.55 m, 3.57
m
2.17 m, 1.51
m

24

22,24

32.59 t

2.28 dd, 11.2,
6.0, 1.60 m

22, 24

24

43.99 d

4.07, d, 4.1

23

39.60 d

2.28 m

23

25

46.76 s

-

12, 22, 25,
26
-

-

46.06 s

-

-

26

70.88 d

3.86, s

-

65.66 d

4.42 d, 16.1

-

28

179.60 s

-

12, 13, 24,
33, 36
-

-

174.97

-

-

29

29.27 t

33.08 t

2.21 m, 1.59 m

29, 30

30

24.04 t

22.83 t

1.87 m, 1.47 m

31

31

26.10 t

21.61 t

2.37 m, 2.17 m

31, 32

32

23.60 t

148.97 d

6.33 m

33

55.78 t

120.11 d

36.42 t

29.84 t

5.85 dd, 10.1,
5.1
1.43 m, 1.32 m

31, 32,
33
32, 34

34
35

173.87 s

1.92 m, 1.67
m
1.87 m, 1.64
m
1.76 m, 1.62
m
1.91 m, 1.74
m
3.80 d,12 ,
3.58 m
3.04 d, 18,
2.90 d, 18
-

36

70.75 t

3.77 m, 3.49
m

34, 16, 15,
11

28

26, 28, 32

32

24, 26, 35

-

-

-

41.43 t

2.17 m, 1.94 m

34

12, 22, 25,
26,34

36

64.53 t

2.68 m, 2.05 d,
10.7

-

26, 24

33, 25

400 MHz for 1H and 100 MHz for 13C-NMR. Carbon multiplicities were determined by DEPT

experiments. s=C, d=CH, t=CH2. b NMR obtained in d6-acetone. c NMR obtained in CDCl3.
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Experimental:
Fractions (98-120) collected from the large scale purification of MA (Scheme II.4, page 42),
that came after the elution of manzamine F, were combined and subjected to a Si gel vacuum
liquid chromatography and eluted in order with n-hexane:acetone:Et3N 85:15:1, 75:25:1, 60:40,1
then 100% of acetone. The column was then washed with methanol and the 100% acetone
fraction was combined with the methanol washing fraction. Further purification was carried out
on a Phenomenex Luna C8 250x10 mm, 5µm Luna reverse-phase HPLC column using gradient
MeOH (0.1% TFA)/water (0.1% TFA) with flow rate of 6 mL/min to gave acantholactone (2)
and compound 3
Acantholactone (2): 4 mg; yellow powder (DCM); [α ]25
31.6 (c 0.045, MeOH); UV
D
(MeOH) λmax 352, 292, 255, 234 nm; CD (CH3CN) λmax 306 nm (∆ε +0.0084), 274 nm (∆ε 0.0047), 244 nm (∆ε -0.0065), 230 nm (∆ε -0.0075); NMR data, see Table II.4.; HRESIMS m/z
595.3416 (calcd for C36H43N4O4, (M+H)+, 595.3498).
2,21,28-trioxomanzamine J (3): 5 mg; [α ]25
D 16.2 (c 0.025, MeOH); UV (MeOH) λmax 346,
292, 230 nm; NMR data, see Table II.4.; HRESIMS m/z 597.4256 (calcd for C36H45N4O4,
(M+H)+, 597.4265).
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Figure II.11. 13C-NMR spectra of acantholactone (2) in d6-acetone at 400 MHz.
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Figure II.12. 135DEPT-NMR spectra of acantholactone (2) in d6-acetone at 400 MHz.
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Figure II.13. 1H-1H COSY experiment of acantholactone (2) in d6-acetone at 400 MHz.
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Figure II.14. HMQC experiment of acantholactone (2) in d6-acetone at 400 MHz.
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Figure II.15. HMBC experiment of acantholactone (2) in d6-acetone at 400 MHz.
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Figure II.16. NOESY experiment of acantholactone (2) in d4-methanol at 400 MHz.
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Figure II.17. Key 2D-correlations of acantholactone (2).
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Figure II.18. 3D structure of the most stable conformer of acantholactone (2) with the key
NOESY correlations and the distance between the hydrogen atoms.
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Figure II.19. 1H-NMR spectra of compound 3 in CDCl3 at 400 MHz.
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Figure II.20. 13C-NMR spectra of compound 3 in CDCl3 at 400 MHz.
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Figure II.21. 135DEPT-NMR spectra of compound 3 in CDCl3 at 400 MHz.
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Figure II.22. HMQC experiment of compound 3 in CDCl3 at 400 MHz.
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Figure II.23. 1H-1H COSY experiment of compound 3 in CDCl3 at 400 MHz.
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THE MANZAMINE ALKALOIDS

SECTION C
STRUCTURE ACTIVITY RELATIONSHIP STUDIES OF MANZAMINE A:
AMIDATION OF POSITIONS 6 AND 8 OF THE β-CARBOLINE MOIETY

Published in Bioorganic and Medicinal Chemistry, 2009, 17, 7775-7782.
Authors: Amir E. Wahba, Jiangnan Peng, Sucheta Kudrimoti, Babu L. Tekwani,
and Mark T. Hamann.
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ABSTRACT: Twenty manzamine amides were synthesized and evaluated for in vitro
antimalarial and antimicrobial activities. The amides of manzamine A (1) showed significantly
reduced cytotoxicity against Vero cells, although were less active than 1. The structure activity
analysis showed that linear, short alkyl groups adjacent to the amide carbonyl at position 8 are
favored for antimalarial activity, while bulky and cyclic groups at position 6 provided the most
active amides. Most of the amides showed potent activity against Mycobacterium intracellulare.
The antimicrobial activity profile for position 8 series was similar to that for the antimalarial
activity profile, in which linear, slightly short alkyl groups adjacent to the amide carbonyl
showed improved activity. Two amides 14 and 21, which showed potent antimalarial activity in
vitro against Plasmodium falciparum were further evaluated in vivo in Plasmodium berghei
infected mice. Oral administration of 14 and 21 at the dose of 30 mg/kg (once daily for three
days) caused parasitemia suppression of 24% and 62%, respectively, with no apparent toxicity.
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Introduction:
By the time resistance to chloroquine has spread around the world, the era of inexpensive
and available antimalarial drugs had ended.47 This in addition to the fact that artemisinins are the
only first-line antimalarial drugs that are still effective against all chloroquine-resistance malaria
parasites has driven the scientific community and funding agencies to invest additional time and
resources for the development of new antimalarial drugs. Malaria still causes more than one
million deaths every year.48 The process of drug discovery includes three major stages: 1) Target
identification and high throughput screening of small molecules 2) lead identification and
optimization, and 3) preclinical and clinical studies.49 Nature has served as the mine for
structurally diverse small molecules utilized for target identification for human diseases. Over
63% of small molecules reported between 1981 and 2006 are either natural, natural product
derived or inspired from natural compounds.49 Manzamine alkaloids (Figure II.24) represents a
unique class of natural products that have shown a diverse range of bioactivities, including
antimicrobial,

40,50,51,52

antiparasitic,44 cytotoxicity,12,53 antiinflammatory,54,55 pesticidial,39 and

was shown to possess activity against HIV-1 and AIDS opportunistic infections.56 They are
particularly attractive candidates for optimization for the control of infectious diseases.57 The
first representative of this family is manzamine A (1) isolated in 1986 by Higa.12 This family has
the unique structural feature of having complex polycyclic ring systems coupled with a βcarboline moiety. Manzamine A (1) and its 8-hydroxy derivative (2), showed the most promising
antimalarial activity within this class of compounds. Both showed improved potency against
malaria parasite in vitro and in vivo over the clinically used drugs chloroquine and artemisinin.57
Oral treatment of 1 (2x100 µmol/kg) and 2 (2x100 µmol/kg) showed 90% reduction in
parasitemia. Mice treated with a single dose (50 or 100 µmol/kg) of 1 or 2 also showed
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significant improvements in survival times over mice treated with chloroquine or artemisinin.44,45
This data revealed significant promise for the development of this new class of antimalarial
drugs. However, the major drawback of this class of compounds is toxicity associated with
higher dosing schedules. The mechanism of action of 1 as an antimalarial agent is not clear and
requires intensive SAR studies for a better understanding of the importance of each moiety of
this complex molecule for the antimalarial activity. The first intensive SAR study on manzamine
alkaloids was completed by our group and focused on exploring the different functional groups
around the molecule.14 This included reduction of the double bonds at the complex polycyclic
ring systems, N-oxidation, 9-N-alkylation, 8-O-alkylation in 2 and reduction of the carbonyl
group in manzamine F (3). In addition, ircinal (4) was coupled with substituted tryptamines
through Pictet-Spengler cyclization. Several analogs were synthesized in this study with good
antimalarial activity but without improvement in regard to cytotoxicity. Experimental evidence
that manzamines arrest the cell cycle in the S phase suggests that this toxicity may be due to
DNA intercalation by the planar β-carboline moiety. However, no significant modifications of
the β-carboline moiety were completed until this study.

Figure II.24. Manzamine alkaloids.
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In this study, we focused our modification on the β-carboline moiety of 1 as an extension
to the previous study for lead optimization as antimalarial agent. Twenty amides of 1 which
differ at C-6 and C-8 in the β-carboline moiety have been synthesized. These amides were
evaluated for in vitro and in vivo antimalarial activity in addition to in vitro antimicrobial
activity.

Results and discussion:
Chemistry:
Manzamine A (1) in addition to 2, 3, and 4 were purified from the Indonesian sponge
Acanthostrongylophora Sp. through an optimized isolation procedure.1 C-6 and C-8 of the βcarboline moiety in 1 could be chemically modified via electrophilic aromatic substitution
reactions, due to the activation by the secondary amine functionality in the indole part of the βcarboline moiety. We began our modifications by nitrating the benzene ring of the β-carboline
moiety with NaNO2 in the presence of TFA (Scheme II.1). This yielded two nitro products, 6nitromanzamine A (3-a), and 8-nitromanzamine A (3-b). Stability of these two nitromanzamine
A products, and the feasibility of converting the nitro group into different functional groups were
the main reasons for selecting nitromanzamines as a key intermediates for synthesizing C-6 and
C-8 analogs. Large-scale nitration of 1 and purification of the nitro products 3a,b were carried
out to provide starting material for additional analogs. Both nitro products were reduced to the
corresponding 6- and 8-aminomanzamine A (4a,b) in almost complete conversion (by LCMS).
However, low yields of amines were recovered owing to their instability, even as a hydrochloric
salts. In addition, aminomanzamines were unstable in solution, especially in the presence of
chloroform or dichloromethane. This lack of stability created challenges in regard to yields of the
amidation reaction. Adding to the challenge is the conjugation with the remaining two nitrogens
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of the β-carboline which appears to produce a highly basic amine after reduction of the nitro
group.

46%

43%

Scheme II.1. Nitration of manzamine A.
Amidation of aminomanzamines at C-6 and C-8 was carried out by reacting the amines
with a slight excess of different acyl chlorides in the presence of the catalyst DMAP, and the
base triethylamine at room temperature in dry THF under nitrogen atmosphere (Scheme II.2).
Twenty amides were synthesized with yields ranging between ~12-17% (Table II.5). The
structures of amidomanzamine A derivatives were confirmed by 1D & 2D-NMR spectroscopy.
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(3 a,b)

(4 a,b)

(5-24)

Reagents and conditions (a) Zn, HOAc/MeOH (5 %), rt, 10 min. (b) 1 equiv. (0.1M in MeOH) HCl. (c)
1.2 eqvui. RCOCl, 1 equiv. Et3N, cat. DMAP, THF, rt, 1 h.

Scheme II.2. General procedure for amidation of manzamine
In vitro Antimalarial activity:

All amides were evaluated in vitro for antimalarial activity against chloroquine sensitive (D6,
Sierra Leone) and resistant (W2, IndoChina) clones of Plasmodium falciparum. In addition they
were tested for cytotoxicity on normal African green monkey kidney fibroblast cells (Vero)
(Table II.6). Manzamine A (1) showed the highest activity with an IC50 of 8.0 nM (D6 clone) and
11 nM (W2 clone). This activity is more potent than the standard antimalarials chloroquine and
artemisinin (IC50 values of 50 and 46 nM, respectively, against the D6 clone). Manzamine A (1)
has a TC50 of 365 nM against Vero cells, providing therapeutic indexes of 44 (D6 clone) and 25
(W2 clone).45 All amides showed similar antimalarial activity against D6 and W2 clones of P.
falciparum. Introduction of acetamido functionality at C-8 (15) reduced the antimalarial activity
to an IC50 of 182 nM against D6 clone. Increasing the length of the alkyl group adjacent to the
amide carbonyl (2, 3, 4, 5 and 7 carbons) (16, 17, 19, 21 and 22) in C-8 series showed
improvement in in vitro antimalarial activity with IC50 values of 123, 35, 53, 32, and 55 nM,
respectively, against D6 clone. Branched alkyl groups adjacent to the amide carbonyl were not
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favored at C-8. For example, 8-isobutamidomanzamine A (18) showed reduced activity with IC50
values of 158 and 205 nM, against D6 and W2 clones, respectively. This is relative to 8-nbutamidomanzamine A (17, 35 nM against D6), which has the same number of carbon atoms as
an acyclic group. Similar results were obtained when adding bulkier groups such as t-butyl either
directly attached to the amide carbonyl (20, IC50=170 & 232 nM against D6 and W2 clones,
respectively) or separated by one carbon as in 8-t-butylacetamidomanzamine A (23, IC50=139 &
127 nM against D6 and W2 clones, respectively). Furthermore, adding a cyclohexyl group as in
8-cyclohexamidomanzamine A (24) markedly diminished antimalarial activity (IC50=950 & 995
nM against D6 and W2 clones, respectively). This data suggests that relatively short linear alkyl
groups (2-7 carbons) attached to the amide carbonyl at C-8 are preferred over branched and
bulky groups for antimalarial activity.
Antimalarial activity profile for C-6 amides was opposite to that of C-8 amides.
Acetamido group at C-6 drastically eliminated antimalarial activity (5, IC50=1288 & 1982 nM
against D6 and W2 clones, respectively). Increasing the number of carbons attached to the amide
carbonyl (2, 3, 4, 5 and 7 carbons) 6, 7, 9, 11, and 12 also resulted in similar reduction in the
antimalarial activity with IC50 values of 1162, 1152, 1235, 680 and 696 nM against D6,
respectively. The amide with an isopropyl group attached to the amide carbonyl 8 also showed
reduced antimalarial activity (IC50s of 1105 & 1547 nM against D6 and W2 clones, respectively).
Addition of a t-butyl group at C-6 slightly improved the activity as in 6-pivalamidomanzamine A
(10) and 6-t-butylacetamidomanzamine A (13) with IC50 values of 231 and 211 nM against D6,
compared to the linear alkyl groups. 6-Cyclohexamidomanzamine A (14) showed the best
antimalarial activity among the C-6 amides with an IC50=34 nM against D6 clone. This data
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suggests that bulky groups at C-6 are preferred for antimalarial activity. It was interesting to note
that all the amides did not show cytotoxicity to Vero cells.
In vivo Antimalarial activity:
With the objective of finding the analogs with reduced toxicity and equivalent or better
antimalarial activity relative to manzamine A, the two most potent amides, 6cyclohexamidomanzamine A (14, IC50 = 34 nM) and 8-n-hexamidomanzamine A (21, IC50 = 32
nM) were evaluated in vivo in a Plasmodium berghei mouse malaria model. Treatment with
compounds 14 and 21 through oral administration caused only moderate suppression in
parasitemia of 24% and 62%, respectively, at three doses (once daily for three days) of 30 mg/kg
with no apparent toxicity. These results indicated that the amides 14 and 21 were less toxic in
vivo; however, their antimalarial potency in vivo was also compromised, as compared to
manzamine A.
In vitro Antimicrobial activity:
In vitro antimicrobial activities of amidomanzamines were investigated against Candida
albicans, E. coli, Pseudomonas aeruginosa, Cryptococcus neoformans, Mycobacterium
intracellulare and Aspergillus fumigatus (Table II.7).
1) Bioactivity against M. intracellulare:
Manzamine A (1) showed potent activity against M. intracellulare with an IC50 value of 0.64
µM which is slightly more potent than ciprofloxacin, (IC50=1.06 µM). Amides at C- 6 with linear
alkyl groups (5, 6, 7, 9 and 11) showed significantly reduced activity against M. intracellulare
with IC50 values of 9.91 5.65, 4.74, 2.32 and 15.12 µM, respectively. Similar results were
obtained when adding branched acyclic alkyl groups such as isopropyl (8, IC50 = 3.16 µM). 6Cyclohexamidomanzamine A (14) and 6-pivalamidomanzamine A (10) showed improved
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activities within the C-6 amides with IC50 values of 1.26 and 1.54 µM, respectively. These
results indicate that amidation at C-6 is not favorable for activity against M. intracellulare. C-8
analogs showed better antimycobacterial potency compared to C-6 amides. The amide with
acetamido (15) and propamido (16) groups at C-8 showed moderate activities with an IC50’s of
1.65 and 1.52 µM, respectively. 8-n-Butamidomanzamine A (17), 8-isobutamidomanzamine A
(18) and 8-n-pentamidomanzamine A (19) showed activities close to manzamine A (1) and the
control with IC50 values of 0.87, 1.03 and 0.70 µM, respectively, while 8-n-octamidomanzamine
A (22) was slightly more potent than manzamine (IC50=0.51 µM). 8-n-Hexamidomanzamine A
(21) was the most potent amide with an IC50 of 0.03 µM, which is one order of magnitude more
potent than the control as well as 1. Marked loss of activity in 8-cyclohexamidomanzamine A
(24, IC50=11.14 µM) suggested that linear acyclic alkyl groups as amide functionality at C-8 are
more favorable than bulkier groups, which is similar to the activity profile for antimalarial
activity.
2) Bioactivity against Cryptococcus neoformans:
All the amides were screened for anticryptococcal activity against Cryptococcus neoformans.
The amides were either not active (5-13 and 24) or showed lower activity compared to 1
(IC50=1.85 µM). All amides were not active against Candida albicans, E. coli and P.
aeruginosa.
Conclusion:
In conclusion, 20 manzamine amides 5-24 have been synthesized and were screened in
vitro for antimalarial and antibacterial activities. Amidation at C-6 and C-8 was a good choice
for eliminating toxicity associated with manzamine A, since all amides (5-24) did not show
cytotoxicities on Vero cells. In general, the amides were less active than 1. Some amides such as
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(14, 17 and 21) showed the best antimalarial activities among the amide series with IC50 values
of 34, 34, and 32 nM against Plasmodium falciparum, respectively. Our structure activity
relationship study showed that linear, short alkyl groups adjacent to the amide carbonyl at C-8
are favored for antimalarial activity, while bulky and cyclic groups at C-6 appear to be the best
choice for achieving better activity. Two of the most active amides, 14 and 21, were evaluated in
vivo in a Plasmodium berghei mouse malaria model. Oral administration of 14 and 21 at the
dose of 30 mg/kg (once daily for three days) caused parasitemia suppression of 24% and 62%,
respectively, with no apparent toxicity.
Most of the amides showed potent activity against M. intracellulare. The activity profile
for the C-8 series was similar to that for the antimalarial activity profile, in which linear, slightly
short alkyl groups adjacent to the amide carbonyl showed improved activity. 8-nHexamidomanzamine A (21) was the most potent amide with an IC50 of 0.03 µΜ which is one
order of magnitude more potent than the control. The potency of 21 against M. intracellulare
will encourage us to continue investigating this amide in animals. C-6 analogs 5-14 were less
potent than those at C-8 against M. intracellulare. 6-Cyclohexamidomanzamine A (14) and 10
showed improved activities within C-6 series with an IC50 of 1.48 and 1.31 µM, respectively,
which was similar to the activity profile of antimalarial activity for C-6 amides.
Experimental section:
General Experimental Procedures. The 1H- and 13C-NMR spectra were recorded in CDCl3 or
d6-acetone on a Bruker DRX NMR spectrometer operating at 400 MHz for 1H and 100 MHz for
13

C. Chemical shift (δ) values are expressed in parts per million (ppm) and are referenced to the

residual solvent signals of CDCl3 or d6-acetone. UV and IR spectra were respectively obtained
using a Perkin-Elmer Lambda 3B UV/VIS spectrophotometer and an AATI Mattson Genesis
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series FTIR instrument. Optical rotations were measured with a JASCO DIP-310 digital
polarimeter. The high resolution ESI-MS spectra were measured using a Bruker Daltonic
(GmbH, Germany) micro-TOF series with electrospray ionization. TLC analysis was carried out
on precoated silica gel G254 aluminum plates.
Nitration of manzamine A: manzamine A (1) (5 g, 9.12 mmol) was dissolved in TFA (133 ml.
1.79 mmol), and kept at 0 oC with stirring for 30 minutes. Sodium nitrite (1 g, 14.5 mmol) was
added in one portion and allowed to stir at 0 oC for an additional 3 hours. The reaction mixture
was poured into water and neutralized by ammonium hydroxide producing a precipitate that was
filtered and dried. The crude nitro products of manzamine A (4.50 g) were loaded onto a column
packed with 450 g of silica gel. 6-Nitromanzamine A (3a) eluted first using 99:1 DCM:MeOH
followed by 8-nitromanzamine A (3b) after the mobile phase polarity was increased with 95:5
DCM:MeOH.
6-Nitromanzamine A (3a): (2.50 g, 46%); yellow powder; 1H-NMR (CDCl3) δ 9.04 (1H, d,
J=2.0 Hz), 8.50 (1H, d, J=5.2 Hz) , 8.40 (1H, dd, J=9.2, 2.0 Hz), 7.89 (1H, d, J=5.2 Hz), 7.77
(1H, d, J=9.2 Hz), 6.50 (1H, s), 6.21 (1H, s), 5.62 (m), 5.42 (1H, t, J=10.8 Hz), 4.70 (br), 3.69
(s), 3.25 (1H, t, J=11.0 Hz), 2.93 (1H, d, J=9.0 Hz), 2.80~2.20 (m), 2.10~1.20 (m); 13C-NMR
(CDCl3) δ 144.5,144.2, 142.7, 141.2, 141.1, 139.4, 135.7, 134.5, 133.2, 129.7, 127.0, 123.7,
123.5, 121.0, 118.4, 114.2, 112.9, 77.9, 71.2, 70.5, 57.6, 53.7 (2C), 49.4, 47.1, 44.9, 40.8, 39.5,
33.9, 28.7, 26.6, 26.6, 25.2, 24.8, 24.3, 20.9; HRESIMS m/z calcd for C36H44N5O3 (M+H)+
594.3444, found 594.3439.
8-Nitromanzamine A (3b): (2.35 g, 43%) yellow powder; 1H-NMR (CDCl3) δ 10.40 (1H, s),
8.57 (1H, d, J=5.2 Hz), 8.48 (1H, d, J=8.0 Hz), 8.45 (1H, d, J=8.1 Hz), 7.87 (1H, d, J=5.2 Hz),
7.40 (1H, t, J=8.0 Hz), 6.45 (1H, s), 5.96 (1H, m), 5.69 (1H, m), 5.55 (1H, m), 5.32 (1H, t,
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J=10.0 Hz), 4.27 (1H, br), 3.58 (1H, s), 3.11 (1H, m), 2.61 (m), 2.50~1.6 (m), 1.4 (m); 13C-NMR
(CDCl3) δ 144.6, 1443.6, 142.7, 141.4, 141.2, 139.4, 135.3, 134.6, 133.2, 130.0, 127.1, 123.8,
123.7, 121.1, 118.5, 114.4, 113.0, 77.8, 71.2, 70.6, 57.7, 53.7, 53.72, 53.68, 49.5, 47.1, 44.8,
40.5, 39.8, 34.1, 28.8, 26.7, 26.6, 25.3, 24.9, 24.3, 21.0; HRESIMS m/z calcd for C36H44N5O3
(M+H)+ 594.3444, found 594.3439.
Reduction of nitromanzamines: 6-nitromanzamine A (3) or 8-nitromanzamine A (4) (118.6
mg, 0.21 mmol) were dissolved in methanol (5 mL). Zinc (50.0 mg) and 5% acetic acid in
methanol (5 mL) were added to the nitromanzamines solution, and the reaction mixture was
stirred for 10 min at room temperature. After complete conversion of the nitro products into the
corresponding amine (monitored by TLC), conc. HCl was added drop wise till no further
precipitate was formed. The precipitate was collected by filtration and used for the following
reactions without further purification.
General preparation of the amide products. 6-Aminomanzamine A or 8-aminomanzamine A
(100 mg, 0.17 mmol) and catalytic amount of DMAP were dissolved in anhydrous THF (3 mL)
under nitrogen atmosphere. Et3N (25 µL, 0.17 mmol) was then added, and the mixture was
stirred at room temperature for 10 minutes. The desired acid chloride was added in excess, and
the reaction mixture was stirred for 1 h. The completion of the reaction was monitored by TLC,
then the reaction was quenched with water, and the product(s) were extracted by DCM (3x10
mL). The organic layer was dried over anhydrous sodium sulfate, and then evaporated under
reduced pressure. The crude amide derivatives were first purified by silica column
chromatography using n-hexane:acetone (9:1). Further purification was carried out on a
Phenomenex Luna C8 250x10 mm, 5µm Luna reverse-phase HPLC column using gradient
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CH3CN (0.1% TFA)/water (0.1% TFA) with flow rate of 6 mL/min to gave the pure amide
derivative.
6-Acetamidomanzamine A (5): (15 mg, 14%); [α ]25
D 12.9 (c 0.11, MeOH); UV λmax (MeOH)
260, 310, 375 nm; IR: 3232 (br), 2935, 2580, 1978, 1703, 1665,1538, 1470, 1437, 1365, 1290,
1178, 1130, 1018 cm-1; 1H-NMR (CDCl3) δ 11.32 (1H, s), 8.65 (1H, s), 8.50 (1H, s), 8.32 (1H, d,
J=7.6 Hz), 7.79 (1H, d, J=7.5 Hz), 7.66 (1H, d, J=7.6 Hz), 7.36 (1H, d, J=7.6 Hz), 6.64 (1H, s),
6.28 (1H, m), 5.57 (1H, m), 5.42 (1H, t, J=4.0 Hz), 4.96 (1H, t, J=8.1 Hz), 4.04 (1H, dd, J=16.1,
8.0 Hz), 3.7 (1H, s), 3.37 (1H, t, J=12.1 Hz), 3.04 (1H, d, J=8.1 Hz), 2.95 (m), 2.77 (m), 2.61
(m), 2.43 (m), 2.31 (m), 2.26 (m) 2.08 (s), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m);

13

C-NMR

(CDCl3) δ 175.04, 166.03, 143.57, 142.05, 141.99, 138.60, 135.78, 134.48, 133.85, 133.42,
130.20, 128.08, 125.35, 122.38, 122.12, 114.63, 112.93, 77.85, 71.70, 70.50, 57.09, 53.49, 49.32,
47.07, 44.82, 31.21, 39.16, 33.62, 28.45, 26.52, 26.36, 24.99, 24.58, 24.32, 23.97, 20.73;
HRESIMS m/z calcd for C38H49N5O2 (M+H)+ 606.3743, found 606.3784.
1
6-n-Propamidomanzamine A (6): (16 mg, 14%); [α ]25
D 17.1 (c 0.15, MeOH); H-NMR (CDCl3)

δ 11.33 (1H, s), 8.66 (1H, s), 8.50 (1H, s), 8.31 (1H, d, J=7.6 Hz), 7.80 (1H, d, J=7.5 Hz), 7.67
(1H, d, J=7.6 Hz), 7.35 (1H, d, J=7.6 Hz), 6.64 (1H, s), 6.29 (1H, m), 5.56 (1H, m), 5.43 (1H, t,
J=4.2 Hz), 4.96 (1H, t, J=8.0 Hz), 4.04 (1H, dd, J=16.1, 8.0 Hz), 3.69 (1H, s), 3.37 (1H, t,
J=12.1 Hz), 3.04 (1H, d, J=8.0 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.41 (2H, q, J=7.2
Hz), 2.31 (m), 2.26 (m), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m), 1.14 (3H, t, J=7.2 Hz); 13C-NMR
(CDCl3) δ 175.04, 166.03, 143.57, 142.05, 141.99, 138.60, 135.78, 134.48, 133.85, 133.42,
130.20, 128.08, 125.35, 122.38, 122.12, 114.63, 112.93, 77.85, 71.70, 70.50, 57.09, 53.49, 49.32,
47.07, 44.82, 31.21, 39.16, 33.62, 30.36, 28.45, 26.52, 26.36, 24.99, 24.58, 24.32, 20.73, 9.86;
HRESIMS m/z calcd for C39H50N5O2 (M+H)+ 620.3936, found 620.3942.
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1
6-n-Butamidomanzamine A (7): (16 mg, 14%); [α ]25
D 11.9 (c 0.11, MeOH); H-NMR (CDCl3)

δ 11.25 (1H, s), 8.70 (1H, s), 8.50 (1H, s), 8.30 (1H, d, J=7.6 Hz), 7.75 (1H, d, J=7.5 Hz), 7.66
(1H, d, J=7.6 Hz), 7.36 (1H, d, J=7.6 Hz), 6.62 (1H, s), 6.25 (1H, m), 5.54 (1H, m), 5.39 (1H, t,
J=4.0 Hz), 4.92 (1H, t, J=8.0 Hz), 4.00 (1H, dd, J=16.1, 8.0 Hz), 3.66 (1H, s), 3.37 (1H, t,
J=12.0 Hz), 3.04 (1H, d, J=8.1 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.37 (2H, t, J=7.0
Hz), 2.31 (m), 2.26 (m), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m), 1.00 (3H, t, J=7.1 Hz); 13C-NMR
(CDCl3) δ 171.45, 166.03, 143.69, 141.99, 141.16, 138.32, 137.62, 134.48, 133.85, 133.42,
130.20, 128.08, 125.35, 122.38, 122.12, 114.63, 112.93, 77.85, 71.70, 70.50, 57.09, 53.49, 49.32,
47.07, 44.82, 40.09, 31.21, 39.16, 33.62, 30.36, 26.52, 26.36, 24.99, 24.58, 24.32, 20.73, 19.72,
14.52; HRESIMS m/z calcd for C40H52N5O2 (M+H)+ 634.4129, found 634.4425.
1
6-Isobutamidomanzamine A (8): (14 mg, 12%); [α ]25
D 20.5 (c 0.21, MeOH); H-NMR (CDCl3)

δ 11.41 (1H, s), 8.57 (1H, s), 8.50 (1H, s), 8.30 (1H, d, J=7.6 Hz), 7.80 (1H, d, J=7.5 Hz), 7.69
(1H, d, J=7.6 Hz), 7.35 (1H, d, J=7.6 Hz), 6.59 (1H, s), 6.30 (1H, m), 5.57 (1H, m), 5.42 (1H, t,
J=4.0 Hz), 4.96 (1H, t, J=8.1 Hz), 4.04 (1H, dd, J=16.1, 8.0 Hz), 3.7 (1H, s), 3.37 (1H, t, J=12.0
Hz), 3.04 (1H, d, J=8.1 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.63 (m), 2.31 (m), 2.26 (m),
2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m), 1.29 (6H, d, J=7.2 Hz);
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C-NMR (CDCl3) δ 175.04,

166.03, 143.57, 142.05, 141.99, 138.60, 135.78, 134.48, 133.85, 133.42, 130.20, 128.08, 125.35,
122.38, 122.12, 114.63, 112.93, 77.85, 71.70, 70.50, 57.09, 53.49, 49.32, 47.07, 44.82, 40.9,
31.21, 39.16, 35.64, 33.62, 26.52, 26.36, 24.99, 24.58, 24.32, 20.73, 20.06, 19.86; HRESIMS
m/z calcd for C40H52N5O2 (M+H)+ 634.4129, found 634.4045.
1
6-n-Pentamidomanzamine A (9): (15 mg,13%); [α ]25
D 9.9 (c 0.15, MeOH); H-NMR (CDCl3) δ

11.32 (1H, s), 8.65 (1H, s), 8.50 (1H, s), 8.32 (1H, d, J=7.6 Hz), 7.79 (1H, d, J=7.5 Hz), 7.66
(1H, d, J=7.6 Hz), 7.36 (1H, d, J=7.6 Hz), 6.64 (1H, s), 6.28 (1H, m), 5.57 (1H, m), 5.42 (1H, t,
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J=4.1 Hz), 4.96 (1H, t, J=8.0 Hz), 4.04 (1H, dd, J=16.0, 8.1 Hz), 3.7 (1H, s), 3.37 (1H, t, J=12.1
Hz), 3.04 (1H, d, J=8.0 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.39 (2H, t, J=7.2 Hz), 2.31
(m), 2.26 (m), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m), 0.99 (3H, t, J=7.1 Hz); 13C-NMR (CDCl3)
δ 175.04, 166.03, 143.57, 142.05, 141.99, 138.60, 135.78, 134.48, 133.85, 133.42, 130.20,
128.08, 125.35, 122.38, 122.12, 114.63, 112.93, 77.85, 71.70, 70.50, 57.09, 53.49, 49.32, 47.07,
44.82, 31.21, 39.16, 37.47, 27.83, 33.62, 30.36, 29.68, 26.52, 26.36, 24.99, 24.58, 24.32, 22.44,
20.87, 13.84; HRESIMS m/z calcd for C41H54N5O2 (M+H)+ 648.4277, found 648.4550.
1
6-Pivalamidomanzamine A (10): (14 mg, 12%); [α ]25
D 31.6 (c 0.21, MeOH); H-NMR (CDCl3)

δ 11.32 (1H, s), 8.65 (1H, s), 8.50 (1H, s), 8.32 (1H, d, J=7.6 Hz), 7.79 (1H, d, J=7.5 Hz), 7.66
(1H, d, J=7.6 Hz), 7.36 (1H, d, J=7.6 Hz), 6.64 (1H, s), 6.28 (1H, m), 5.57 (1H, m), 5.42 (1H, t,
J=4.0 Hz), 4.96 (1H, t, J=8.1 Hz), 4.04 (1H, dd, J=16.0, 8.0 Hz), 3.7 (1H, s), 3.37 (1H, t, J=12.1
Hz), 3.04 (1H, d, J=8.0 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.31 (m), 2.26 (m), 2.03 (m),
1.96 (m), 1.74 (m), 1.49 (9H, s), 1.48 (m); 13C-NMR (CDCl3) δ 175.04, 166.03, 143.57, 142.05,
141.99, 138.60, 135.78, 134.48, 133.85, 133.42, 130.20, 128.08, 125.35, 122.38, 122.12, 114.63,
112.93, 77.85, 71.70, 70.50, 57.09, 53.49, 49.32, 47.07, 44.82, 39.31, 39.16, 33.62, 29.69, 28.45,
26.52, 26.36, 24.99, 24.58, 24.32,

20.73; HRESIMS m/z calcd for C41H54N5O2 (M+H)+

648.4277, found 648.4550.
36.1 (c 0.25, MeOH); 1H-NMR
6-n-Hexamidomanzamine A (11): (17 mg, 14%); [α ]25
D
(CDCl3) δ 11.32 (1H, s), 8.65 (1H, s), 8.50 (1H, s), 8.32 (1H, d, J=7.6 Hz), 7.79 (1H, d, J=7.5
Hz), 7.66 (1H, d, J=7.6 Hz), 7.36 (1H, d, J=7.6 Hz), 6.64 (1H, s), 6.28 (1H, m), 5.57 (1H, m),
5.42 (1H, t, J=4.0 Hz), 4.96 (1H, t, J=8.1 Hz), 4.04 (1H, dd, J=16.0, 8.0 Hz), 3.7 (1H, s), 3.37
(1H, t, J=12.1 Hz), 3.04 (1H, d, J=8.0 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.56 (2H, t,
J=7.1 Hz), 2.31 (m), 2.26 (m), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m), 0.94 (3H, t, J=7.0 Hz);
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13

C-NMR (CDCl3) δ 175.39, 166.03, 143.57, 142.05, 141.99, 138.60, 135.78, 134.48, 133.85,

133.42, 130.20, 128.08, 125.35, 122.38, 122.12, 114.63, 112.93, 77.85, 71.70, 70.50, 57.09,
53.49, 49.32, 47.07, 44.82, 31.21, 39.16, 37.47, 32.11, 29.68, 27.12, 26.78, 26.40, 25.54 25.28,
24.90, 23.05, 21.34, 14.22; HRESIMS m/z calcd for C42H56N5O2 (M+H)+ 662.4488, found
662.4448.
1
6-n-Octamidomanzamine A (12): (15 mg, 12%); [α ]25
D 25.4 (c 0.12, MeOH); H-NMR (CDCl3)

δ 11.32 (1H, s), 8.65 (1H, s), 8.50 (1H, s), 8.32 (1H, d, J=7.6 Hz), 7.79 (1H, d, J=7.5 Hz), 7.66
(1H, d, J=7.6 Hz), 7.36 (1H, d, J=7.6 Hz), 6.64 (1H, s), 6.28 (1H, m), 5.57 (1H, m), 5.42 (1H, t,
J=4.0 Hz), 4.96 (1H, t, J=8.1 Hz), 4.04 (1H, dd, J=16.0, 8.1 Hz), 3.7 (1H, s), 3.37 (1H, t, J=12.0
Hz), 3.04 (1H, d, J=8.1 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.46 (2H, t, J=7.2 Hz), 2.31
(m), 2.26 (m), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m), 0.90 (3H, t, J=7.1 Hz); 13C-NMR (CDCl3)
δ 176.14, 166.69, 143.57, 142.05, 141.99, 138.60, 135.78, 134.48, 133.85, 133.42, 130.20,
128.08, 125.35, 122.38, 122.12, 114.63, 112.93, 77.85, 71.70, 70.50, 57.09, 53.49, 49.32, 47.07,
44.82, 38.60, 37.47, 31.61, 29.68, 28.17, 26.78, 26.40, 25.54 25.28, 24.90, 22.82, 21.34, 14.47;
HRESIMS m/z calcd for C44H60N5O2 (M+H)+ 690.4732, found 690.4785.
1
6-(t-Butyl)-acetamidomanzamine A (13): (18 mg, 15%); [α ]25
D 21.5 (c 0.10, MeOH); H-NMR

(CDCl3) δ 11.32 (1H, s), 8.65 (1H, s), 8.50 (1H, s), 8.32 (1H, d, J=7.6 Hz), 7.79 (1H, d, J=7.5
Hz), 7.66 (1H, d, J=7.6 Hz), 7.36 (1H, d, J=7.6 Hz), 6.64 (1H, s), 6.28 (1H, m), 5.57 (1H, m),
5.42 (1H, t, J=4.0 Hz), 4.96 (1H, t, J =8.0 Hz), 4.04 (1H, dd, J=16.0, 8.1 Hz), 3.7 (1H, s), 3.37
(1H, t, J=12.1 Hz), 3.04 (1H, d, J=8.0 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.24 (2H, s),
2.26 (m), 2.03 (m), 1.96 (m), 1.74 (m), 1.02 (9H, s);

13

C-NMR (CDCl3) δ 175.89, 166.03,

143.51, 142.09, 142.01, 138.60, 135.78, 134.48, 133.85, 133.42, 130.20, 128.08, 125.35, 122.38,
122.12, 114.63, 112.93, 77.85, 71.70, 70.50, 57.09, 53.49, 49.32, 47.07, 44.82, 39.3, 33.62,
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31.65, 29.69, 28.80, 24.99, 24.58, 24.32, 20.73; HRESIMS m/z calcd for C42H56N5O2 (M+H)+
662.4425, found 662.4451.
1
6-Cyclohexamidomanzamine A (14): (20 mg, 17%); [α ]25
D 18.5 (c 0.13, MeOH); H-NMR (d6-

acetone) δ 11.33 (1H, s), 9.02 (1H, s), 8.53 (1H, s), 8.22 (1H, d, J=7.6 Hz), 7.76 (1H, d, J =7.5
Hz), 7.56 (1H, d, J=7.6 Hz), 7.46 (1H, d, J=7.6 Hz), 6.68 (1H, s), 6.08 (1H, m), 5.51 (1H, m),
5.42 (1H, t, J=4.0 Hz), 4.77 (1H, t, J=8.0 Hz), 3.84 (1H, dd, J=16.0, 8.1 Hz), 3.66 (1H, s), 3.26
(1H, t, J=12.0 Hz), 2.91 (1H, d, J=8.1 Hz), 2.78 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.31 (m), 2.26
(m), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m);

13

C-NMR (d6-acetone) δ 175.04, 166.03, 143.57,

142.05, 141.99, 138.60, 135.78, 134.48, 133.85, 133.42, 130.20, 128.08, 125.35, 122.38, 122.12,
114.63, 112.93, 77.85, 71.70, 70.50, 57.09, 53.49, 49.32, 47.07, 44.82, 39.16, 33.62, 28.45,
26.52, 26.36, 24.99, 24.58, 24.32, 23.97, 20.73; HRESIMS m/z calcd for C43H56N5O2 (M+H)+
674.4434, found 674.4464.
8-Acetamidomanzamine A (15): (14 mg, 13%); [α ]25
D 16.2 (c 0.15, MeOH); UV λmax (MeOH)
260, 310, 375 nm; IR neat: 3232, 2935, 2580, 1703, 1665, 1538, 1470, 1437, 1365, 1290, 1178,
1130, 1018 cm-1; 1H-NMR (CDCl3) δ 11.37 (1H, s), 8.52 (1H, d, J=8.0 Hz), 8.33 (1H, d, J=7.6
Hz), 7.82 (1H, d, J=7.5 Hz), 7.79 (1H, d, J=7.6 Hz), 7.23 (1H, d, J=7.6 Hz), 6.64 (1H, s), 6.28
(1H, m), 5.57 (1H, m), 5.42 (1H, t, J=4.0 Hz), 4.96 (1H, t, J=8.0), 4.04 (1H, dd, J=16.0, 8.1 Hz)
3.7 (1H, s), 3.37 (1H, t, J=12.1 Hz), 3.04 (1H, d, J=8.0 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43
(m), 2.31 (m), 2.26 (m) 2.08 (3H, s), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m); 13C-NMR (CDCl3) δ
174.04, 166.01, 143.27, 141.95, 141.80, 138.64, 136.00, 134.49, 133.85, 133.42, 130.20, 128.08,
125.35, 122.38, 122.12, 114.63, 112.93, 77.85, 71.70, 70.50, 57.09, 53.49, 49.32, 47.07, 44.82,
31.21, 39.16, 33.62, 28.45, 26.52, 26.36, 24.99, 24.58, 24.32, 23.97, 20.73; HRESIMS m/z calcd
for C38H49N5O2 (M+H)+ 606.3843, found 606.3811.
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8-n-Propamidomanzamine A (16): (15 mg, 14%); [α ]25
6.1 (c 0.09, MeOH); ); 1H-NMR
D
(CDCl3) δ 11.38 (1H, s), 8.51 (1H, d, J=8.0 Hz), 8.36 (1H, d, J=7.6 Hz), 7.80 (1H, d, J=7.5 Hz),
7.78 (1H, d, J=7.6 Hz), 7.26 (1H, d, J=7.6 Hz), 6.68 (1H, s), 6.29 (1H, m), 5.56 (1H, m), 5.43
(1H, t, J=4.0 Hz), 4.96 (1H, t, J=8.1 Hz), 4.04 (1H, dd, J=16.1, 8.0 Hz) 3.69 (1H, s), 3.37 (1H, t,
J=12.0 Hz), 3.04 (1H, d, J=8.0 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.41 (2H, q, J=7.0
Hz), 2.31 (m), 2.26 (m), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m), 1.14 (3H, t, J=7.1 Hz); 13C-NMR
(CDCl3) δ 174.84, 166.09, 143.51, 142.25, 142.12, 138.62, 135.78, 134.48, 133.85, 133.42,
130.20, 128.08, 125.35, 122.38, 122.12, 114.63, 112.93, 77.85, 71.70, 70.50, 57.09, 53.49, 49.32,
47.07, 44.82, 31.21, 39.16, 33.62, 30.36, 28.45, 26.52, 26.36, 24.99, 24.58, 24.32, 20.78, 10.01;
HRESIMS m/z calcd for C39H50N5O2 (M+H)+ 620.3936, found 620.3981.
1
8-n-Butamidomanzamine A (17): (16 mg, 14%); [α ]25
D 13.2 (c 0.12, MeOH); H-NMR (CDCl3)

δ 11.25 (1H, s), 8.70 (1H, s), 8.51 (1H, d, J=8.2 Hz), 8.36 (1H, d, J=7.6 Hz), 7.80 (1H, d, J=7.5
Hz), 7.78 (1H, d, J=7.6 Hz), 7.26 (1H, d, J=7.6 Hz), 6.62 (1H, s), 6.25 (1H, m), 5.54 (1H, m),
5.39 (1H, t, J=4.0 Hz), 4.92 (1H, t, J=8.0 Hz), 4.00 (1H, dd, J=16.1, 8.0 Hz), 3.66 (1H, s), 3.37
(1H, t, J=12.0 Hz), 3.04 (1H, d, J=8.1 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.37 (2H, t,
J=7.2 Hz), 2.31 (m), 2.26 (m), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m), 1.00 (3H, t, J=7.2 Hz);
13

C-NMR (CDCl3) δ 173.41, 143.82, 142.97, 141.90, 138.48, 135.17, 133.45, 133.29, 132.45,

130.42, 130.01, 127.30, 125.15, 123.99, 122.87, 120.67, 116.50, 114.32, 78.41, 71.70, 70.74,
63.42, 57.67, 53.88, 49.65, 47.45, 45.03, 41.44, 39.48, 34.05, 32.26, 30.36, 27.41, 26.36, 24.99,
24.58, 24.32, 20.73, 19.76, 14.42; HRESIMS m/z calcd for C40H52N5O2 (M+H)+ 634.4011, found
634.4101.
1
8-Isobutamidomanzamine A (18): (16 mg, 14%); [α ]25
D 14.2 (c 0.10, MeOH); H-NMR (d6-

acetone) δ 11.41 (1H, s), 8.50 (1H, d, J=8.0), 8.32 (1H, d, J=8.1), 7.78 (1H, d, J=7.9), 7.77 (1H,
91

d, J=7.8 Hz), 7.29 (1H, d, J=7.6 Hz), 6.67 (1H, s), 6.30 (1H, m), 5.57 (1H, m), 5.42 (1H, t, J=4.2
Hz), 4.96 (1H, t, J=8.1 Hz), 4.04 (1H, dd, J=16.0, 8.1 Hz), 3.7 (1H, s), 3.37 (1H, t, J=12.1 Hz),
3.04 (1H, d, J=8.0 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.63 (m), 2.31 (m), 2.26 (m), 2.03
(m), 1.96 (m), 1.74 (m), 1.48 (m), 1.29 (6H, d, J=7.2 Hz);

13

C-NMR (d6-acetone) δ 172.35,

143.57, 142.57, 142.14, 138.19, 135.87, 133.91, 133.78, 133.04, 129.86, 128.13, 126.75, 123.60,
120.36, 116.20, 114.02, 77.97, 71.70, 70.33, 57.35, 53.50, 49.25, 47.07, 44.63, 40.9, 39.16,
35.64, 33.75, 29.68, 28.36, 25.00, 24.34, 20.74, 20.06, 19.86; HRESIMS m/z calcd for
C40H52N5O2 (M+H)+ 634.4011, found 634.4095.
8-n-Pentamidomanzamine A (19): (17 mg,15%); [α ]25
17.2 (c 0.16, MeOH); 1H-NMR
D
(CDCl3) δ 11.29 (1H, s), 8.51 (1H, d, J=8.0 Hz), 8.34 (1H, d, J=8.2 Hz), 7.80 (1H, d, J=7.9 Hz),
7.77 (1H, d, J=7.8 Hz), 7.24 (1H, d, J=7.6 Hz), 6.54 (1H, s), 6.28 (1H, m), 5.57 (1H, m), 5.42
(1H, t, J=4.1 Hz), 4.96 (1H, t, J=8.0 Hz), 4.04 (1H, dd, J=16.1, 8.0 Hz), 3.7 (1H, s), 3.37 (1H, t,
J=12.0 Hz), 3.04 (1H, d, J=8.1 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.39 (2H, t, J=7.1
Hz), 2.31 (m), 2.26 (m), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m), 0.99 (3H, t, J=7.2);

13

C-NMR

(CDCl3) δ 172.97, 143.57, 142.60, 141.99, 138.18, 135.78, 134.88, 133.85, 133.42, 130.02,
127.22, 125.35, 123.63, 119.65, 116.18, 114.01, 78.07, 71.70, 70.40, 57.33, 53.53, 49.30, 47.07,
44.72, 41.08, 39.08, 37.07, 33.72, 31.91, 30.36, 29.68, 26.51, 26.36, 25.01, 24.59, 24.34, 22.67,
22.48, 20.75, 13.97; HRESIMS m/z calcd for C41H54N5O2 (M+H)+ 648.4277, found 648.4281.
1
8-Pivalamidomanzamine A (20): (15 mg, 12%); [α ]25
D 17.2 (c 0.11, MeOH); H-NMR (CDCl3)

δ 11.40 (1H, s), 8.40 (1H, d, J=8.1 Hz), 8.38 (1H, d, J=8.0 Hz), 7.84 (1H, d, J=7.9 Hz), 7.82 (1H,
d, J=7.8 Hz), 7.24 (1H, d, J=7.6 Hz), 6.78 (1H, s), 6.26 (1H, m), 5.58 (1H, m), 5.36 (1H, t, J=4.0
Hz), 4.85 (1H, t, J=8.1 Hz), 4.04 (1H, dd, J=16.0, 8.1 Hz), 3.67 (1H, s), 3.21 (1H, t, J=12.1 Hz),
3.04 (1H, d, J=8.1 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.31 (m), 2.26 (m), 2.03 (m), 1.96
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(m), 1.74 (m), 1.49 (9H, s), 1.48 (m);

13

C-NMR (CDCl3) δ 175.04, 166.03, 143.57, 142.05,

141.99, 138.27, 135.04, 134.48, 133.85, 133.86, 131.87, 127.11, 125.35, 123.99, 121.91, 116.86,
113.96, 77.23, 71.70, 70.52, 58.36, 57.11, 53.56, 49.37, 47.07, 44.59, 39.29, 38.74, 33.77, 32.76,
29.69, 28.45, 26.71, 26.36, 25.61, 24.58, 24.44, 22.68, 20.80, 14.03; HRESIMS m/z calcd for
C41H54N5O2 (M+H)+ 648.4277, found 648.4268.
1
8-n-Hexamidomanzamine A (21): (16 mg, 14%); [α ]25
D 21.1 (c 0.11, MeOH); H-NMR (d6-

acetone) δ 11.22 (1H, s), 8.72 (1H, d, J=8.0 Hz), 8.45 (1H, d, J=8.0 Hz), 7.99 (1H, d, J=7.9 Hz),
7.91 (1H, d, J=7.8 Hz), 7.27 (1H, d, J=7.6 Hz), 6.78 (1H, s), 6.12 (1H, m), 5.53 (1H, m), 5.16
(1H, t, J=4.0 Hz), 4.88 (1H, t, J=8.1 Hz), 4.04 (1H, dd, J=16.1, 8.0 Hz) 3.79 (1H, s), 3.41 (1H, t,
J=12.0 Hz), 2.94 (1H, d, J=8.0 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.56 (2H, t, J=7.4
Hz), 2.31 (m), 2.26 (m), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m), 0.94 (3H, t, J=7.1 Hz); 13C-NMR
(d6-acetone) δ 173.50, 164.75, 142.69, 142.28, 142.10, 139.23, 133.93, 132.38, 130.65, 126.01,
124.70, 123.46, 119.50, 117.24, 114.89, 77.47, 71.57, 70.07, 58.06, 53.77, 53.38, 49.61, 47.18,
44.99, 40.87,40.26, 37.56, 34.60, 30.11, 29.73, 29.53, 28.73, 27.12, 26.78, 26.40, 25.54, 24.90,
23.05, 21.34, 14.22; HRESIMS m/z calcd for C42H56N5O2 (M+H)+ 662.4488, found 662.4521.
1
8-n-Octamidomanzamine A (22): (18 mg, 15%); [α ]25
D 19.9 (c 0.11, MeOH); H-NMR (CDCl3)

δ 11.32 (1H, s), 8.61 (1H, d, J=8.1 Hz), 8.52 (1H, d, J=8.0 Hz), 7.87 (1H, d, J=7.9 Hz), 7.84 (1H,
d, J=7.8 Hz), 7.23 (1H, d, J=7.6 Hz), 6.69 (1H, s), 6.28 (1H, m), 5.57 (1H, m), 5.42 (1H, t, J=4.0
Hz), 4.96 (1H, t, J=8.1 Hz), 4.04 (1H, dd, J=16.1, 8.0 Hz), 3.7 (1H, s), 3.37 (1H, t, J=12.1 Hz),
3.04 (1H, d, J=8.0 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.46 (2H, t, J=7.1 Hz), 2.31 (m),
2.26 (m), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m), 0.90 (3H, t, J=7.1 Hz);

13

C-NMR (CDCl3) δ

173.54, 164.54, 142.87, 142.25, 142.04, 138.60, 136.12, 134.48, 133.85, 133.42, 130.20, 128.08,
125.35, 122.38, 122.12, 116.26, 114.33, 77.85, 71.70, 70.50, 57.09, 53.49, 49.32, 47.07, 44.82,

93

38.60, 37.47, 31.61, 29.68, 28.17, 26.78, 26.40, 25.54 25.28, 24.94, 22.45, 21.34, 14.51 ;
HRESIMS m/z calcd for C44H60N5O2 (M+H)+ 690.4732, found 690.4772.
1
8-(t-Butyl)-acetamidomanzamine A (23): (16 mg, 14%); [α ]25
D 25.7 (c 0.12, MeOH H-NMR

(CDCl3) δ 11.32 (1H, s), 8.63 (1H, d, J=8.0 Hz), 8.51 (1H, d, J=8.1 Hz), 7.88 (1H, d, J=7.9 Hz),
7.86 (1H, d, J=7.8 Hz), 7.27 (1H, d, J=7.6 Hz), 6.71 (1H, s), 6.28 (1H, m), 5.57 (1H, m), 5.42
(1H, t, J=4.0 Hz), 4.96 (1H, t, J=8.1 Hz), 4.04 (1H, dd, J=16.0, 8.1 Hz), 3.7 (1H, s), 3.37 (1H, t,
J=12 Hz).1, 3.04 (d, J=8 Hz), 2.95 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.24 (2H, s), 2.26 (m), 2.03
(m), 1.96 (m), 1.74 (m), 1.02 (9H, s);

13

C-NMR (CDCl3) δ 174.15, 164.43, 143.59, 142.41,

142.01, 138.27, 135.04, 134.48, 133.85, 132.86, 131.87, 127.11, 123.99, 122.38, 121.91, 116.86,
113.96, 77.23, 70.52, 58.35, 57.11, 53.56, 52.92, 49.37, 45.52, 44.59, 39.29, 33.77, 32.76, 29.69,
27.86, 26.71, 26.48, 25.10, 24.72, 24.44, 22.68, 20.80; HRESIMS m/z calcd for C42H56N5O2
(M+H)+ 662.4425, found 662.4478.
1
8-Cyclohexamidomanzamine A (24): (19 mg, 16%); [α ]25
D 19.5 (c 0.17, MeOH); H-NMR

(CDCl3) δ 11.30 (s), 9.52 (s), 8.49 (1H, d, J=8.0 Hz), 8.33 (1H, d, J=8.1 Hz), 7.79 (1H, d, J=7.9
Hz), 7.76 (1H, d, J=7.8 Hz), 7.20 (1H, d, J=7.6 Hz), 6.55 (s), 6.28 (m), 5.55 (m), 5.39 (1H, t,
J=4.0 Hz), 4.90 (1H, t, J=8.0 Hz), 4.02 (1H, dd, J=16.1, 8.0 Hz), 3.72 (s), 3.26 (1H, t, J=12.0
Hz), 2.91 (1H, d, J=8.0 Hz), 2.78 (m), 2.77 (m), 2.61 (m), 2.43 (m), 2.31 (m), 2.26 (m), 2.03 (m),
1.96 (m), 1.74 (m), 1.48 (m);

13

C-NMR (CDCl3) δ 174.12, 164.03, 143.57, 142.52, 141.99,

138.13, 134.92, 134.48, 133.85, 133.00, 130.86, 128.78, 126.79, 123.64, 120.29, 119.60, 116.05,
113.97, 77.96, 77.23, 71.70, 70.48, 58.32, 57.34, 53.54, 53.39, 49.31, 45.70, 44.78, 40.98, 39.11,
33.73, 31.90, 29.81, 29.75, 29.67, 29.33, 28.48, 26.48, 26.41, 25.68, 25.64, 25.00, 24.59, 24.28,
22.66, 20.75; HRESIMS m/z calcd for C43H56N5O2 (M+H)+ 674.4434, found 674.4432.
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In vitro antimalarial and antimicrobial activities: The detailed materials and methods used for
in vito antimalarial and in vitro antimicrobial assays were reported elsewhere.58
In vivo antimalarial activity:
In vivo antimalarial activity of compounds was determined in mice infected with
Plasmodium berghei (NK-65 strain). Male mice (Swiss Webster strain) weighing 18-20 g were
intraperitoneally inoculated with 2x107 parasitized red blood cells obtained from a highly
infected donor mouse. Mice were divided into different groups with 5 mice in each group. Test
compounds were prepared in DMSO: 0.1N HCl: Tween-80: PEG-400: water (5:1:0.5:40:53.50)
and administered orally to the mice about 2 h after the infection (Day 0). The compounds were
tested at three doses of 3.3, 10 and 30 mg/kg body weight. The test compounds were
administered to the mice once a day for 3 consecutive days (Days 0-3). A control group was
treated with equal volume of vehicle and another control group was treated with chloroquine (10
mg/kg). The mice were closely observed after every dose for any apparent signs of toxicity.
Blood smears were prepared on different days (till day 28 post infection) by clipping the tail end,
stained with Giemsa and observed under microscope for determination of the parasitemia.
Suppression in development of parasitemia was monitored on day 5 and day 7 post infection.
Mice without parasitemia until day 28 post infection were considered as cured. Treatment of
mice with three doses of chloroquine caused 100% suppression of the parasitemia.
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Table II.5. The synthesized manzamine A amides.
Compound

R

Entry

Yield %

CH3

5
15

14
13

6-n-Propamidomanzamine A
8-n-Propamidomanzamine A

6
16

14
14

6-n-Butamidomanzamine A
8-n-Butamidomanzamine A

7
17

14
14

6-Isobutamidomanzamine A
8-Isobutamidomanzamine A

8
18

12
14

6-n-Pentamidomanzamine A
8-n-Pentamidomanzamine A

9
19

13
15

6-Pivalamidomanzamine A
8-Pivalamidomanzamine A

10
20

12
12

6-n-Hexamidomanzamine A
8-n-Hexamidomanzamine A

11
21

14
14

6-n-Octamidomanzamine A

12

12

8-n-Octamidomanzmaine A

22

15

6-(t-Butyl)-acetamidomanzamine
A
8-(t-Butyl)-acetamidomanzamine
A
6-Cyclohexamidomanzamine A
8-Cyclohexamidomanzamine A

13
23

15
14

14
24

17
16

6-Acetamidomanzamine A
8-Acetamidomanzamine A
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Table II.6. In vitro antimalarial activity of manzamine amides against chloroquine sensitive
(D6, Sierra Leone) and resistant (W2, IndoChina) strains of Plasmodium falciparum

Compound

Entr
y

6-Acetamidomanzamine A

5

8-Acetamidomanzamine A

15

6-n-Propamidomanzamine A

6

8-n-Propamidomanzamine A

16

6-n-Butamidomanzamine A

7

8-n-Butamidomanzamine A

17

6-Isobutamidomanzamine A

8

8-Isobutamidomanzamine A

18

6-n-Pentamidomanzamine A

9

8-n-Pentamidomanzamine A

19

6-Pivalamidoanzamine A

10

8-Pivalamidomanzamine A

20

6-n-Hexamidomanzamine A

11

8-n-Hexamidomanzamine A

21

6-n-Octamidomanzamine A

12

8-n-Octamidomanzamine A

22

6-(t-Butyl)acetamidomanzamine A
8-(t-Butyl)acetamidomanzamine A
6-Cyclohexamidomanzamine
A
8-Cyclohexamidomanzamine
A

13
23
14
24

P. falciparum
(D6 Clone)
IC50 (nM)

P. falciparum (W2
Clone)
IC50 (nM)

Cytotoxicity
(Vero)

1288

1982

NC

182

231

NC

1162

1937

NC

123

87

NC

1152

1894

NC

35

121

NC

1105

1547

NC

158

205

NC

1235

1482

NC

53

49

NC

231

417

NC

170

232

NC

680

786

NC

32

65

NC

696

754

NC

55

43

NC

211

302

NC

139

127

NC

34

53

NC

950

995

NC

97

IC50 (nM)

Manzamine A

8.0

11

11

14

Chloroquine

50

484

-

Artemisinin

46

28

-

8-Hydroxymanzamine A

1
2

NC, no cytotoxicity up to 470 nM
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Table II.7. In vitro antimicrobial data of manzamine amides (all values in µM)
IC50/MIC
C. neoformans

M.
intracellulre

A.
fumiga
tus

-/-

-/-

9.91/16.51

-/-

15

-/-

33.35/-

1.65/2.06

-/-

6

-/-

-/-

5.65/8.07

-/-

16

>32.28/-

NT/NT

1.52/2.02

>32.28
/-

7

-/-

-/-

4.74/7.89

-/-

17

-/-

23.68/-

0.87/1.97

-/-

8

-/-

-/-

3.16/3.95

-/-

18

-/-

3.16/-

1.03/1.97

-/-

9

-/-

-/-

2.32/3.86

-/-

19

-/-

4.63/-

0.70/0.97

-/-

6-Pivalamidomanzamine A

10

-/-

-/-

1.54/3.86

-/-

8-Pivalamidomanzamine A

20

-/-

-/-

0.54/0.97

-/-

11

-/-

-/-

15.12/30.22

-/-

21

-/-

3.78/-

0.03/0.47

-/-

12

-/-

-/-

17.40/29.01

-/-

22

-/-

1.01/29.01

0.51/1.81

-/-

-/-

-/-

1.36/1.89

-/-

23

-/-

14.36/-

1.51/3.78

-/-

14

-/-

22.27/-

1.26/1.86

-/-

Compound

Entr
y

C. albicans

6-Acetamidomanzamine A

5

8-Acetamidomanzamine A
6-n-Propamidomanzamine
A
8-n-Propamidomanzamine
A
6-n-Butamidomanzamine
A
8-n-Butamidomanzamine
A
6-Isobutamidomanzamine
A
8-Isobutamidomanzamine
A
6-n-Pentamidomanzamine
A
8-n-Pentamidomanzamine
A

6-n-Hexamidomanzamine
A
8-n-Hexamidomanzamine
A
6-n-Octamidomanzamine
A
8-n-Octamidomanzamine
A
6-(t-Butyl)acetamidomanzamine A
8-(t-Butyl)acetamidomanzamine A
6Cyclohexamidomanzamine
A

13

99

8Cyclohexamidomanzamine
A

24

-/-

-/-

11.14/14.85

Manzamine A

1

3.656

1.85

0.64

8-Hydroxymanzamine A

2

6.20

3.55

0.177

0.49/1.35

0.92/2.70

Amphotericin B

-/-

1.62/2.
70
1.06

Ciprofloxacin

IC50, the concentration that affords 50% inhibition of growth; minimum inhibitory concentration
(MIC) is the lowest test concentration that allows no detectable growth; Amphotericin B and
ciprofloxacin are used as positive antifungal and antibacterial controls, respectively, “-“ not
active, “NT” not tested.
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6-n-HexamidoMA (11)
1
H-NMR in CDCl3

Figure II.25. 1H-NMR spectra of 6-n-hexamidomanzamine A (11) in CDCl3 at 400 MHz.
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6-CyclohexamidoMA (14)

Figure II.26. 1H- and 13C-NMR spectra of 6-cyclohexamidomanzamine A (14) in d6-acetone at
400 and 100 MHz, respectively.
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6-n-ButamidoMA (7)

Figure II.27. 1H- and 13C-NMR spectra of 6-n-butamidomanzamine A (7) in CDCl3 at 400 and 100
MHz, respectively.
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Figure II.28. 1H-NMR spectra of 6-isobutamidomanzamine A (8) in CDCl3 at 400 MHz.
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6-n-PentamidoMA (9)

Figure II.29. 1H- and 135DEPT-NMR spectra of 6-n-pentamidomanzamine A (9) in CDCl3 at
400 and 100 MHz, respectively.
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Figure II.30. 1H-NMR spectra of 6-n-propamidomanzamine A (6) in CDCl3 at 400 MHz.
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Figure II.31. 1H-NMR spectra of 6-(t-butyl)acetamidomanzamine A (13) in CDCl3 at 400 MHz.
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Figure II.32. 1H- and 135DEPT-NMR spectra of 8-cyclohexamidomanzamine A (24) in
CDCl3 at 400 and 100 MHz, respectively.

108

N

N
H HN
OH

H
N
H

O

N

8-PivalamidoMA (20)

Figure II.33. 1H- and 135DEPT-NMR spectra of 8-pivalamidomanzamine A (20) in CDCl3 at 400
and 100 MHz, respectively.
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Figure II.34. 1H- and 13C-NMR spectra of 8-n-butamidomanzamine A (17) in CDCl3 at 600
and 100 MHz, respectively.
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Figure II.35. 1H- and 13C-NMR spectra of 8-n-hexamidomanzamine A (21) in d6-acetone at 400
and 100 MHz, respectively.
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Figure II.36. 1H- and 135DEPT-NMR spectra of 8-isobutamidomanzamine A (18) in d6-acetone
at 400 and 100 MHz, respectively.
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Figure II.37. 1H-NMR spectra of 8-n-propamidomanzamine A (16) in CDCl3 at 400 MHz.
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8-n-PentamidoMA (19)

Figure II.38. 1H- and 135DEPT-NMR spectra of 8-n-pentamidomanzamine A (19) in CDCl3 at
400 and 100 MHz, respectively.
114

CHAPTER II.

SECTION D

SYNTHETIC STUDIES TOWARD THE REPLACEMENT OF THE β-CARBOLINE MOIETY
IN MANZAMINE ALKALOIDS
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Introduction:

Nature has served as a gold mine of structurally diverse small molecules utilized for
target identification and treatment of human diseases. Over 63% of small molecules reported
between 1981 and 2006 are either natural, natural product derived or inspired from natural
compounds.49 However, natural products are not perfectly designed to fit our needs in regard to
their application in disease treatment and hence optimization is a key step in the drug
development process. Toxicity associated with bioactive natural products is considered a major
obstacle in the process of drug discovery. The outstanding diverse biological activities of the
manzamine alkaloids, especially for malaria and neuroprotection, support the development of
these alkaloids as potential drugs. However, toxicity associated with high dose schedules of MA
requires further optimization. The mechanism of MA toxicity as well as the diverse bioactivities
is not understood. Thus detailed structure activity studies were completed modifying several
moieties in the manzamine structure.14-18 These SAR studies revealed that the modification of the
β-carboline moiety decreases the toxicity and improves biological activities.
Molecular modeling studies showed that MA and several analogs docked well with DNA,
suggesting that manzamines act as DNA intercalator and this might be expected from the planar
aromatic β-carboline ring found in the manzamines (Figure II.39). This was supported
experimentaly by the fact that MA was able to arrest the cell cycle in the S phase.14 To validate
the DNA intercalation hypothesis, we incubated MA with hepG2 cells in order to examine
whether or not MA can enter the nucleus and intercalate with DNA. The fluorescence of MA
was strong enough to be visualized by fluorescence microscopy and we were able to observe the
uptake of MA by the nucleus (Figure II.40).
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Figure

II.39.

Docked

diazaundecamethylene)bis

poses

of

MA

and

1,1'-(4,4,8,8-tetramethyl-4,8-

[4-(3-methyl-2,3-dihydrobenzo-1,3-thiazolyl-2-

ethylidene)quinolinium] tetraiodide (TOTO) within DNA. TOTO is shown with green
carbons and manzamines with white carbons. DNA is shown in wire mode.
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Blue fluorescence

Green fluorescence

Merge

A
Untreated
(negative
control)

B
1 µM MA

Figure II.40. Manzamine A uptake by the nucleus: A) HepG2 untreated cells (control) stained
with DAPI (blue fluorescence). B) HepG2 cells incubated with 1mM MA (green fluorescence)
for 4 hours. Cells were visualized by confocal microscopy (40x magnification, Zeiss 510META).
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Based on our SAR studies the replacement of the β-carboline moiety with other
heterocycles is the next key step in the lead optimization process. It is important to mention that
most naturally reported manzamine alkaloids contain β-carboline moiety but not others, which
suggests that generating a manzamine-like analog with different heterocycle will be beyond the
biosynthetic manzamine alkaloids.

Synthetic strategies:
Although gram and even kilogram quantities of MA is readily available, removal of the
β-carboline moiety from the entire structure is quite difficult to achieve. This is due to the highly
conjugated system that tightly linked the β-carboline with the rest of the molecule. Therefore,
using MA as a starting material for replacing the β-carboline moiety is not practical. To
breakdown the conjugated system, Birch reduction could be utilized. Our goal was to reduce the
pyridine ring in the β-carboline as a first step for a retro-Pictet-Spengler approach. However,
Birch reduction of MA resulted in the reduction of the ∆11 double bond but not the β-carboline
itself (Scheme II.3).

Scheme II.3. Birch reduction of MA.
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We then turned our attention to using ircinal A as a starting material instead and C-C
coupling reactions. C-C bond formation requires the reaction of two components with opposite
polarity: a nucleophile (metal-carbon species) and an electrophile (carbon-halogen or carbonpseudohalogen bond). In order to utilize a coupling approach, ircinal A should be converted first
to either an electrophilic or a nucleophilic partner (Figure II.41). The only disadvantage of using
ircinal A is the limited quantities available from the natural source.
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Figure II.41. Different proposed routes for utilizing ircinal A in a C-C coupling reaction.
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Ircinal A as a nucleophilic partner:
Decarboxylative cross coupling approach:
Synthetic chemists are always concerned about developing new C-C bond methodologies
to construct up complex natural products and medicinally important molecules. Since the
discovery of Ullmann reaction (copper catalyzed reductive symmetrical cross coupling of aryl
halides), metal catalyzed cross coupling reactions have become the most important tools for C-C
construction.59 Several metals have been used as the nucleophile partner including: palladium,
copper, zinc and nickel;59 however, several drawbacks remains including toxicity and limited
commercial availability of some coupling partners. Carboxylic acids are widely available and are
easy to make and have been used recently to generate nucleophilic partner through elimination of
CO2.60 Nilsson reported the first copper catalyzed decarboxylative coupling between onitrobenzoic acid and iodobenzene in 1966,61 followed by coupling of 2,6-dinitrobenzoic acid in
1968.62 Since then, no improvement in regard to copper load or high temperature until more
recently when Myers reported in 2002 the palladium catalyzed decarboxylative-Heck type
olefination of arene carboxylates,63 and the palladium catalyzed decarboxylative cross coupling
of heteroaromatic carboxylic acids with aryl bromides developed by the Bilodeau’s group in
2006.64 Goossen et al. used a palladium source in addition to copper (I) as a cocatalyst to
catalyze the extrusion of CO2 and the generation of the carbon nucleophile; which is
subsequently transmetalated to the palladium cycle for coupling with the carbon electrophile
(Figure II.42).64, 65
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Figure II.42. Cu/Pd catalyzed decarboxylative cross coupling. M=Ag, Cu; R=hetero, aryl, vinyl,
acyl; R`=heterocycles, aryl; X=I, Cl, Br, OTf61-70

Initial catalyst system developed by Goossen consisted of 10 mol% of CuBr/1,10phenanthroline and 3 mol% palladium bromide;64,65 however, several improvements of the
catalytic system, substrate and reaction temperature have been made.66-71 Electrophilic partners
were extended from aryl bromides64,66 to aryl chlorides,67 aryl triflates68,69 and aryl tosylates.70
Silver was shown to be effective metal for the decarboxylative step with lowered reaction
temperatures.71
The straight forward oxidation of ircinal A to the corresponding carboxylic acid, ircinoic
acid, encouraged us to utilize the decarboxylative cross coupling (DCCC) approach for the
replacement of the β-carboline moiety. Oxidation of ircinal A was optimized using different
oxidizing agents. Perchlorate oxidation as well as silver-catalyzed hydrogen peroxide oxidation
gives excellent yields (93%) of ircinoic acid (Scheme II.4).
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Scheme II.4. Oxidation of ircinal A to ircinoic acid.

We optimized the decarboxylative cross coupling reaction with (S)-perillic acid as a
model compound with several aryl bromides. Excellent yields were obtained with several aryl
halides (Scheme II.5) including the desired hetereocycle 7-bromo-1H-pyrrolo(2,3-c)pyridine 4.

Scheme II.5. Optimized decarboxylative cross coupling conditions with (S)-perillic acid
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However, the optimized conditions failed with ircinoic acid.

Part of this failure is

because of complexity of the structure as well as the high basisity of ircinoic acid relative to Sperillic acid. Another important issue is that ircinoic acid is placed in contact with two highly
activated metals with the possibility of having many side products; especially when having a
number of basic nitrogens and double bonds within the structure that could interact with
palladium (0). As a result, we decided to optimize the DCCC reaction using ircinoic acid. Our
optimization strategy was based on minimizing side reactions as well as reducing reaction
temperature to avoid any damage to the ircinal skeleton. Based on the proposed reaction
mechanism (Figure II.43), the best approach for minimizing side reactions is to physically
separate the two catalytic cycles; in other words, generating the cupric-ircinal like salt I
separately and allows to react with palladium (0) complex II through the transmetalation step.
This separation will minimize interaction of ircinoic acid with palladium (0) that will indeed
eliminate most side reactions.
Although we obtained the coupled product after several trials, the yield was low (~5%)
and the reaction was not reproducible. One explanation is that decarboxylation of ircinoic acid is
hard to achieve. These negative results and the limitation of starting material concluded the fact
that decarboxylative cross coupling strategy needs further optimizations.
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Figure II.43. Proposed mechanism for the decarboxylative cross coupling reaction with ircinoic
acid.

Ircinal A as an electrophilic partner:
Ircinal-derived Triflate:
The field of cross coupling reactions is rich in several outstanding synthetic tools for C-C
bond construction with a variety of metals as well as nucleophilic partners used. Among these
tools Suzuki cross coupling reaction is practical and has been used with a variety of substrates
and in the real applications in the field of total synthesis of natural products. In all cases, utilizing
ircinal A as an electrophilic partner in C-C cross coupling reaction requires the removal of the
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formyl group with insertion of an electron withdrawing group such as a halogen or a triflate
group (pseudohalogen) (Figure II.44).

Figure II.44. Suzuki cross coupling approach utilizing ircinal-derived triflate.

Our synthetic approach for this oxidative deformylation is outlines in Figure II.45. Birch
reduction of the α,β-unsaturated aldehyde functionality should deliver the reduced ircinal A (6)
with the generation of a new stereogenic center. An oxidative deformylation reaction will be then
utilized to convert this formyl group into the ircinal-derived ketone (8) which is very crucial and
important intermediate due to its straightforward conversion to the corresponding enolate that
could be trapped as a triflate analog (9). Oxidative deformylation process starts with enolate
formation followed by the reaction with oxygen which after decomposition of the formed adduct
will give the keto derivative.72
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Figure II.45. Our proposed route for the formation of ircinal-derived triflate

However, Birch reduction of ircinal A under atmospheric air resulted in the formation of
an interesting and unexpected product 10 (Scheme II.6). The HRESIMS data of 10 (m/z
381.3025 (M+H+)) revealed the loss of a formyl and a hydroxy groups from the ircinal A
structure. The presence of the singlet resonance at δΗ 6.08 in the 1H-NMR spectrum of 10 and its
HMBC correlation to the carbonyl group C1 (δc 197.39) suggested that the newly formed double
bond is in conjugation with the carbonyl group. A sequential one-pot Birch reduction-elimination
and deformylation reactions were occurred that yielded the unexpected ircinal-derived enone
(10). A possible mechanism for this sequence is shown in Figure II.46. An electron attack on the
β-position of the α,β-unsaturated functionality followed by a proton extraction of the generated
enolate will yield radical species (III). A second electron attack will occur and then instead of
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regular proton abstraction, an elimination of the 3o hydroxy group is more likely to happen that
will generate a stabilized conjugated system with the aldehyde group (in the enolate form) (IV).
In this highly basic conditions, aldehyde group will be in the enolate form (V) which will then
react with oxygen in a [2+2] cycloaddition way to generate the dioxetane intermediate (VI).
Rapid decomposition of this intermediate will deliver the unexpected product (10) with release
of formate salt.

Scheme II.6. Birch reduction of ircinal A
Ircinal-derived enone (10) will be useful in generating the deoxy-ircinal-derived triflate
(11) (Scheme II.7). Although this is not our desired end product, this will give us a chance to
optimize the Suzuki cross coupling reaction as well as generating some useful SAR studies at
this position. Basically, this enone will be subjected to Birch reduction condition. An enolate
(VII) will be generated after the second electron attack that could be trapped as a triflate.

Scheme II.7. Planned Birch reduction for the generation of the deoxyircinal-derived triflate 11.
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Figure II.46. Proposed mechanism for the formation of the unexpected ircinal-derived enone
(10).
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Conclusion:
In conclusion, the decarboxylative cross coupling reaction is relatively a new approach for the
generation of nucleophilic partners in C-C cross coupling reactions. However, this approach was
not practical in coupling ircinoic acid with other heterocycles. New and unexpected sequences of
reactions were observed in the Birch reduction of ircinal A under atmospheric air. A sequential
Birch reduction-elimination-oxidative deformylation were occurred and yielded the unexpected
ircinal-derived enone (10). This enone will be utilized in another Birch reduction condition in
order to trap the generated enolate as a triflate analog. This deoxyircinal-derived triflate will be
used for the optimization of a Suzuki coupling reaction.
Experimental:
General Experimental Procedures. The 1H- and 13C-NMR spectra were recorded in CDCl3 or
d6-acetone on a Bruker DRX NMR spectrometer operating at 400 MHz for 1H and 100 MHz for
13

C. Chemical shift (δ) values are expressed in parts per million (ppm) and are referenced to the

residual solvent signals of CDCl3 or d6-acetone. The high resolution ESI-MS spectra were
measured using a Bruker Daltonic (GmbH, Germany) micro-TOF series with electrospray
ionization. TLC analysis was carried out on precoated silica gel G254 aluminum plates.
Birth reduction of manzamine A: Ammonia (10 mL) was condensed with sodium (5 equiv.) in
a three-neck flask at -78 oC. A solution of manzamine A (100 mg, 0.182 mmol) dissolved in
THF:ethanol (9:1) was first cooled to -78 oC and then added to ammonia. The reaction mixture
was kept stirring at -78 oC for 30 min. Aqueous NH4Cl was added and ammonia was allowed to
evaporate at room temperature. The aqueous solution was extracted with dichloromethane (3x10
mL). The combined organic phases were washed successively with 10% aqueous sodium
thiosulphate and brine, dried over MgSO4. The crude product was purified by silica gel column.
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10,11-dihydromanzamine A: (2); yellow powder; 1H-NMR (CDCl3) δ 9.04 (1H, d, J=2.0 Hz),
8.50 (1H, d, J=5.2 Hz) , 8.40 (1H, dd, J=9.2, 2.0 Hz), 7.89 (1H, d, J=5.2 Hz), 7.77 (1H, d, J=9.2
Hz), 6.21 (1H, s), 5.62 (m), 5.42 (t, J=10.8 Hz), 4.70 (br), 3.69 (s), 3.25 (1H, t, J=11.0 Hz), 2.93
(d, J=9.0 Hz), 2.80~2.20 (m), 2.10~1.20 (m); HRESIMS m/z calcd for C36H37N5O (M+H)+
551.3512, found 551.3645.
Oxidation of Ircinal A: Ircinal A (30 mg, 0.07 mmol) was dissolved in a mixture of t-butanol (5
mL), acetonitrile (2 mL) and water (1 mL). To this solution were added sequentially at room
DMSO (excess), NaH2PO4 (144 mg, 1.2 mmol) and NaClO2 (140 mg, 1.2 mmol). The reaction
mixture was stirred at room temperature for one hour and NaCl (sat.) solution was added and the
mixture was extracted with dichloromethane (3x10 mL).
Ircinoic Acid (3): (29 mg, 93%); white powder; 1H-NMR (CDCl3) δ 9.04 (1H, s), 6.50 (1H, s),
6.21 (1H, s), 5.62 (m), 5.42 (t, J=10.8 Hz), 4.70 (br), 3.69 (s), 3.25 (1H, t, J=11.0 Hz), 2.93 (d,
J=9.0 Hz), 2.80~2.20 (m), 2.10~1.20 (m); HRESIMS m/z calcd for C26H39N2O3 (M+H)+
427.2145, found 427.2456.
Decarboxylative cross coupling of (S)-perillic acid with 7-bromo-1H-pyrrolo(2,3-c)pyridine
(4): (S)-perillic acid (100 mg, 0.602 mmol) and 7-bromo-1H-pyrrolo(2,3-c)pyridine (119 mg,
0.031 mmol) were dissolved in dry DMSO (10 mL) in an oven dried two neck round bottom
flask under nitrogen atmosphere. To this solution were added subsequently CuI (5 mg, 0.03
mmol), Pd(OAc)2 (13.5 mg, 0.06 mmol), PPh3 (47.3 mg, 0.181 mmol) and anhydrous K2CO3
(4.15 mg, 0.031 mmol). The reaction mixture was heated at 80 oC for 5 h and the progress of the
reaction was monitored by TLC. Water (10 mL) was added and the aqueous phase was extracted
with DCM (3x20 mL) and the combined organic layer was dried over Na2SO4 and concentrated
under vacuum. The crude product was purified by silica column to afford the coupled product.
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7-perillyl-1H-pyrrolo(2,3-c)pyridine (5(: (133 mg, 91.7%); white powder; 1H-NMR (CDCl3) δ
8.05 (1H, d, J=7.5 Hz), 7.51 (1H, d, J=5.0 Hz), 7.44 (1H, d, J=5.2 Hz), 7.12 (1H, brd s), 6.66
(1H, brd s), 4.74 (2H, brd s), 2.49~1.10 (m), 1.75 (3H, s);

13

C-NMR (CDCl3); 148.86, 141.54,

138.89, 133.93, 132.08, 129.78, 128.46, 125.13, 115.52, 109.40, 103.81, 40.11, 31.38, 27.13,
24.45, 20,86; HRESIMS m/z calcd for C16H19N2 (M+H)+ 238.1491, found 238.1502.
Birch reduction of ircinal A:
Ammonia (5 mL) was condensed with sodium (5 equiv.) in a three-neck flask at -78 oC. A
solution of ircinal A (30 mg, 0.073 mmol) dissolved in THF:ethanol (9:1) was first cooled to -78
o

C and then added to the ammonia solution. The reaction mixture was kept stirring at -78 oC for

30 min. Aqueous NH4Cl was added and ammonia was allowed to evaporate at room temperature.
The aqueous solution was extracted with dichloromethane (3x10 mL). The combined organic
phases were washed successively with 10% aqueous sodium thiosulphate and brine, dried over
MgSO4. The crude product was purified by silica gel column.
Ircinal-derived enone (10): (3 mg, 11%); 1H-NMR (CDCl3) δ 8.26 (1H, s), 6.08 (1H, d, J=5.2
Hz) , 5.97 (1H, s), 5.34 (1H, d, J=5.2 Hz), 5.32 (1H, d, J=5 Hz), 5.30 (1H, d, J=5 Hz), 4.41 (1H,
m), 3.37 (1H, m), 3.25 (1H, m), 2.99~1.4 (m);

13

C-NMR (CDCl3); 197.39, 136.79, 131.77,

131.49, 130.90, 130.16, 128.15, 64.57, 63.91, 55.19, 53.26, 49.45, 48.33, 45.77, 43.22, 41.48,
37.63, 33.09, 28.40, 27.72, 27.47, 27.38, 25.59, 23.86, 18.73; HRESIMS m/z calcd for
C25H37N2O (M+H)+ 381.2877, found 381.3025.
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Ircinoic acid

Figure II.47. 1H-NMR of ircinoic acid in CDCl3 at 400 MHz.
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7-perillyl-1H-pyrrolo(2,3c)pyridine (5)

Figure II.48. 1H-NMR of 7-perillyl-1H-pyrrolo(2,3-c)pyridine (5) in CDCl3 at 400 MHz.
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7-perillyl-1H-pyrrolo(2,3c)pyridine (5)

Figure II.49. 13C-NMR of 7-perillyl-1H-pyrrolo(2,3-c)pyridine (5) in CDCl3 at 100 MHz.
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Ircinal-derived enone (10)

Figure II.50. 1H-NMR of the ircinal-derived enone (10) in CDCl3 at 400 MHz.
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Ircinal-derived enone (10)

Figure II.51. 145DEPT-NMR of the ircinal-derived enone (10) in CDCl3 at 100 MHz.
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Ircinal-derived enone (10)

Figure II.52. HMQC experiment of the ircinal-derived enone (10) in CDCl3 at 400 MHz.
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Abstract: A simple and practical approach for the one-pot conversion of nitroarenes into amide
derivatives has been developed. HOAc/Zn are utilized as a reducing agent, and acyl
chloride/Et3N are used as the acylating agent in DMF with good yield (~60%) of the amide. This
method was applicable to 6-nitromanzamine A, where the yield of 6-cyclohexamidemanzamine
A (7) was significantly improved (56%) by this approach relative to starting with 6aminomanzamine A (17%).
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Introduction:
Aryl amides are important structural units of many biologically important compounds as well
as a number of drug candidates (Figure III.1).73 Usually, amide is obtained from the
corresponding nitro analog in two separate steps: reduction of the nitro group to the
corresponding 1o amine, followed by amidation with an activated carboxylic acid. Reduction of
the nitro group to the corresponding 1o amine can be completed using a number of approaches.
Metal catalyzed reduction is the most common in which a variety of metals/metal oxides/metal
sulfides have been reported including: zinc,74 iron,75 platinum oxide,76 palladium,77 Raney
nickel,78 copper,79 and ruthenium sulfide.80
Although the 1o amine can be purified and subsequently reacted with an activated carboxylic
acid, stability of some 1o aromatic amines, especially complex natural product derived 1o amines,
may affect the yield of the acylation reaction. Good examples of unstable amines are 6- and 8aminomanzamine A (5, 6). Manzamine A (1), the first representative of the manzamine
alkaloids, was isolated by Higa and coworkers in 1986.12 This class of compounds has shown a
variety of bioactivities.1 Although 1 and its 8-hydroxy analog (2) showed an outstanding
antimalarial activities both in vitro and in vivo compared to the currently utilized first line
antimalarial drugs, chloroquine and artemesinin,57 their toxicities limited their development as a
potential drugs. As part of a continued investigation of SAR and optimization studies of 1 against
malaria, we prepared amide analogs of 1 for evaluation in vitro against chloroquine sensitive and
resistant P. falciparum strains as well as their cytotoxicity (Chapter II.C).
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Amicetin
Ertapenem

Figure III.1. Drugs that possess aryl amide moieties.
Nitration of 1 (Scheme III.1) by NaNO2 and TFA gave two nitro products: 6- (3) and 8nitromanzamine A (4). HOAc/Zn reduction of nitromanzamines afforded the corresponding
aminomanzamines (5, 6), which were unstable even as the HCl salts. This lack of stability
created numerous challenges during the amidation of aminomanzamines. These difficulties were
the driving force to explore an effective, practical and gentle one-pot reductive amidation of
nitroarenes.
Examples of a one-pot reductive amidation of nitroarenes have been reported. Watanabe using
PtCl2(PPh3)2/ tin(IV)chloride/CO/carboxylic acid as a reductive amidation system requires high
temperature (180 oC) and pressure (60 atm),81 and is not applicable to sensitive and complex
natural products.
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Scheme III.1. Nitration of manzamine A
Samarium diiodide has been used to reduce nitroarenes in the presence of a proton source to
generate a nitrogen anion equivalent which can then be acylated with esters.82 This method is
valuable in regard to the use of esters as acylating agents. However the major disadvantage of
this method is that the preformed nitrogen anion equivalent is basic enough to generate side
reactions in complex natural products which normally have a diverse range of functional groups.
Another disadvantage of using samarium diiodide is that it is sensitive to moisture, and requires
highly dry reaction conditions. Limited examples for reductive acetamidation are reported. One
example uses nucleophilic attack of thioacetate anion at the nitro group,83 providing acetamide
derivative without the intermediate amine. This method could be expanded for the synthesis of
amides other than acetamide, but it is not applicable to a complex structure with base sensitive
functional groups such as 1. Dehydration of the allylic 3o hydroxy group at C-12 is always
obtained as a byproduct in most of the base mediated reactions of 1.84 Kim has used zinc and
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acetic anhydride for the conversion of nitroarenes into N,O-diacetylated N-arylhydroxyamines in
good yields. However, the acetamide yields were low.85 Furthermore, Kim reported high yields
of the acetamide derivatives when nitroaromatics were treated with acetic anhydride and acetic
acid catalyzed by indium, with trace yield of the diacetylated product.86 These two methods,
although showed selectivity to both products and high yields of each, are not applicable to
manzamine A or related structures. Manzamine alkaloids have yielded unexpected rearranged
products when treated with acetic anhydride.17 We report here the reductive amidation of
nitroarenes promoted by zinc and acetic acid as the reducing system and acyl chloride and
triethylamine as the acylating agent in a one-pot approach. Application to manzamine alkaloids
is utilized as an example of the applicability of this method to complex natural products.
Reduction of the nitro group generally requires a protic solvent as a carrier of hydrogen
generated in situ. However, amidation reaction using acyl chloride requires aprotic solvent as
well as dry conditions to prevent a side reaction with the solvent. In addition, amidation reaction
using acyl chlorides require basic conditions, in which the base will neutralize hydrochloric acid
librated from the reaction as a by-product. Because of this contrast, we decided to explore the
ability of adding 3o amine base (Et3N) in the reduction step, where equimolecular amounts of
acetic acid and zinc are used, in addition to the acyl chloride. Once the 1o amine is formed in
situ, it will immediately react with the acyl chloride facilitated by the 3o amine base. Solvent
optimization of this one-pot reaction was completed using 4-nitroanisole and butyryl chloride as
a test reaction (Table III.1).
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Table III.1. Solvent optimization for the reductive amidation reaction

Yielda (%)
Entry

a

Solvent

Time (h)
2a

3a

1

MeOH

4

98

0

2

DCM

4

80

15

3

DMF

4

30

65

4

Toluene

4

60

37

Isolated yield

All reactions were done using 1.0 mmol of 4-nitroanisole
All reactions showed complete conversion of the starting material

145

Table III.2. Reductive amidation of several nitroarenes
Acyl
Time
Entry
Starting material
Amide product
chloride
(h)
O

NO2

O

OMe

1

Yielda (%)

HN

4.5

OMe

Cl

64

O
NO2

O

2

HN

4

58

Cl

OMe

OMe
O

NO 2
O

3

HN

Cl

5

60

OMe

OMe
O

NO2

O

CH3

4

HN

4

56

CH3

Cl
O

NO2

O

5

Cl

CH3

HN

4

51
CH3

NO2

O
HN

O

6

62

4.5
Cl
CH3

CH3

NO2

O

O

7

HN

Cl

64

5
CH3

CH3

O

NO2
HN

O

8

Cl

5.5

53

CO2 Et

CO2Et

6

9

N

N
H

8

NO2

O
Cl

0.5

N

N
H

55b
HN
O
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NO2
6

10

N

N
H

8

H
N

O
Cl

0.5

N

a

Isolated yields.

b

Reactions were done using 0.4 mmol of nitroharmanes

O
N
H

58b

All reactions were done using 1.0 mmol of starting material

DMF gave the best results, in which the yield of the amide obtained from the nitro
compound was the same as that obtained from the corresponding amine. Using the optimized
reaction conditions, we screened several nitro compounds with butyryl chloride as well as other
acyl chlorides (Table III.2). All reactions showed 100% conversion of starting material to the
corresponding amines and amides, with moderate to good yield of the amides.
After optimizing the reaction conditions, we investigated the applicability of this reaction
to the synthesis of 6-cyclohexamidemanzamine A (7) (scheme III.2). This amide analog was
synthesized from 5 using normal amidation reaction with low yield (17%). This analog showed
potent antimalarial activity in vitro with an IC50 of 0.032 µM against the D6 clone of P.
falciparum with no cytotoxicity up to 4.7 µM. It was surprising that the reductive amidation of 3
with cyclohexylcarbonyl chloride (CCC) runs smoothly and quickly (10 min.) without the
addition of Et3N and with a significant improvement in the yield (56%). A reasonable
explanation is that nitromanzamines have two internal 3o amino functionalities, which likely
accelerate the amidation reaction.
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Method A: 1.2 equiv. CCC, 1.1 equiv. Et3N, cat. DMAP, THF, rt, 1 h
Method B: Reductive amidation approach
Scheme III.2. Amidation of manzamine A
To validate this, we utilized harmane (8) as a precursor to the synthesis of the closely
related model compounds 6-nitroharmane (9) and 8-nitroharmane (10). Harmane (8) was nitrated
using the same conditions as 1 (Scheme III.3) which gave 9 and 10 in 45% and 43% yields,
respectively. Applying the reductive amidation conditions to 9 and 10 without the addition of
Et3N did not gave the amides, even after 12 h of stirring. The amides of 9, 10 were obtained after
the addition of Et3N to the solution (Table III.2, entry 9 and 10). These results clearly validated
our explanation regarding the 3o amino capacity of manzamine alkaloids.
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Scheme III.3. Nitration of harmane
In conclusion, this is the first report of using 3o amine base in the reduction step of the
nitro compounds in addition to acyl chloride in a one-pot approach to form the corresponding
amides. The yields of the amides are reasonable for the model compounds however more
significant is that the reaction conditions are mild and well tolerated with 1 and showed
significant improvement in the yield of the amide analog of 1. This reaction is certain to have
utility in the optimization studies of various natural product heterocyclic systems.

General Experimental Procedures. 1H- and

13

C-NMR spectra were recorded in CDCl3, d4-

methanol, or d6-acetone on a Bruker Avance NMR spectrometer operating at 400 MHz for 1H
and 100 MHz for 13C. Chemical shift (δ) values are expressed in parts per million (ppm) and are
referenced to the residual solvent signals of the solvent used. UV and the high resolution ESI-MS
spectra were measured using a Bruker Daltonics (GmbH, Germany) micrO-TOF series with
electrospray ionization. TLC analysis was carried out on precoated silica gel G254 aluminum
plates. Reagents were purchased from Aldrich and used without further purification. Reactions
were carried out in oven-dried glassware.
General procedure for reductive amidation: Et3N (0.002 mole), zinc (0.002 mole), acetic acid
glacial (0.004 mole), and the acyl chloride (0.0013 mole) was added to a solution of the
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nitroarene (1 mmol) in anhydrous DMF.1 The mixture was stirred at 40 oC for about 5 h. Water
(10 mL) was added to the reaction mixture and extracted with ethyl acetate (3x10 mL). The
organic layer was dried over anhydrous Na2SO4 and evaporated under vacuum. The crude
products were purified by silica column using 98:2 n-hexane:acetone.
6-Cyclohexamidemanzmaine A (7):
Method A: 6-aminomanzamine A (100 mg, 0.177 mmol) and catalytic amount of DMAP
were dissolved in anhydrous THF (3 mL) under nitrogen atmosphere. Et3N (25 µL, 0.177 mmol)
was then added, and the mixture was stirred at room temperature for 10 minutes.
Cyclohexylcarbonyl chloride was added (1.2 equiv.), and the reaction mixture was stirred for 1 h.
The completion of the reaction was monitored by TLC, then the reaction was quenched with
water, and the product was extracted by DCM (3x10 mL). The organic layer was dried over
anhydrous sodium sulphate, and then evaporated under reduced pressure. Purification of 7 was
carried out on a Phenomenex Luna C8 250x10 mm, 5µm HPLC column using a gradient form
CH3CN (0.1% TFA)/water (0.1% TFA) with flow rate of 6 mL/min to give 7 (20 mg, 17.62%)
Method B (reductive amidation method): 6-nitromanzmaine A (100 mg, 0.169 mmol)
was utilized with the general reductive amidation procedure above without the addition of Et3N.
The crude reaction mixture after evaporation was purified on a Phenomenex Luna C8 250x10
mm, 5 µm HPLC column using a gradient CH3CN (0.1% TFA)/water (0.1% TFA) with flow rate
of 6 mL/min to give 7 (63.5 mg, 55.94%).
Nitration of harmane: harmane (8) (1 g, 5.494 mmol) was dissolved in TFA (40 ml., 0.538
mmol), and kept at 0 oC with stirring for 30 min. Sodium nitrite (0.6 g, 8.695 mmol) was added
in one portion and allowed to stir at 0 oC for an additional 3 h. The reaction mixture was poured

1

After the addition of all the reagents, the pH should be around 6. If not, 0.001 mole of Et3N was added.
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into water and neutralized by ammonium hydroxide producing a precipitate that was filtered and
dried. The crude nitro products of harmane were loaded onto a column packed with 50 g of silica
gel. 8-Nitroharmane (9) was eluted first with 99:1 DCM:MeOH, followed by 6-nitroharmane
(10) after the mobile polarity was increased with 95:5 DCM:MeOH (opposite to manzamine A).
6-Nitroharmane (9): (0.56 g, 45.16%); yellow powder; IR: 3020, 2951, 2587, 2079, 1664, 1637,
1534, 1490, 1428, 1402, 1336.93, 1319, 1286, 1266, 1206, 1179, 1131, 1118, 1054, 990, 836,
820, 794, 751, 742, 730 cm-1; 1H-NMR (CDCl3) δ 8.83 (1H, d, J=2.4 Hz), 8.13 (1H, d, J=2.4
Hz), 8.11 (1H, d, J=2.4 Hz), 8.08 (1H, d, J=6.8 Hz), 7.96 (1H, d, J=6.8 Hz), 7.38 (1H, d, J=8.0
Hz), 2.87 (s);

13

C-NMR (CDCl3) δ 145.59, 141.93, 139.86, 135.56, 132.58, 130.42, 125.24,

119.59, 119.43, 115.35, 112.63, 15.29; HRESIMS m/z calcd for C12H10N3O2 (M+H)+ 228.0773,
found 228.0770.
8-Nitroharmane (10): (0.54 g, 43.54%) yellow powder; IR: 3020, 2951, 2587, 2079, 1664,
1637, 1534, 1490, 1428, 1402, 1336.93, 1319, 1286, 1266, 1206, 1179, 1131, 1118, 1054, 990,
836, 820, 794, 751, 742, 730 cm-1; 1H-NMR (CDCl3) δ 9.87 (s, brd), 8.44 (1H, d, J=5.6 Hz), 8.41
(1H, d, J=8.0 Hz), 8.37 (1H, d, J=8.0 Hz), 7.78 (1H, d, J=5.6 Hz), 7.33 (1H, t, J=8.0 Hz), 2.86
(s);

13

C-NMR (CDCl3) δ 143.32, 140.84, 134.85, 133.97, 133.29, 129.23, 127.58, 126.39,

124.43, 119.61, 112.87, 20.43; HRESIMS m/z calcd for C12H10N3O2 (M+H)+ 228.0773, found
228.0770.
6-n-Butamidoharmane (TableIII.2, entry 10): starting from 6-nitroharmane (9, 100 mg, 0.441
mmol) and using the general reductive amidation procedure above: (64.35 mg, 54.71%); 1HNMR (CDCl3) δ 8.56 (s), 8.23 (1H, d, J=8.0 Hz), 8.20 (1H, d, J=6.0 Hz), 7.75 (1H, d, J=8.8 Hz),
7.61(1H, d, J=8.0 Hz), 2.97 (s), 2.43 (2H, t, J=7.6 Hz), 1.79 (2H, p, J=8.0 Hz), 1.06 (3H, t, J=8.0
Hz);
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DEPT (CDCl3) δ 130.15 (CH), 126.62 (CH), 115.86 (CH), 114.78 (CH), 113.68 (CH),
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39.69 (CH2), 20.33 (CH3), 20.03 (CH2), 13.93 (CH3). HRESIMS m/z calcd for C16H18N3O
(M+H)+ 268.1450, found 268.1448.
8-n-Butamidoharmane (TableIII.2, entry 9): starting from 8-nitroharmane (10, 100 mg, 0.441
mmol) and using the general reductive amidation procedure: (67.86 mg, 57.69%); 1H-NMR
(CDCl3) δ 8.03 (1H, d, J=6.0 Hz), 7.72 (1H, d, J=8.0 Hz), 7.67 (1H, d, J=8.0 Hz), 7.64 (1H, d,
J=6.0 Hz), 7.05 (1H, t, J=8.0 Hz), 2.90 (s), 2.21 (2H, t, J=7.2 Hz), 1.73 (2H, p, J=8.0 Hz), 0.91
(3H, t, J=7.2 Hz);

135

DEPT (CDCl3) δ 131.31 (CH), 119.95 (CH), 118.01 (CH), 114.02 (CH),

113.04 (CH), 39.11 (CH2), 19.71 (CH3), 19.07 (CH2), 13.79 (CH3), HRESIMS m/z calcd for
C16H18N3O (M+H)+ 268.1450, found 268.1448.
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4-(n-butamido)anisole (Table III.2, entry 3)
H-NMR (CDCl3)

1

Figure III.2. 1H-NMR of 4-(n-butamido)anisole (Table III.2, entry 3) in CDCl3 at 400 MHz.
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Figure III.3. 1H-NMR of 2-(n-butamido)anisole (Table III.2, entry 1) in CDCl3 at 400 MHz.
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Figure III.4. 1H-NMR of 3-(n-butamido)anisole (Table III.2, entry 2) in CDCl3 at 400 MHz.
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2-(n-butamido)toulene (Table III.2, entry 4)
1
H-NMR (CDCl3)

Figure III.5. 1H-NMR of 2-(n-butamido)toulene (Table III.2, entry 4) in CDCl3 at 400 MHz.
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Figure III.6. 1H-NMR of 3-(n-butamido)toulene (Table III.2, entry 5) in CDCl3 at 400 MHz.
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Figure III.7. 1H-NMR of 4-(n-butamido)toulene (Table III.2, entry 6) in CDCl3 at 400 MHz.
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Figure III.8. 1H-NMR of 4-(benzamido)toulene (Table III.2, entry 7) in CDCl3 at 400 MHz.
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Figure III.9. 1H-NMR of 4-(n-butamido)ethylbenzoate (Table III.2, entry 8) in CDCl3 at 400
MHz.
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6-nitroharmane (9)

Figure III.10. 1H- and

13

C-NMR spectra of 6-nitroharmane (9) in CDCl3 at 400 and 100 MHz,

respectively.
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N
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NO2

8-nitroharmane (10)

Figure III.11. 1H- and 13C-NMR spectra of 8-nitroharmane (10) in CDCl3 at 400 and 100 MHz,
respectively.
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6-n-Butamidoharmane (Table III.2, entry 10)

Figure III.12. 1H- and

135

DEPT-NMR spectra of 6-n-butamidoharmane (Table III.2, entry 10)

in CDCl3 at 400 and 100 MHz, respectively.
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8-n-Butamidoharmane (Table III.2, entry 9)

Figure III.13. 1H- and 135DEPT-NMR spectra of 6-n-butamidoharmane (Table III.2, entry 9) in
CDCl3 at 400 and 100 MHz, respectively.
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CHAPTER IV.

REDUCTIVE N-ALKYLATION OF NITROARENES: A PRACTICAL GREEN APPROACH
FOR THE N-ALKYLATION OF NATURAL PRODUCTS

Publication in The Journal of Organic Chemistry, 2012, 77, 4578-4584.
Authors: Amir E. Wahba and Mark T. Hamann
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ABSTRACT: A simple, mild, cost effective and green approach for the reductive mono Nalkylation of nitroarenes has been developed. HOAc/Zn are utilized as the reducing system
together with a carbonyl compound as an alkyl source in methanol. Excellent yields were
obtained with stoichiometric control of mono over dialkylated products. Application to five
complex natural products demonstrated the practical utility of the method.
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Introduction:
One-pot reactions are those in which two or more chemical transformations take place under
the

same

reaction

conditions

without

purification

of

intermediates

and

avoiding

protection/deprotection steps.2 Due to this advantage, one-pot reactions are highly practical in
organic process development and in the field of total synthesis of complex natural products.1-10
Indeed the value of such reactions is maximized if they maintain the green chemistry principles
such as: waste prevention, atom economy, safer solvents and catalysis selectivity.87 Simple and
gentle chemical modifications are a key element for lead optimization studies where the
pharmacological properties of leads must be altered through synthesis or semisynthesis. Nitration
of aromatic and heterocyclic compounds is a simple and useful reaction for introduction of a
stable nitro group onto a natural product skeleton. The benefit of introducing the nitro group is
the ease of conversion to the corresponding amine that can be further alkylated to create primary
and secondary aromatic amines. These alkylated amines are important building blocks for drug
candidates.
During our detailed structure activity relationship (SAR) and lead optimization studies of
manzamine A against malaria and neuroinflammation,14-18, 88-91 we introduced a nitro group at C6 and C-8 of the β-carboline moiety. These nitromanzamines are stable while the corresponding
amines are not.15 This instability was the inspiration for development of our one-pot reductive
amidation method using Zn/HOAc as the reducing system and acyl chloride/Et3N as the
acylating agent in DMF.19 The same challenges occurred when attempting to N-alkylate
aminomanzamines by direct and reductive alkylation methods. As a result, we explored the
utility of our previously used reducing system (Zn/HOAc) to accomplish an effective one-pot
reductive N-alkylation of nitroarenes with carbonyl compounds as the alkyl source.
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Several examples of one-pot reductive mono N-alkylations of nitroarenes with different
reducing systems using carbonyl compounds as the alkyl source have been reported. Bae et al.
used decaborane and 10% Pd/C92 in methanol as a reducing system with a carbonyl compound as
the alkyl source.

Although this method showed high yields (~90%) of the mono N-alkyl

products, it has several drawbacks. Addition of the reducing agent in one batch resulted in an
incomplete reaction due to formation of the corresponding ether through reductive etherification.
Another report used hydrogen over 10% Pd/C as reducing system and aldehydes as an alkyl
source.93 This method is not selective and not applicable to natural products modification since
H2/10% Pd/C will reduce isolated double bonds. In a similar reaction, ammonium formate was
used as in situ hydrogen donor with 5% Pd/C as a reducing system in addition to aldehydes as
alkyl source.94 Xiang et al reported the use of aqueous-MeOH as an in situ source of H2 over an
Au-Pd/Al2O3 catalyst for the conversion of nitroarenes into the corresponding imines.95 Nitriles
have also been used as alkylating agents. Hudson et al. have used nitriles and ammonium
formate with 5% Pd/C as reducing agent in methanol.96 This approach gave relatively low yields
with nitroarenes bearing electron withdrawing groups. Polymethylhydrosiloxane was also used
as reducing agent in the presence of Pd(OH)2/C as catalyst and nitriles as alkylating agents.97
These two methods have the drawback of long reaction time in the first method and an expensive
reducing agent in the second method. Other reductive alkylation methods have been reported
including: allylic amination of cyclohexene by nitroarenes catalyzed by ruthenium complexes,98
electrochemical reduction,99 addition of functionalized arylmagnesium compounds to
nitroarenes,100 the palladium catalyzed coupling of allyl carbonate,101 the addition of
allymagnesium chloride to nitroarenes followed by reduction with LAH,102 and the zinc
promoted reductive alkylation utilizing alkyl halides as the alkyl source.103
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Apparently, none of the previously reported one-pot reductive N-alkylation methods of
nitroarenes is suitable for drug development either because of selectivity problems or the use of
costly or toxic reagents (i.e., a deviation from green chemistry principles). Moreover, they all
lack the application to a real drug lead or natural products. Herein, we report the development of
a one-pot reductive N-alkylation of nitroarenes using inexpensive zinc metal with acetic acid as a
selective reducing system (alkenes are stable under these conditions)104 and carbonyl compounds
as alkyl source with an application to five natural products scaffolds.
Results and discussion:
Solvent optimization using 4-nitroanisole as a model reaction revealed that methanol was the
solvent of choice with quantitative yield of the mono N-alkyl product (Table IV.1). We then
optimized the reaction conditions using simple nitroarenes and several carbonyl compounds.
Mono N-alkyl products were obtained in high yields when one mole of carbonyl compound was
used. (Table IV.2). Addition of two equivalents or more of carbonyl compound resulted in the
formation of tertiary amines in excellent yields in an atom economical approach.
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Table IV.1. Solvent optimization for the reductive mono N-alkylation of nitroarenes

a

Entry

Solvent

Time (min)

Yield (%)a

1

DCM

30

94

2

MeOH

30

Quant.

3

DMF

30

91

4

Toluene

30

86

5

THF

30

87

Isolated yield; All reactions were done using 1 mmol of 4-nitroanisole
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Table IV.2. Screening of simple nitroarenes under optimized conditions
R1
NO2

HN

O
R + 1.2 equiv. R 1

R2

4 equiv. Zn/ 8 equiv. HOAc
R2

R
MeOH
1 a-f

30 min.

Entry

Nitro compound

Carbonyl compound

Product

Yield
(%)a

HN
CHO

Quant.

1
OMe
1a

NO 2
HN

O

2

96

OMe
OCH 3
1b

NO 2

HN

O

3

95

OMe

OCH3
1c
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HN

NO2

Quant.

4
CHO
CO 2Et
1d

CO2 Et

HN
Cl

97

5
OMe
1e

N

6

96b

HCHO
OMe
1g

a

Isolated yields. All reactions were done using 1.0 mmol of starting material

b

2.2

equiv. HCHO, 10 equiv. Zn and 20 equiv. HOAc were used. The reaction time was 1 h.

We utilized our optimized conditions for the synthesis of several N-alkyl analogs of
biologically active natural product scaffolds. Five natural products were nitrated to generate
starting nitro materials (Scheme IV.1). Manzamine F (2), selected as an example of manzamine
alkaloids, yielded upon nitration three nitro products: 7-nitromanzamine F (3), 5-nitromanzamine
F (4) and 5,7-dinitromanzamine F (5). The regiochemistry of the nitro group in 3 was assigned
based on the strong HMBC correlations of H-5 (δΗ 7.91) to C-4a (δc 131.4) and C-4b (δc 129.1).
Nitration of harmane (6), a β-carboline alkaloid, with sodium nitrite gave two nitro products: 8nitroharmane (7) and 6-nitroharmane (8). Recently, several β-carboline related alkaloids
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identified as prototypes to potent and orally efficient antimalarial leads were synthesized via
similar reductive amination chemistry.105,106 This supports our use of β-carbolines as model
compounds. Nitration of the steroid, estradiol (9), led to simultaneous nitration of the phenol
moiety and oxidation of the C-17 hydroxy functionality to afford 2-nitroestrone (10) and the 2,4dinitro analog (11). Nitration of quinine (12) resulted in an interesting hydroxynitration of the
terminal double bond which led to the formation of compound 13 in moderate yield. The 1H- &
13

C-NMR of 13 revealed the absence of the olefinic resonances and the presence of a

disubstituted quinoline ring (1H-NMR: δ 8.95, 1H, d, J=4.4 Hz; 8.25, 1H, d, J=7.7; 8.14, 1H, d,
J=10.9; 7.74, 1H, d, J=10.0 Hz and 7.61, 1H, s) which indicated that the double bond was
nitrated instead of the quinoline ring. This could be attributed to the deactivation of the quinoline
ring by TFA. The molecular formula of 13 was determined as C20H26N3O5 (M+H)+ from
HRESIMS (m/z 388.1872) and the NMR data, which confirmed the addition of a hydroxy group
and a nitro group in the molecule. The presence of the methylene resonance at δ 79.2 as well as
the oxygenated methine resonance at δ 68.5 in the

13

C-NMR spectra confirmed the

regiochemistry of the nitro and the hydroxy groups to be at C11 and C10 respectively. Nitration
of curcudiol (14) gave the mononitro (15) and dinitro products (16). The nitro group in 15 was
assigned at C4 based on the presence of the two singlet resonances at δ 7.51 and 6.31 in the 1HNMR spectra.
.
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Method A: 1 equiv. of natural product dissolved in TFA, 1.1 equiv. NaNO2. 0 oC to rt., 1.5 h.
Method B: 1 equiv. of natural product dissolved in HOAc, 3 equiv. HNO3 0 oC to rt., 1 h.

Scheme IV.1. Nitration of natural products scaffolds

The optimized reductive N-alkylation conditions applied to the nitrated natural products gave
moderate to excellent yields (Table IV.3). 7-Nitromanzamine F gave a high yield (91%) of the
corresponding 7-N-ethylaminomanzamine F (17) when one equivalent of acetaldehyde was used.
The nitroquinine product 13 gave a moderate yield of 47% of the N-ethylamino product 18.
Moreover, nitrocurcudiol 15 gave 64% yield of the N-ethylamino analog 19. A high yield of the
6-N-butylaminoharmane (20, 97%) was obtained from the reductive alkylation of 6-nitroharmane
(8). Moreover, a high yield (88%) of the N,N-dimethylamino analog 21 was obtained in the case
of 2-nitroestrone when reacted with two equivalents of formaldehyde.
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Table IV.3. Reductive N-alkylation of nitrated natural products
Entry

Nitro products
N

N
H

H

NO 2
OH

OH

N

1

Yield (%)a

N-alkyl products

91
N

H

O

3

17

NO 2

HN
OH

OH

2

47

N

HO

N

HO
MeO

MeO
N

N

13

18
OH

OH

3
NO2

OH

NH

15

19
H
N

R1
N

4

N
H
R2
R 1=R 2=H: Harmane (6 )
R 1=H, R 2=NO2: 8-nitroharmane (7)
R 1=NO2, R 2=H: 6-nitroharmane (8)

N

N
H

97
20

O

5

64

OH

O

88b

O 2N

N

HO

HO

176

21

10
a

Isolated yields. 1.2 equiv. of aldehydes were used. Reaction time was 1 h.

b

2.2 equiv. HCHO, 10 equiv. Zn and 20 equiv. HOAc were used.

Conclusion:
In conclusion, a practical, mild, cost-effective and environmentally benign green method for
the one-pot reductive mono N-alkylation of nitroarenes has been developed. This method gives
excellent yields with our model compounds with high selectivity for the mono N-alkyl over the
dialkylated product in an atom economical approach with easy workup step (no hazardous
waste). The reaction conditions were well tolerated by a variety of natural product models and
afforded moderate to excellent yields. The major advantage of our method is the use of
inexpensive zinc metal and acetic acid as a mild and selective reducing system to nitro group
which makes our method greener. When taken in conjunction with the mild reaction conditions,
this

method

may

well

find

applications
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in

drug

development

Experimental:

General Experimental Procedures. The 1H- and 13C-NMR spectra were recorded in CDCl3, d4methanol or d6-acetone on NMR spectrometer operating at 400 MHz for 1H and 100 MHz for
13

C. Chemical shift (δ) values are expressed in parts per million (ppm) and are referenced to the

residual solvent signals of the solvent used. High resolution ESI-MS spectra were measured
using electrospray ionization mass spectrometer. TLC analysis was carried out on precoated
silica gel G254 aluminum plates. Reagents were purchased from commercial sources and used
without further purification. Reactions were carried out in oven-dried glassware.
General procedure for the mono N-alkylation of nitroarenes: carbonyl compound (1.2
equiv.), zinc dust (4 equiv.) and acetic acid glacial (8 equiv.) were added to a solution of the
nitroarene (1 mmol) in MeOH (2 mL). The mixture was stirred at room temperature for 30 min.
Water (5 mL) was added to the reaction mixture and extracted with ethyl acetate (3x10 mL). The
organic layer was dried over anhydrous Na2SO4 and evaporated under vacuum. The crude
products were purified by silica column using 98:2 n-hexane:acetone.
4-N(n-butylamino)anisole (1a):107 (179 mg, Quant.); yellow oil; 1H-NMR (CDCl3) δ 6.84 (2H,
d, J=9.1 Hz), 6.63 (2H, d, J=9.0 Hz), 3.77 (3H, s), 3.09 (2H, t, J=7.6 Hz), 1.61 (2H, t, J=7.5 Hz),
1.47 (2H, m), 1.00 (3H, t, J=7.5 Hz); HRESIMS m/z calcd for C11H18NO (M+H)+ 180.1388,
found 180.1394.
4-N(2-methylcyclohexylamino)anisole (1b):108 (212 mg, 96%); yellow oil; 1H-NMR (CDCl3) δ
6.77 (2H, d, J=8.7 Hz), 6.67 (2H, d, J=8.9 Hz), 3.76 (3H, s), 1.4-2.2 (2H, m), 1.08 (3H, d, J=7.1
Hz); HRESIMS m/z calcd for C14H22NO (M+H)+ 220.1701, found 220.1687.
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4-N(isopropylamino)anisole (1c):109 (157 mg, 95%); yellow oil; 1H-NMR (CDCl3) δ 6.78 (2H,
d, J=8.7 Hz), 6.60 (2H, d, J=8.9 Hz), 3.77 (3H, s), 3.56 (1H, m), 1.2 (6H, d, J=7.1 Hz);
HRESIMS m/z calcd for C10H16NO (M+H)+ 166.1232, found 166.1197.
4-N(n-butylamino)ethyl benzoate (1d):110 (221 mg, Quant.); yellowish solid (m.p. 134); 1HNMR (CDCl3) δ 7.84 (2H, d, J=8.9 Hz), 6.55 (2H, d, J=8.7 Hz), 4.29 (2H, q, J=7.4 Hz), 3.12
(2H, q, J=7.1 Hz), 1.58 (2H, m), 1.41 (2H, m), 1.33 (3H, t, J=7.0 Hz), 0.93 (3H, t, J=7.0 Hz);
HRESIMS m/z calcd for C13H20NO2 (M+H)+ 222.1494, found 222.1510.
4-(p-chlorobenzylamino)anisole (1e):111 (240 mg, 97%); yellow oil; 1H-NMR (CDCl3) δ 7.22
(2H, d, J=8.6 Hz), 7.07 (2H, d, J=8.9 Hz), 6.74 (2H, d, J=8.9 Hz), 6.52 (2H, d, J=8.9 Hz) 4.42
(1H, brs), 3.72 (3H, s);

13

C-NMR (CDCl3): 152.8 (C), 140.7 (C), 140.2 (C), 138.7 (C), 133.3

(CH), 129.0 (CH), 128.9 (CH), 128.6 (CH), 115.7 (CH), 115.7 (CH), 115.0 (CH), 114.9 (CH),
64.6 (CH2), 55.7 (CH3); HRESIMS m/z calcd for C14H15ClNO (M+H)+ 248.0842, found
248.0857.
4-(N,N-dimethylamino)anisole (1f):112 (145 mg, 96%); yellowish white oil; 1H-NMR (CDCl3) δ
6.84 (2H, d, J=8.6 Hz), 6.75 (2H, d, J=8.9 Hz), 2.86 (6H, s), 3.76 (3H, s); HRESIMS m/z calcd
for C9H14NO (M+H)+ 152.1075, found 152.1102.

General methods for the nitration of natural products.
Method A: 1 equiv. of natural product was dissolved in TFA (3 mL) and stirred for 10 min. at 0
o

C. NaNO2 (1.1 equiv.) was added at once and the reaction mixture was stirred at 0 oC for 1 h

and then for 30 min. at room temperature. The reaction mixture was poured into water and
neutralized by ammonium hydroxide producing a precipitate that was filtered and dried. If no
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precipitate was formed, the aqueous mixture was extracted with DCM (3x10 mL) and the
organic layers were combined and dried over Na2SO4 and concentrated under vacuum.
Method B: 1 equiv. of natural product was dissolved in glacial acetic acid (3 mL) and nitric
acid (2 equiv.) at 0 oC. The reaction mixture was stirred for 30 min. at 0 oC then for another 30
min at room temperature. The reaction mixture was poured into water and neutralized by
ammonium hydroxide producing a precipitate that was filtered and dried. If no precipitate was
formed, the aqueous mixture was extracted with DCM (3x10 mL) and the organic layers were
combined and dried over Na2SO4 and concentrated under vacuum.
Nitration of manzamine F (2): Manzamine F (100 mg, 0.172 mmol) and NaNO2 (13 mg, 0.188
mmol) were reacted by method A. After workup, the crude nitromanzamine F products were
purified by silica column chromatography using n-hexane:acetone (9:1). Further purification was
carried out on a Phenomenex Luna C8 250x10 mm, 5µm Luna reverse-phase HPLC column
using gradient CH3CN (0.1% TFA)/water (0.1% TFA) with flow rate of 6 mL/min to gave the
pure nitro analogs.
Manzamine F (2):

1

H-NMR (CDCl3) δ 8.41 (1H, d, J=7.6 Hz), 7.88 (1H, d, J=7.5 Hz), 7.63

(1H, d, J=7.6 Hz), 7.61 (1H, d, J=7.6 Hz), 7.12 (1H, d, J=7.6 Hz), 6.66 (1H, s), 5.60 (2H, m),
3.70 (1H, s), 3.11 (m), 2.92 (m), 2.57 (m), 2.38 (m), 2.10 (m); 13C-NMR (CDCl3) δ 211.0 (C),
143.7 (C), 143.1 (C), 141.3(C), 138.3 (CH), 137.7 (CH), 133.3 (C), 132.6 (C), 130.1 (C), 128.0
(CH), 123.4 (C), 121.1 (CH), 113.8 (CH), 112.2 (CH), 82.1 (CH), 69.6 (C), 63.5 (CH), 53.2
(CH2), 49.8 (CH2), 47.6 (C), 46.7 (CH2), 46.1 (CH2), 45.1 (CH2), 42.5 (CH), 39.9 (CH2), 38.9
(CH2), 34.2 (CH2), 32.7 (CH2), 26.9 (CH2), 25.7 (CH2), 25.2 (CH2), 24.6 (CH2), 21.5 (CH2).
25
7-nitromanzamine F (3): (21 mg, 20%); [α ]D +11.5 (c 0.05, MeOH); yellow solid; (Rf = 0.6,

9:1 DCM:MeOH); IR: 3534 (br), 3211, 3050, 2959, 2924, 2852, 1711, 1650, 1574, 1507, 1457,
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1421, 1260, 1072, 1024, 911, 802, 729 cm-1; 1H-NMR (d6-acetone) δ 8.55 (1H, d, J=7.6 Hz),
8.38 (1H, d, J=7.5 Hz), 8.18 (1H, d, J=7.6 Hz), 7.91 (1H, d, J=7.6 Hz), 6.71 (1H, s), 5.65 (2H,
m), 3.70 (1H, s), 3.44 (m), 3.29 (m), 3.14 (m), 2.92 (m), 2.72 (m), 2.53 (m), 2.34 (m), 2.24 (m)
2.08 (s), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m);

13

C-NMR (d6-acetone) δ 211.0 (C), 150.9 (C),

139.6 (C), 136.1 (CH), 135.2 (CH), 133.7 (CH), 132.6 (C), 131.4 , 129.1 (CH), 122.3 (C), 121.7
(C), 121.6 (C), 119.6 (C), 115.4 (CH), 113.3 (CH), 79.8 (CH), 70.6 (C), 69.2 (CH2), 58.8 (CH2),
55.7 (CH), 51.1 (CH2), 47.3 (CH2), 45.6 (CH2), 41.6 (CH2), 36.6 (CH2), 36.3 (CH2), 34.7 (CH2),
28.1 (CH2), 25.1 (CH2), 24.3 (CH2), 22.9 (CH2), 20.7 (CH2); HRESIMS m/z calcd for
C36H44N5O5 (M+H)+ 626.3342, found 626.3335.
25
5-nitromanzamine F (4): (21 mg, 20%); [α ]D +12.1 (c 0.05, MeOH); pale orange solid; (Rf =

0.50, 9:1 DCM:MeOH); IR: 3194 (br), 3090, 2964, 2930, 2854, 2802, 1710, 1671, 1649, 1560,
1456, 1417, 1335, 1202, 1194, 1073, 1026, 911, 820, 805, 729 cm-1; 1H-NMR (d6-acetone) δ
8.70 (1H, d, J=7.6 Hz), 8.53 (1H, d, J=7.5 Hz), 8.12 (1H, d, J=7.6 Hz), 7.12 (1H, d, J=7.6 Hz),
6.99 (1H, s), 5.65 (2H, m), 3.70 (1H, s), 3.44 (m), 3.29 (m), 3.14 (m), 2.92 (m), 2.72 (m), 2.53
(m), 2.34 (m), 2.24 (m) 2.08 (s), 2.03 (m), 1.96 (m), 1.74 (m), 1.48 (m); 13C-NMR (d6-acetone) δ
211.0 (C), 149.3 (C), 141.7 (C), 141.0 (C), 136.0 (CH), 135.1 (C), 132.5 (CH), 131.9 (CH),
129.4 (C), 122.5 (C), 121.7 (C), 118.0 (CH), 117.1 (CH), 115.2 (CH), 114.0 (CH), 79.0 (CH),
72.0 (CH2), 67.5 (CH2), 56.6 (CH2), 56.3 (CH), 53.5(CH2), 52.2 (CH2), 49.3 (CH2), 46.3(CH2),
42.4 (CH), 36.8(CH2), 36.6 (CH2), 33.4 (CH2), 30.6 (CH2), 29.6 (CH2), 29.2 (CH2), 28.6 (CH2),
27.5 (CH2), 25.2 (CH2), 22.1 (CH2), 20.0 (CH2); HRESIMS m/z calcd for C36H44N5O5 (M+H)+
626.3342, found 626.3335.
25
5,7-dinitromanzamine F (5): (46 mg, 43%); [α ]D +18.5 (c 0.1, MeOH); orange solid; (Rf = 0.4,

9:1 DCM:MeOH); IR: 3239 (br), 3050, 2932, 2854, 2797, 1693, ,1562, 1446, 1418, 1365, 1330,
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1271, 1245, 1112, 1075, 823, 789 cm-1; 1H-NMR (d6-acetone) δ 8.59 (1H, d, J=7.6 Hz), 8.21
(1H, d, J=7.5 Hz), 8.20 (1H, s), 6.52 (1H, s), 5.36 (2H, m), 3.70 (1H, s), 3.44 (m), 3.29 (m),
3.14 (m), 2.92 (m), 2.72 (m), 2.53 (m), 2.34 (m), 2.24 (m) 2.08 (s), 2.03 (m), 1.96 (m), 1.74 (m),
1.48 (m); 13C-NMR (d6-acetone) δ 212.0 (C), 151.1 (C), 143.6 (C), 141.5 (C), 138.4 (CH), 137.7
(CH), 136.9 (C), 133.5 (C), 131.8 (CH), 130.2 (CH), 128.3 (C), 124.1 (C), 120.2 (C), 114.3
(CH), 109.3 (CH), 80.5 (CH), 70.1 (CH2), 69.9 (CH2), 57.1 (CH2), 55.7 (CH2), 53.9 (CH), 51.4
(CH2), 46.8 (CH2), 43.3 (CH), 39.7 (CH2), 36.6 (CH2), 36.4 (CH2), 34.6 (CH2), 32.7 (CH2), 27.3
(CH2), 25.2 (CH2), 24.3 (CH2), 22.1 (CH2), 21.0 (CH2); HRESIMS m/z calcd for C36H43N6O7
(M+H)+ 671.3193, found 671.3207.
Nitration of harmane (6): Harmane (100 mg, 0.440 mmol) and NaNO2 (33.4 mg, 0.480 mmol)
were reacted by method A. After workup, the crude nitro products of harmane were loaded onto
a column packed with 15 g of silica gel. 8-Nitroharmane (7) was eluted first with 99:1
DCM:MeOH, followed by 6-nitroharmane (8) after the mobile polarity was increased with 95:5
DCM:MeOH.
8-Nitroharmane (7):113 (54 mg, 43%); yellow powder (m.p. 211-212 oC; lit. 209-210 oC); (Rf =
0.8, 9:1 DCM:MeOH); IR: 3087, 3044, 2974, 2865, 2784, 1660, 1640, 1530,1491, 1339, 1288,
1202, 1184, 1131, 833 cm-1; 1H-NMR (CDCl3) δ 9.87 (s, brd), 8.44 (1H, d, J=5.6 Hz), 8.40 (1H,
d, J=8.0 Hz), 8.37 (1H, d, J=8.0 Hz), 7.78 (1H, d, J=5.6 Hz), 7.33 (1H, t, J=8.0 Hz), 2.86 (s);
13

C-NMR (CDCl3) δ 143.3 (C), 140.6 (CH), 134.8 (C), 134.0 (C), 133.7 (C), 127.4 (CH), 127.6

(C), 126.4 (C), 124.2 (CH), 119.4 (CH), 112.6 (CH), 20.2 (CH3); HRESIMS m/z calcd for
C12H10N3O2 (M+H)+ 228.0773, found 228.0770.
6-Nitroharmane (8):113 (56 mg, 45%); yellow powder (m.p. 297-299 oC; lit. 299-300 oC); (Rf =
0.7, 9:1 DCM:MeOH); IR: 3305, 3086, 2869, 1673, 1640, 1531, 14942, 1434, 1338, 1201, 1138,
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832 cm-1; 1H-NMR (CDCl3) δ 8.83 (1H, d, J=2.4 Hz), 8.13 (1H, d, J=2.4 Hz), 8.11 (1H, d, J=2.4
Hz), 8.08 (1H, d, J=6.8 Hz), 7.96 (1H, d, J=6.8 Hz), 7.38 (1H, d, J=8.0 Hz), 2.87 (s); 13C-NMR
(CDCl3) δ 150.0 (C), 144.2 (C), 137.0 (C), 134.8 (CH), 129.6 (CH), 123.8 (CH), 119.7 (CH),
119.4 (CH), 117.0 (CH), 19.6 (CH3); HRESIMS m/z calcd for C12H10N3O2 (M+H)+ 228.0773,
found 228.0770.
Nitration of β-estradiol (9): β-estradiol (100 mg, 0.36 mmol) was nitrated with method B. After
workup, the crude nitro products was purified with silica column eluted with DCM:MeOH
(95:5). The hydroxy group was oxidized under these conditions.
25
2-nitroestrone (10):114 (19.8 mg, 17%); [α ]D +96.2 (c 0.1, DCM); yellow powder (m. p. 178-

179 oC; lit. 178-180 oC); (Rf = 0.56, 100% DCM) ; IR: 3078, 2928, 2857, 1736, 1631, 1525,
1479, 1433, 1374, 1310, 1263, 1053, 897, 734, 703 cm-1; 1H-NMR (CDCl3) δ 7.99 (1H,s), 6.88
(1H,s), 2.97 (2H, m), 2.53 (1H, dd, J=17.0, 8.3 Hz), 2.46 (1H, m), 2.31-1.97 (6H, m), 1.75-1.40
(8H, m), 0.91 (3H,s); 13C-NMR (CDCl3) δ 220.1 (C), 153.0 (C), 148.9 (C), 133.2 (C), 131.7 (C),
121.7 (CH), 119.1 (CH), 50.5 (CH), 48.0 (C), 43.6 (CH), 37.8 (CH), 35.9 (CH2), 31.4 (CH2),
29.8 (CH2),

26.0 (CH2), 25.8 (CH2), 21.7 (CH2), 13.9 (CH3); HRESIMS m/z calcd for

C18H22NO4 (M+H)+ 316.1549, found 316.1552.
25
2,4-dinitroestrone (11):114 (64 mg, 55%); [α ]D +90.1 (c 0.1, DCM); yellow powder (m. p. 186-

188 oC; lit. 185-188 oC); (Rf = 0.4, 100% DCM); IR: 3350, 3008, 2987, 1734, 1631, 1532, 1345,
1308, 1259, 1061, 897 cm-1; 1H-NMR (CDCl3) δ 8.14 (1H,s), 2.88 (2H, m), 2.53 (1H, dd,
J=17.0, 8.3 Hz), 2.46 (1H, m), 2.31-1.97 (6H, m), 1.75-1.40 (8H, m), 0.91 (3H,s);

13

C-NMR

(CDCl3) δ 220.1 (C), 144.8 (C), 141.7 (C), 139.2 (C), 133.6 (C), 132.1 (C), 122.7 (CH), 50.0
(CH), 47.7 (C), 43.5 (CH), 37.0 (CH), 35.7 (CH2), 31.2 (CH2), 28.2 (CH2), 25.8 (CH2), 24.9
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(CH2), 24.8, 21.5 (CH2), 13.7 (CH3); HRESIMS m/z calcd for C18H21N2O6 (M+H)+ 361.1399,
found 361.1402.
Nitration of quinine (12): Quinine (100 mg, 0.31 mmol) was nitrated by method B. After
workup, the crude product was fractionated using solid phase extraction (SPE-C18) and the
fraction eluted with H2O:MeOH (80:20) was further purified on a Phenomenex Luna C8 250x22
mm, 5µm Luna reverse-phase HPLC column using gradient CH3CN (0.1% TFA)/water (0.1%
TFA) with flow rate of 20 mL/min to gave the pure nitro analog.
Quinine (12): 1H-NMR (d4-methanol) δ 8.61 (1H, d, J=8.0 Hz), 7.90 (1H, d, J=8.0 Hz), 7.65
(1H, d, J=4.0 Hz), 7.36 (1H, s), 7.33 (1H, s), 6.23 (1H, d, J=4.0 Hz), 5.65 (1H, m), 5.56 (1H, m),
4.82 (1H, m), 3.92 (3H, s), 3.65 (1H, m), 3.07 (2H, m), 2.63 (2H, m), 2.26 (1H, m), 1.82 (2H,
m), 1.70 (1H, m), 1.52 (1H, m), 1.36 (1H, m); 13C-NMR (d4-methanol) δ 159.5 (C), 150.6 (C),
148.0 (CH), 144.7 (C), 142.7 (CH), 131.4 (CH), 131.3, 128.0 (C), 123.2 (CH), 120.0 (CH),
119.9, 114.9 (CH2), 102.3 (CH), 72.2 (CH), 60.1 (CH), 57.7 (CH2), 56.4 (CH3), 44.1 (CH2), 40.1
(CH), 29.2 (CH), 28.2 (CH2), 21.6 (CH2).
25
11-nitro-10-hydroxyquinine (13): (63 mg, 53%); [α ]D +133.0 (c 1, MeOH); yellow-orange

powder m. p. 167-170 oC); (Rf = 0.5, 100% DCM); IR: 3368, 3007, 2971, 2839, 1672, 1621,
1556, 1510, 1473, 1242, 1229, 1133, 1027, 834, 799 cm-1; 1H-NMR (d4-methanol) δ 8.95 (1H, d,
J=4.4 Hz), 8.25 (1H, d, J=7.7 Hz), 8.14 (1H, d, J=10.9 Hz), 7.74 (1H, d, J=10.0 Hz), 7.61 (1H,
s), 6.23 (1H, m), 4.50 (2H, t, J=9.8 Hz), 4.29 (1H, m), 4.04 (3H, s), 3.88 (1H, m), 3.49 (1H, m),
3.25 (1H, m), 2.33-1.50 (6H, m);

13

C-NMR (d4-methanol) δ 162.9 (C), 162.5 (C), 162.3 (C),

157.0 (C), 142.4 (CH), 135.8 (C), 129.0 (C), 128.8 (CH), 124.7 (CH), 121.3 (CH), 119.3 (CH),
102.8 (CH), 98.9 (C), 89.0 (C), 81.5 (C), 79.2 (CH2), 68.5 (CH), 67.1 (CH), 61.0 (CH), 57.4
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(CH), 53.6 (CH2), 53.4 (CH2), 45.5 (CH2), 38.3 (C), 38.1 (CH2), 25.8 (CH2), 25.5 (CH2), 20.0
(CH2); HRESIMS m/z calcd for C20H26N3O5 (M+H)+ 388.1872, found 388.1859.
Nitration of curcudiol (14): Curcudiol (100 mg, 0.423 mmol) and NaNO2 (32 mg, 0.463 mmol)
were reacted by method A. After workup, the crude products were purified by silica column
eluted with n-hexane:acetone (85:15).
Curcudiol (14): 1H-NMR (CDCl3) δ 7.04 (1H, d, J=8.0 Hz), 6.70 (1H, d, J=8.0 Hz), 3.14 (1H,t,
J=7.2 Hz), 2.25 (3H, s), 1.64-1.20 1.20 (8H, m), 1.20-1.18 (9H, m); 13C-NMR (CDCl3) δ 153.8
(C), 136.6 (C), 131.2 (C), 127.2 (CH), 121.7 (CH), 116.8 (CH), 72.2 (C), 43.9 (CH2), 38.2 (CH2),

31.6, 31.3 (CH), 29.9 (CH3), 29.1 (CH3), 22.6 (CH2), 21.6 (CH3).

o
4-nitrocurcudiol (15): (24 mg, 20%); [α ]25
D +8.3 (c 0.2, MeOH); yellow powder (m. p. 103 C);

(Rf = 0.6, 7:3 hexane:EtOAc); IR: 3365, 3177, 3067, 2919, 2850, 2793, 2298, 1776, 1714, 1638,
1602, 1571, 1443, 1370, 1216, 1151, 1134, 1030, 997, 851, 814, 762 cm-1; 1H-NMR (CDCl3) δ
7.51 (1H, s), 6.31 (1H, s), 3.00 (1H,m), 2.17 (3H, s), 1.6-1.2 (12H, m), 1.20 (6H, s), 1.12 (3H, d,
J=5.3 Hz);

13

C-NMR (CDCl3) δ 187.4 (C), 150.8 (C), 148.3 (C), 146.1 (C), 129.6 (C), 119.5

(CH), 89.4 (C), 40.4 (CH2), 36.3 (CH2), 31.5 (CH), 29.9 (CH3), 25.7 (CH3), 21.9 (CH3), 19.9
(CH2), 17.2 (CH3); HRESIMS m/z calcd for C15H22NO4 (M-H)- 280.1548, found 280.1541.
25
2,4-dinitrocurcudiol (16): (24 mg, 20%); [α ]D +10.1 (c 0.1, MeOH) ; yellow powder (m. p.

125 oC); (Rf = 0.3, 7:3 hexane:EtOAc); IR: 3329, 3013, 2928, 2863, 1705, 1618, 1585, 1518,
1453, 1420, 1374, 1288, 1228, 1150, 1108, 944, 909, 859, 775, 766 cm-1; 1H-NMR (CDCl3) δ
8.20 (1H, s), 2.95 (1H,m), 2.12 (3H, s), 1.6-1.2 (12H, m), 1.16 (6H, s), 1.07 (3H, d, J=5.3 Hz);
13

C-NMR (CDCl3) δ 186.5 (C), 152.1 (C), 149.9 (C), 148.4 (C), 129.2 (C), 119.1 (C), 71.6 (C),

43.6 (CH2), 36.6 (CH2), 31.5 (CH), 29.1 (CH3), 25.7 (CH3), 21.9 (CH2), 19.9 (CH3), 17.0 (CH3);
HRESIMS m/z calcd for C15H21N2O6 (M-H)- 325.1399, found 325.1392.
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Reductive N-alkylation of natural products scaffolds:
7-N-ethylaminomanzamine F (17): 7-nitromanzamine F (3, 21 mg, 0.034 mmol) and
acetaldehyde (2.0 µL, 0.040 mmol) were reacted by the general reductive alkylation method (0.2
mL of DCM was added as a cosolvent). The reaction mixture was stirred for 1 h at room
temperature under nitrogen atmosphere. The crude product was purified on a Phenomenex Luna
C8 250x10 mm, 5µm Luna reverse-phase HPLC column using gradient CH3CN (0.1%
TFA)/water (0.1% TFA) with flow rate of 6 mL/min to gave the pure N-ethylamino analog. 7-N25
ethylaminomanzamine F: (19 mg, 91%); [α ]D +17.2 (c 0.1, MeOH); pale yellow powder; (Rf

= 0.5, 9:1 DCM:MeOH); IR: 3239, 3210, 3050, 2932, 2854, 2797, 1693, 1562, 1446, 1418,
1365, 1330, 1271, 1245, 1112, 1075, 823, 789 cm-1; 1H-NMR (CDCl3) δ 8.46 (1H, d, J=7.6
Hz), 7.71 (1H, d, J=7.5 Hz), 7.35 (1H, d, J=7.6 Hz), 7.03 (1H, d, J=7.6 Hz), 6.50 (1H, s), 5.53
(2H, m), 3.50 (1H, s), 3.44 (m), 3.01 (m), 2.60 (m), 2.40 (m), 2.35 (m), 2.34 (m), 1.70 (m), 1.56
(m), 1.35 (3H, t, J=10 Hz);

13

C-NMR (CDCl3) δ 211.0 (C), 142.2 (C), 140.6 (C), 137.1 (CH),

137.7 (CH), 135.9 (C), 132.2 (CH), 131.9 (CH), 130.3 (C), 129.4 (C), 126.5 (C), 121.4 (C),
115.1 (CH), 112.4 (CH), 111.9 (CH), 109.4 (CH), 81.5 (CH), 70.1 (CH2), 63.2 (CH2), 55.9
(CH), 55.0 (CH2), 51.1 (CH2), 44.8 (CH), 38.2 (CH2), 35.8 (CH2), 35.6 (CH2), 34.7 (CH2), 27.3
(CH2), 26.0 (CH2), 25.3 (CH2), 23.5 (CH2), 20.8 (CH2), 14.1 (CH3); HRESIMS m/z calcd for
C38H50N5O3 (M+H)+ 624.3913, found 624.3932.
10-N-ethylamino-11-hydroxyquinine (18): 10-nitro-11-hydroxyquinine (13, 50 mg, 0.129
mmol) and acetaldehyde (9.0 µL, 0.155 mmol) were reacted by the general reductive alkylation
method The reaction mixture was stirred for 1 h at room temperature under nitrogen atmosphere.
The crude product was purified on a Phenomenex Luna C8 250x10 mm, 5µm Luna reversephase HPLC column using gradient CH3CN (0.1% TFA)/water (0.1% TFA) with flow rate of 6
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mL/min to gave the pure N-ethylamino analog. 10-N-ethylamino-11-hydroxyquinine: (23 mg,
25
47%); [α ]D +140.9 (c 1, DCM); brown powder (m. p. 156-158 oC); (Rf = 0.3, 100% DCM); IR:

3345, 3239, 3156, 3007, 2932, 1620, 1591, 1552, 1509, 1469, 1448, 1430, 1371, 1332, 1324,
1228, 1174, 1136, 1082, 1025, 988, 953, 827, 760 cm-1; 1H-NMR (d4-methanol) δ 8.95 (1H, d,
J=4.4 Hz), 8.20 (1H, d, J=7.7 Hz), 8.14 (1H, d, J=10.9 Hz), 7.74 (1H, d, J=10.0 Hz), 7.61 (1H,
s), 6.27 (1H, m), 4.50 (2H, t, J=9.8 Hz), 4.29 (1H, m), 4.06 (3H, s), 3.78 (1H, m), 3.49 (1H, m),
3.33 (1H, m), 2.99 (2H, q, J=10.0 Hz), 2.33-1.50 (6H, m), 1.23 (3H, t, J=10.0 Hz);

13

C-NMR

(d4-methanol) δ 162.0 (C), 162.5 (C), 162.3 (C), 157.0 (C), 142.4 (CH), 135.8 (C), 128.9 (CH),
128.8 (C), 124.7 (CH), 121.3 (C), 119.3 (CH), 102.8 (CH), 98.9 (C), 89.0 (C), 81.5 (CH), 70.2
(CH2), 68.5 (CH), 61.0 (CH), 57.4 (CH2), 53.6 (CH2), 53.4 (CH2), 45.5 (CH2), 44.0 (CH2), 38.3
(CH2), 38.1 (CH2), 25.8 (CH2), 25.5 (CH2), 20.0 (CH2), 11.1 (CH3); HRESIMS m/z calcd for
C22H32N3O3 (M+H)+ 386.2443, found 386.2424.
4-N-ethylaminocurcudiol (19): 4-nitrocurcudiol (15, 20 mg, 0.071 mmol) and acetaldehyde (5.0
µL, 0.085 mmol) were reacted by the general reductive alkylation method The reaction mixture
was stirred for 1 h at room temperature under nitrogen atmosphere. The crude product was
purified on a Phenomenex Luna C8 250x10 mm, 5µm Luna reverse-phase HPLC column using
gradient CH3CN (0.1% TFA)/water (0.1% TFA) with flow rate of 6 mL/min to gave the pure Nethylamino analog. 4-N-ethylaminocurcudiol (19): (13 mg, 64%); [α ]25
D +4.7 (c 0.05, DCM);
pale-yellow oil; (Rf = 0.7, 7:3 hexane:EtOAc);IR: 3402(brd), 3012, 2960, 2932, 2873, 2359,
2341, 1775, 1705, 1637, 1513, 1420, 1367, 1219, 1164, 1091, 1009, 987, 830 cm-1; 1H-NMR
(CDCl3) δ 6.50 (1H, s), 6.39 (1H, s),3.14 (2H, q, J= Hz), 3.02 (1H,m), 2.13 (3H, s), 1.79-1.56
(12H, m), 1.47 (6H, s), 1.21 (3H, d, J=5.3 Hz); 13C-NMR (CDCl3) δ 155.7 (C), 149.4 (C), 135.6
(C), 133.8 (C), 132.1 (C), 118.1 (CH), 89.4 (C), 43.1 (CH2), 40.1 (CH2), 36.8 (CH2), 31.6 (CH),
187

29.5 (CH3), 25.4 (CH3), 22.2 (CH2), 21.5 (CH3), 20.6 (CH3), 16.6 (CH3), 12.8 (CH3); HRESIMS
m/z calcd for C17H28NO2 (M-H)- 278.2120, found 278.2131.
6-N-n-butylaminoharmane (20): 6-nitroharmane (8, 50 mg, 0.220 mmol) and butyraldehyde
(24.0 µL, 0.264 mmol) were reacted by the general reductive alkylation method The reaction
mixture was stirred for 1 h at room temperature under nitrogen atmosphere. The crude product
was purified on a Phenomenex Luna C8 250x10 mm, 5µm Luna reverse-phase HPLC column
using gradient CH3CN (0.1% TFA)/water (0.1% TFA) with flow rate of 6 mL/min to gave the
pure N-ethylamino analog. 6-N-n-butylaminoharmane (55 mg, 98%); brownish oil; (Rf = 0.6,
100% DCM); IR: 3258, 3012, 2941, 2587, 2079, 1664, 1637, 1534, 1490, 1428, 1402, 1336.93,
1319, 1286, 1266, 1206, 1179, 1131, 1118, 1054, 990, 836, 820, 794, 751, 742, 730 cm-1; 1HNMR (CDCl3) δ 8.26 (1H, d, J=8.0 Hz), 7.74 (1H, d, J=7.8 Hz), 7.29 (1H, d, J=8.0 Hz), 7.25
(1H, d, J=8.0 Hz), 6.90 (1H, d, J=8.0), 3.19 (2H, t, J=7.6 Hz), 2.75 (s), 2.43 (2H, t, J=7.6 Hz),
1.66 (2H, q, J=8.0 Hz), 1.43 (2H, p, J=8.0 Hz), 1.00 (3H, t, J=8.0 Hz);

13

C-NMR (CDCl3) δ

143.2 (C), 141.7, 136.9 (CH), 135.4 (C), 134.5 (C), 128.4 (C), 122.9 (CH), 118.3 (CH), 113.2
(CH), 112.7 (C), 102.8 (CH), 45.1 (CH2), 32.0 (CH2), 20.6 (CH2), 21.0 (CH3), 14.2 (CH3).
HRESIMS m/z calcd for C16H20N3 (M+H)+ 254.1657, found 254.1649.
2,2-N,N-dimethylaminoestrone (21): 2-nitroestrone (10, 20 mg, 0.062 mmol) and
formaldehyde (17 µL, 0.140 mmol) were reacted by the general reductive alkylation method (0.2
mL of DCM was added as a cosolvent). The reaction mixture was stirred for 1 h at room
temperature under nitrogen atmosphere. The crude product was purified on a Phenomenex Luna
C8 250x10 mm, 5µm Luna reverse-phase HPLC column using gradient CH3CN (0.1%
TFA)/water (0.1% TFA) with flow rate of 6 mL/min to gave the pure analog. 2,2-N,N25
dimethylaminoestrone: (17 mg, 88%); [α ]D +148.8 (c 1, DCM); yellow powder (m. p. 162-165
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o

C); (Rf = 0.4, 100% DCM); IR: 3362, 3016, 2928, 2862, 2784, 1737, 1581, 1502, 1453, 1260,

1081, 801 cm-1; 1H-NMR (CDCl3) δ 7.07 (1H,s), 6.66 (1H,s), 2.61 (6H, s), 2.53 (1H, dd, J=17.0,
8.3 Hz), 2.46 (1H, m), 2.31-1.97 (6H, m), 1.59-1.23 (8H, m), 0.89 (3H,s); 13C-NMR (CDCl3) δ
221.0 (C), 149.3 (C), 138.3 (C), 134.1 (C), 131.1 (C), 117.4 (CH), 113.8 (CH), 50.4 (CH), 48.0
(C), 45.3 (CH3), 44.2 (CH3), 38.3 (CH), 35.8 (CH2), 31.5 (CH), 29.6 (CH2), 29.2 (CH2), 26.5
(CH2), 26.1 (CH2), 21.5 (CH2), 13.8 (CH3); HRESIMS m/z calcd for C20H28NO2 (M+H)+
314.2120, found 314.2101.
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Figure IV.1. 1H-NMR of 4-(n-butylamino)anisole (1a) in CDCl3 at 400 MHz.
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Figure IV.2. 1H-NMR of 4-(2-methylcyclohexylamino)anisole (1b) in CDCl3 at 400 MHz.

191

HN

OMe

4-(isopropylamino)anisole (1c)
1
H-NMR (CDCl3)

Figure IV.3. 1H-NMR of 4-(isopropylamino)anisole (1c) in CDCl3 at 400 MHz.
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Figure IV.4. 1H-NMR of 4-(n-butylamino)ethylbenzoate (1d) in CDCl3 at 400 MHz.
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Figure IV.5. 1H-NMR of 4-(p-chlorobenzylamino)anisole (1e) in CDCl3 at 400 MHz.
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Figure IV.6. 1H-NMR of 4,4-N,N-dimethylaminoanisole (1f) in CDCl3 at 400 MHz.
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Manzamine F, 2

Figure IV.7. 1H- and

13

C-NMR spectra of manzamine F (2) in CDCl3, at 400 and 100 MHz,

respectively.
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Figure IV.8. 1H- and 13C-NMR spectra of 7-nitromanzamine F (3) in d6-acetone, at 400 and 100
MHz, respectively.
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Figure IV.9. IR spectra (neat) of 7-nitromanzamine F (3).
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Figure IV.10. 1H- and

13

C-NMR spectra of 5-nitromanzamine F (4) in d6-acetone, at 400 and

100 MHz, respectively.
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Figure IV.11. IR spectra (neat) of 8-nitroharmane (7) and 6-nitroharmane (8).
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Figure IV.12. 1H- and

13

C-NMR spectra of 2-nitroestrone (10) in CDCl3 at 400 and 100 MHz,

respectively.
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Figure IV.13. IR spectra (neat ) of 2-nitroestrone (10).

202

O
O2 N
HO
NO 2

2,4-Dinitroestrone, 11

Figure IV.14. 1H- and

13

C-NMR spectra of 2,4-dinitroestrone (11) in CDCl3 at 400 and 100

MHz, respectively.
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Quinine, 12

Figure IV.15. 1H- and

13

C-NMR spectra of quinine (12) in d4-methanol at 400 and 100 MHz,

respectively.
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Figure IV.16. 1H- and
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DEPT-NMR spectra of 11-nitro-10-hydroxyquinine (13) in d4-

methanol at 400 and 100 MHz, respectively.
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Figure IV.17. IR spectra (neat ) of 11-Nitro-10-hydroxyquinine (13).
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Curcudiol, 14

Figure IV.18. 1H- and

13

C-NMR spectra of curcudiol (14) in CDCl3 at 400 and 100 MHz,

respectively.
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4-nitrocurcudiol, 15

Figure IV.19. 1H- and 13C-NMR spectra of 4-nitrocurcudiol (15) in CDCl3 at 400 and 100 MHz,
respectively.
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4-nitrocurcudiol, 15

Figure IV.20. IR spectra (neat ) of 4-nitrocurcudiol (15).
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7-N-ethylaminomanzamine F (17)

Figure IV.21. 1H- and

13

C-NMR spectra of 7-N-ethylaminomanzamine F (17) in CDCl3 at 400

and 100 MHz respectively.
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11-N-ethylamino-10-hydroxyquinine (18)

Figure IV.22. 1H- and

13

C-NMR spectra of 11-N-ethylamino-10-hydroxyquinine (18) in d4-

methanol at 400 and MHz respectively.

211

4-N-ethylaminocurcudiol (19)

Figure IV.23. 1H- and

13

C-NMR spectra of 4-N-ethylaminocurcudiol (19) in CDCl3 at 400 and

100 MHz respectively.

212

H
N
N

N
H

6-N-(n-butylamino)harmane (20)

Figure IV.24. 1H- and 13C-NMR spectra of 6-N-n-butylaminoharmane (20) in CDCl3 at 400 and
100 MHz, respectively.
213

O
N
HO

2,2-N,N-dimethylaminoestrone (21)

Figure IV.25. 1H- and

13

C-NMR spectra of 2-N,N-dimethylaminoestrone (21) in CDCl3 at 400

and 100 MHz respectively.
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